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ABSTRACT 
 
NK cells belong to the innate immune system and are important in the defense against virus 
infections and malignant cells. They mediate their effector functions via release of cytotoxic 
granules and by cytokine production which can influence the status of other (immune) cells. NK 
cells are regulated by germline encoded receptors, both activating and inhibitory, recognizing 
molecules that are induced upon infection or cellular stress and self ligands respectively. Ly49 
receptors (Ly49r) make up the largest NK cell receptor family in mice. It contains both activating 
and inhibitory receptors most of which bind to major histocompatibility complex class I (MHC I) 
molecules. NK cells patrol tissues and inspect surrounding cells for alterations in activating ligands 
and MHC I expression, balancing the input for decision of response. If the activation exceeds the 
inhibition, the target cell is eliminated. This ability to sense loss of self MHC I is referred to as 
missing self recognition. It can be directed against virus infected cells and tumor cells which often 
downmodulate MHC I, while they upregulate activating ligands. 
NK cells are educated via Ly49r-MHC I interactions to ensure self-tolerance and reactivity 
against aberrant cells. MHC I dependent education influences the NK cell population in at least two 
ways; modulation of responsiveness of each cell and skewing of the inhibitory receptor repertoire, i 
e the frequencies of NK cells expressing different combinations of Ly49r. The main aim of this 
thesis has been to study missing self recognition and MHC I dependent NK cell education and how 
these phenomena are influenced by different factors. 
In paper I, we characterized a genetic defect leading to Impaired Missing Self Recognition, in a 
mouse strain that we have termed IMSR mice. These mice had originally been developed by 
targeting a non-classical MHC gene, but the defect and the IMSR defect segregated independently. 
The IMSR mice were found to have a normal number of NK cells, which retained some functions, 
while missing self rejection and some activation pathways were partly or completely impaired. This 
defect was found to be NK cell intrinsic; it was not due to total lack of inhibitory receptors function, 
nor lack of MHC dependent education. 
In paper II and III we investigated how NK cells respond to altered inhibitory input from the 
environment in the host. Antibody mediated inhibitory receptor blockade was used as a tool to 
reduce the inhibitory input, which led to two different effects on the targeted NK cell populations 
1) increased in vivo elimination of MHC I
+ 
tumor cells without breaking tolerance towards normal 
healthy cells (paper II) and 2) induction of hyporesponsiveness i e reduced in vitro responsiveness 
or reduced capacity to eliminate MHC I
- 
spleen cells. Importantly, elimination of MHC I
- 
tumor 
cells was maintained. This was also investigated in an adoptive transfer model where the NK cell 
responsiveness could be either increased or reduced, depending on the MHC I expression in the 
recipient host (paper III). In conclusion, we found that NK cells can retune their responsiveness 
upon altered inhibitory input, but that responsiveness levels are adapted to healthy cells, still 
allowing efficient killing of tumor cells of the same missing self phenotype. 
In paper IV, we investigated whether skewing of the inhibitory receptor repertoire occurs 
already during NK cell development, before they reach the blood and the spleen. We found that the 
process leading to overrepresentation of NK cells expressing only one self MHC receptor is 
initiated during in the bone marrow already at the first NK cell developmental stage where 
inhibitory Ly49 receptors are expressed. This is most probably influenced both by selective 
proliferation and apoptosis. 
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1    INTRODUCTION 
 
1.1 THE DISCOVERY OF NATURAL KILLER CELLS AND THEIR 
REGULATION BY MHC GENES 
 
Natural Killer cells (NK cells) were discovered and described in 1974 by Rolf Kiessling, 
Hans Wigzell and Eva Klein after first having been being considered as “background 
noise” in assays searching for cytotoxic T cells in tumor bearing and normal individuals. 
They represented a new cell type detectable in non-immunized mice, with a rapidly 
occurring, natural in vitro cytotoxicity against YAC-1, a lymphoma induced by Moloney 
leukemia virus. (1). The follow up paper from the same group showed that these new 
cytotoxic cells could be found in mice from 3-10 weeks of age and were most abundant in 
the spleen (1-5% of spleen cells), although they could also be found in lymph nodes (LN) 
and bone marrow (BM) (2). They described their finding as follows: “We have found a 
spontaneously occurring cell with cytolytic activity against in vitro grown Moloney 
Leukemia cells. It is present predominantly in the spleen of normal, young mice with 
limited activity to be found in other lymphoid organs….. At present we can only conclude 
that the present killer cells have a morphology of small lymphocytes” cited from (1). 
Competition studies suggested that these new killer cells were mainly reactive against 
Moloney leukemia virus antigens (Ag). However, this was already proven to be incorrect 
by Herberman et al. the same year who in an independent but similar study in the mouse 
showed that natural cytotoxicity occurred against various tumor targets, not only virus 
induced (3). Both groups came to the conclusion that the cytotoxicity observed was not 
mediated by T cells, B cells or macrophages, nor was it likely to reflect so called antibody 
dependent cell mediated cytotoxicity (ADCC) (2, 4). These newly found cytotoxic cells 
were termed ”natural” Killer cells (NK cells) in the paper of Kiessling et al., a name 
originally suggested by Eva Klein. 
 
One of the first published studies on human NK cells by Pross et al. showed that natural 
cytotoxicity varied between different donors but was stable over time in the same 
individual. This study also suggested that the cytotoxicity of human NK cells can at least 
in part be mediated through ADCC, since removal of Fc receptor expressing cells and lack 
of antibody (ab) coating of target cells in some settings could abolish the natural 
cytotoxicity (4a).   A third paper from Kiessling et al. in 1975 investigated the genetic 
control behind the natural cytotoxicity and its correlation with tumor resistance in vivo. 
By injection of YAC-1 cells subcutaneously into several F1 crosses between A/Sn (from 
which YAC-1 cells had originated) and other mouse strains with different MHC I (H-2
a 
or 
H-2
b
) they found that rejection efficiency against tumors as well as levels of NK 
cytotoxicity were both controlled by genes linked to the H-2 locus. In 1977 the first 
connection between NK cells and radioresistant rejection of bone marrow (BM) grafts was 
published (5). It was known from before mainly through studies of Cudkowicz et al that 
F1  hybrid mice rejected not only completely allogeneic but also parental hematopoietic 
grafts via a poorly characterized mechanism that was radioresistant. The 1977 study 
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showed that mouse NK cells and BM graft resistance shared many common features; both 
phenomena emerged at the age of three weeks, both were quite resistant to total body 
irradiation, both were sensitive to depletion of cells in the bone marrow and both could be 
suppressed by repeated injection of parental spleen cells in to F1 hybrids. 
 
Already at this stage within five years of the discovery, speculations on the importance of 
NK cells in regulation of hematopoiesis and tumor surveillance were put forward. After 
that, the NK cell field became influenced by the mainstream interest in immunology at 
that time, and many studies addressed the capability of NK cells to produce and respond to 
different cytokines as well as their involvement and role in infections. However, the key 
principles behind their specificity remained elusive. 
 
In the 80´s Klas Kärre et al. postulated the “missing self” hypothesis to explain how MHC 
genes could control hybrid resistance mediated by NK cells. It was based on the 
assumption that NK cells expressed inhibitory receptors that recognized self MHC I 
molecules; when an NK cell failed to recognize some self MHC I molecules e g on a 
grafted parental bone marrow cell, this would lead to NK cell activation. NK cells would 
thus recognize “missing self”, rather than the presence of a foreign antigen. To further 
investigate and test the missing self hypothesis they showed that in vivo rejection of 
lymphoma cells was strongly dependent on the expression of syngeneic H-2 molecules: 
H-2
- 
tumor cell variants failed to grow in syngeneic mice while H-2
+ 
tumor cells seemed 
resistant to rejection (6). This phenomenon was T cell independent but NK cell dependent; 
an even stronger reduction of tumor burden was observed when H-2
- 
cells were inoculated 
into athymic nude mice, while they grew out when mice were NK cell depleted (7).  The 
missing self hypothesis was later further strengthened by studies of MHC I transfected 
tumor cells and MHC I transgenic mice, and most importantly, by identification of 
inhibitory MHC I specific receptors, both in mice (8, 9)and humans (10, 11). 
 
1.2   NK CELLS TODAY 
 
Today, we understand that NK cells belong to a special branch of the innate immune 
system  containing different types of innate lymphoid  cells  (further discussed  below) 
which can initiate a rapid immune response to viral infections and intracellular pathogens 
((12-17)(18)). NK cells are also important in tumor surveillance, in elimination of virus 
infected cells and reactions associated with hematopoietic grafts, such as host-versus-graft 
rejection and graft vs leukemia reactivity (19-22). In addition, they are of importance 
during reproduction: they accumulate in the maternal-fetal interface in the placenta and 
influence the development of the fetus, most probably by taking part in the regulation of 
angiogenesis and blood flow to the placenta (23). 
 
NK cells are characterized as bone marrow derived large granular lymphocytes that 
constitute about 3-5% of spleen cells in the mouse and 5-15% of human peripheral blood 
(24, 25). Cell surface markers are used to identify NK cells: they are characterized by 
absence of CD3, TCR and Ig in combination with expression of NK1.1 or Dx5 in mice, 
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and of CD56 in humans (26-28). In both species, NK cells can be identified by expression 
of NKp46 (however, NKp46 can also be expressed by other ILC populations, see below 
(29, 30). 
 
Natural Killer cells are found also throughout the body in different tissues, for example 
bone marrow, spleen, lymph nodes, liver, lung, pancreas, joints and placenta. They can 
display organ specific functions at different sites ((26, 27) and reviewed in (31, 32)). 
 
It is usually considered that two main criteria need to be fulfilled in order to classify a cell as 
part of the adaptive immune system 1) the receptor used to recognize the antigen should be 
generated by gene rearrangement and 2) the repertoire should be further selected by clonal 
deletion, survival and expansion and ultimately generate immunological memory. Each NK 
cell expresses a variety of receptors, both activating and inhibitory, and is regulated by a 
balance between these two different types of receptors (reviewed in (33)). NK cell receptor 
genes are germ line encoded, they do not go through rearrangement to achieve diversity and 
specificity, as required for assembling B and T cell receptors (reviewed in (34)).  Regarding 
the second criterion there is a debate in the NK cell field. The original view was that the 
whole (or most of the) NK cell population can be rapidly activated upon stimulation to 
mediate effector functions and proliferate, but without differences between subsets or clones, 
and without subsequent generation of immunological memory. They would thus give the 
same response in the second encounter with the same pathogen while B and T cells exhibit a 
much faster, more potent response during a secondary infection. But more recent studies, 
mainly in relation to virus infections, indicate that certain NK cell subsets can expand, 
resulting in long-lived effector cells that act more efficiently in a second encounter of the 
same pathogen (see section 1.10 below). However, NK cells are still usually referred to as 
being part of the innate immune system, since they do express several germline encoded 
receptors and the nature of their “memory” remains uncertain. 
 
NK cells mediate their effector functions through both contact dependent and contact 
independent mechanisms. Upon cognate interaction NK cells can directly lyse the target 
by delivery of continuously produced granules containing perforin and granzymes or by 
inducing apoptosis through death receptor mediated pathways such as Fas-L and TRAIL 
(35, 36) and reviewed in (37). NK cells do not express TRAIL except for an immature NK 
cell population in the liver which can exert function through TRAIL and also further 
develop to give rise to mature NK cells (38). NK cells can recognize and kill antibody 
coated targets through binding via the Fc receptor in the so called ADCC reaction (27, 
39). Upon activation, NK cells can secrete cytokines, chemokines and growth factors such 
as IFNγ, TNF-α, MIP-1α/β and GM-CSF. This can lead to direct control of infections. 
Alternatively, it can alter the immune response by activation and maturation other cell 
types (27, 40, 41). NK cells need several factors to be functional, such as IL-15, IL-12 or 
IL-18. There is evidence that IL-15 has to be presented by either macrophages or dendritic 
cells (42-44). 
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The last decades much more have been learned about the regulation of NK cell activity; 
activating and inhibitory receptors, NK cell education status, responses to and secretion of 
cytokines - both pro- and anti-inflammatory.  One, if not the most important, regulatory 
mechanism of NK cell reactivity is the “missing self” recognition. The molecular 
mechanisms behind this reaction are partly known, but they are far from clear and still 
under investigation. The NK cell research field today continues to search for and 
characterize basic features of the cells and their interactions with the environment, but 
attempts to exploit NK cell manipulation for clinical purposes have also started. 
 
1.3   NK CELL DEVELOPMENT 
 
The cells of immune system are called leukocytes and are all generated from hematopoietic 
stem cells in the bone marrow. The immune cells are further divided into a myeloid and a 
lymphoid cell lineage dependent on different developmental steps further discussed below. 
The adaptive immune system contains the B and T lymphocytes which are generated in the 
lymphoid cell lineage. These cells express antigen specific receptors and are called adaptive 
since they can give rise to a faster and more efficient  immune response upon a second 
encounter with the same antigen. The innate immune system contains several cell types, both 
of the myeloid and the lymphoid cell lineage. They express an array of germ line encoded 
receptors, some of which show a broader specificity. Examples of cells belonging to the 
innate immune system are macrophages, granulocytes, dendritic cells which are the main 
antigen presenting cells, with the power to activate and regulate the adaptive immune system, 
and NK cells. Development of hematopoietic cells occurs in the bone marrow and is divided 
into several steps, each phase controlled by cytokines, activation of transcription factors and 
interaction with stromal cells in the bone marrow. Different combinations of these factors 
contribute to the decision for the next differentiation step. Whether the development is 
completed when the cell exits the bone marrow depends on cell type, for example the NK cell 
is functional and ready while T cells need further development in the thymus. 
 
1.3.1  Commitment to the common lymphocyte linage 
 
The transition to go from pluripotent hematopoietic stem cells (HSC) to a committed 
lymphoid progenitor, ELP and CLP (early or common lymphoid progenitors respectively), is 
dependent on specific gene expression. Both ELP and CLP can give rise to all 3 lymphoid 
cell types; B, T and NK cells.(45, 46).  It has been shown that several transcription factors 
(TF) are important in this process. TFs important in the generation of lymphoid progenitors 
are the Ikaros and Ets families ((47, 48) and reviewed in (49-51)). The involvement of these 
transcription factors is indicated by the fact that Ikaros deficient mice lack all T, B and NK 
cells and that the loss of Ets-1 leads to the absence of NK cells in the bone marrow, lymph 
node and spleen while the family member PU.1 affects all lymphoid cells, although mainly B 
and T cells, and also the development of some myeloid cell types (52). The transition from 
ELP to CLP has been shown be at least partly regulated by Helix-loop-Helix (HLH) proteins 
which can act as both transcription activators and inhibitors. Mutant mice lacking an 
inhibitory Helix-loop-Helix protein, Id2, have no NK cells (53). 
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1.3.2  Commitment to the NK cell lineage 
 
The first identification of a committed NK cell progenitor was done in vitro: Lin
- 
CD3
- 
CD122
+
NK1.1
-
Dx5
- 
cells were shown to give rise to NK1.1
+ 
cells only but not to T or B cells 
(54).  These committed NK cell progenitors had transcripts for IL-15Ra chain, Ets-1, Id2 and 
GATA-3. GATA-3 is needed to achieve mature NK cells with Ly49r expression and proper 
function (55).  NK cells were suggested to develop via the following stages:  CD122
+
NK1.1
- 
Dx5
- 
- CD122
+
NK1.1
+
Dx5
- 
- CD122
+
NK1.1
+
Dx5
+
. Ly49 expression was acquired at the 
second stage and fully cytotoxic functions were achieved in the most mature population (54). 
 
More recently an additional intermediate step on the way from CLP to NKP has been 
identified (pre-NKP) and the definition of the NKP was refined (rNKP) (56). Pre-NKPs 
lacked CD122 expression but both pre-NKP and (r)NKP developed to functional Ly49 
expressing NK cells, but not to T or B cells, in vivo after transfer to an immune deficient 
host. 
 
In vitro cultures and the use of different knockout (KO) mouse strains, show the importance 
of several critical factors such as cytokines and transcription factors in the development of 
NK cells from CLPs. NK cell development and differentiation in vitro to a mature and 
functional cytotoxic cell requires cytokine cocktails in combination with stromal cell 
interactions (57-59). In vitro cultures with only cytokine supplements generated small 
amounts of cytotoxic cells but did not lead to Ly49 receptor expression or mature NK cells 
(see  below).  Mice  deficient  for  IL-2,  -7  and  -15  have  shown  that  these  cytokines  are 
important for NK cell maintenance and function but not for development per see, at least not 
at the early stage (60, 61). 
 
1.3.3  NK cell maturation 
 
When a pre-NKP has become an NKP, the NK cell has a long way to go before it becomes a 
mature and functional cytotoxic cell. This developmental process includes several 
intermediate stages, differently named by different investigators. Here the steps will be 
referred to as stage I-IV (classification by Yokoyama) (62), (see figure 1 for additional steps 
and combined nomenclature). These steps are defined by expression of cell surface markers, 
integrins and receptors, and selective proliferation ((62) and reviewed in (63)). Some of these 
markers are expressed transiently while others are permanently expressed. The first step is 
defined by expression of CD122 and approximately 10% of these NK cells express the 
activating receptor NKG2D (stage I) (61). This is followed by up-regulation of NK1.1 (NKR- 
P1c), the inhibitory receptor CD94/NKG2A and the death receptor TRAIL (stage II). All 
these markers are expressed on fully mature NK cells, except for TRAIL which is mainly 
found at stage II and III but can be up-regulated on mature NK cell after stimulation. At stage 
II, the integrin Mac-1 (CD11b) and CD43 start to be expressed initially at a low level that 
will increase with NK cell maturation. At stage III, Ly49 receptors are expressed together 
with the tyrosine kinase receptor c-kit and αv integrin. Stage IV is characterized by high 
expression of Dx5 (integrin α2), down-regulation of the integrin αv and NK cell expansion by 
6  
massive proliferation. In stage V, NK cells are fully mature with high expression of Mac-1, 
CD43 and full cytotoxic capacity. How different transcription factors such as GATA-3, T-bet 
and MEF regulate these maturation steps after commitment to the NK cell linage is not fully 
understood and will not be discussed here. 
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Figure 1, Described in section 1.3.1-3, nomenclature according to Yokoyama and Di Santo 
 
 
1.3.4  Maturation based on CD27 and CD11b expression 
 
The late maturation process and the acquisition of functional competence can be further 
divided into sub-steps. NK cells can be divided in to 4 different subgroups based on CD27 
and Mac-1 expression (62, 64-66). CD27 is a member of the TNF super family and its 
expression has been shown to correlate with increased survival and maturity in T and B cells 
(67). Activation of NK cells through CD27 can induce cytokine production (68, 69) 
Macrophage-1 antigen (Mac-1, CD11b, Integrin αM) is an integrin expressed on several 
leukocytes and is important in several processes such as cell adhesion and migration (70). 
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Adoptive transfer together with gene expression analysis showed the following sequential 
maturation stages CD27
lo
Mac-1
lo  
(DN) – CD27hiMac-1lo  – CD27hiMac-1hi  (DP) – 
CD27
lo
Mac-1
hi 
(62). The ability to proliferate was highest in the DN subpopulation and 
decreased with every successive maturation step. The intermediate DP population is the most 
functionally  active  regarding  cytotoxicity,  cytokine  production  (IFNγ,  GM-SCF),  has  a 
greater proliferating potential and is the most migratory population responding to chemokine 
stimulation. Mac-1
hi 
but not Mac-1
lo 
expressing NK cells from bone marrow, spleen and liver 
produce IFNγ in response to cytokine stimulation (62, 66). The most mature NK cell 
population, CD27
lo
Mac-1
hi
, has an increased expression level of the self-specific inhibitory 
receptors Ly49C/I and KLRG-1 (an inhibitory receptor expressed on fully mature NK cells, 
for description see below) compared to cells from the other developmental stages. These fully 
mature NK cells have a low functional level e g poor cytokine production capacity, almost no 
cytotoxic function, low or no chemotactic activity and reduced proliferation. Hayakawa et al. 
speculate that the most mature NK cells may represent a long lived/senescent NK cell 
population due to the reduced proliferation (65). NK cell subsets based on CD27Mac-1 
expression also display different tissue distribution. Spleen and liver contain all maturation 
steps while the bone marrow and lymph nodes contain mainly immature and DP cells and the 
blood and lungs are mainly sources for fully mature NK cells. 
 
1.3.5  Innate lymphoid cells 
 
During the last years of research, a new branch of the innate immune system has been 
characterized, the innate lymphoid cells (ILCs) which earlier only comprised NK cells 
(reviewed in (71-73)). The innate lymphoid cells differentiate from a common lymphoid 
progenitor (CPL) in an IL-2 dependent manner and none of them express an antigen specific 
receptor. There are multiple systems suggested for how to group ILCs. According to the 
classification system by Diefenbach et al., there are four subgroups of ILCs; cytotoxic ILCs 
(NK  cells)  and  cytokine  producing  ILCs  (ILC1-3).  ILCs  are  mostly  located  at  barrier 
surfaces, such as in the interface of the intestine, were they protecting us from pathogen 
invasion. The innate lymphoid cells differentiate from a common lymphoid progenitor (CLP) 
(like T cell, B cells and NK cells) in an IL-2 dependent manner. It has been suggested that the 
ILCs develop from a common innate lymphoid progenitor (CILP), an intermediate step 
between CLP and pre-NKP/NKP (see fig 1). The subgroups of ILC1-3 are divided due to 
their  developmental  requirements  (expression  of  transcription  factors)  and  their  mature 
effector  functions.    ILC1  is  defined  as  NKp46
+
NK1.1
+
cells,  produce  IFNγ  (enhancing 
response against intracellular bacteria) and are found preferentially in the small intestine and 
liver. ILC2 express the IL-7 receptor, the IL-2 high affinity receptor CD25 and can stimulate 
a Th2 response by production of type 2 cytokines e g IL-4, -5, -9 and -13. ILC3 consists of 
many cell populations which express the transcription factor RoRγt, but differ in NKp46 
expression. A population of both ILC2 and ILC3 have the possibility to regulate T cell 
responses, ILC2 have a direct and indirect effect on TH2 responses via expression of MHC II 
molecules and via production of type 2 cytokine while the ILC3 can induce T cell anergy by 
expression of MHC II without any additional co-stimulatory receptors. In addition ILC3 can 
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produce several cytokines such as IL-17 and -22, and are important in immunity against 
extracellular bacteria. A recent study by T Kim et al. showed that the RoRγt+ ILCs are 
important for creating a good stromal environment participating in the development and 
function (e g elimination by RMA-S in vivo) of NK cells (74). 
 
1.4   NK CELL RECOGNITION: MAJOR HISTOCOMPATIBILITY COMPLEX 
 
NK cells express activating and inhibitory receptors. Both categories include receptors that 
bind MHC I and receptors that bind to other ligands (75). Inhibitory NK cell receptors carry 
intracellular signaling motifs (immunoreceptor tyrosine based inhibitory motif, ITIMs), that 
transfer the inhibitory signal into the cell. The activating receptors lack intrinsic signaling 
motifs and depend on association with transmembrane adaptor proteins such as DAP12 and 
DAP10. These adaptor proteins carry different signaling motifs in their intracellular parts and 
transfer the activating signals into the cell. In the early 90’s the first MHC I specific receptor 
(Ly49A) and the NK cell gene complex (NKC) located on chromosome 6 were discovered in 
mice by Yokoyama and colleges (8, 76). NKC codes for many NK cell receptors, including 
the main receptor families Ly49 and NKR-P1 (8, 76).The molecules of the largest NK cell 
receptor family in mice, C-type lectin-like Ly49 receptors, recognize different alleles of 
MHC I (77). Both of these receptor families are type II transmembrane glycoproteins that 
belong to the C type lectin-like family. 
 
There is an extensive homology between the extracellular domains of the different Ly49 
receptors, e g almost 90% homology between the inhibitory Ly49A and the activating Ly49D 
receptor (both recognizing H-2D
d
; hereafter referred to as D
d
). However, they still interact 
differently with the D
d  
molecule (75). The main difference between activating and inhibitory 
receptors  is  in  the  intracellular  signaling  part  where  the  former  signal  via  the  adaptor 
molecule DAP-12 (via immunoreceptor tyrosine based activating motifs, ITAM) and the 
latter via ITIM (see below). The receptor family mediating the corresponding function in 
humans is the killer immunoglobulin-like receptors (KIR) which also contain both activating 
and inhibitory family members. This family can also be divided in two groups of receptors 
which differ in their cytoplasmic tail, short or long, and for which signaling is mediated via 
DAP12 or ITIM respectively (75b). 
 
To be able to understand how the NK cell function and responsiveness are influenced by 
MHC I interactions, the MHC will be briefly discussed with focus on parts important for this 
thesis. The major histocompatibility complex (MHC) is called histocompatibility-2 (H-2) in 
mouse and human leukocyte antigen (HLA) in humans. It contains three sets of genes; class I, 
II and III, and is located on chromosome 17 in the mouse and 6 in the human. Mice have two 
or three MHC Ia loci; K, D and some strains also express L. The equivalent genes in humans 
are; HLA-A, -B and –C. Examples of non-classical MHC Ib genes in the mouse are Qa-1b 
and in human HLA-G, -E and MICA and B. MHC I molecules are expressed on almost all 
cell types at various levels and presents mainly intracellularly derived peptides for cytotoxic 
T cells while MHC II is expressed on antigen presenting cells such as dendritic cells and B 
cells (upon activation) and their major task is to present extracellular peptides to T helper 
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cells. MHC I is subdivided into class Ia and Ib where Ia is called classical and Ib is called 
non-classical MHC I; both subclasses are important for NK cell education and proper 
function. 
 
The MHC I molecule is composed of one membrane anchored α-chain that non-covalently 
associates with shorter β2-microglobulin (β2m) subunit encoded outside of the MHC complex 
(on chromosome 3 in mouse and 12 in human). For a MHC I molecule to be presented on the 
cell surface the α-chain needs to be associated with a β-chain and the complete molecules has 
to be loaded with a peptide. Cells lacking the β-chain express only very low levels of unstable 
MHC I molecules. MHC I molecules are loaded mainly with peptides from intracellular 
proteins which are transported from the cytoplasm into the endoplasmatic reticulum (where 
the MHC I molecule is assembled) by the protein transporter associated with antigen 
processing (TAP). Cells deficient for TAP, such as the RMA-S line used in this thesis, also 
express low levels of MHC I. 
 
MHC is one of the most polymorphic chromosome regions leading to an enormous variation 
between individuals. This variation increases the number of antigen peptides that can be 
presented at the population level, resulting in a higher chance that the species will survive 
infections with different pathogens. Different inbreed mouse strains carry different MHC 
haplotypes (genotypes). This makes it possible to study influence of allelic variation with 
known differences. For this thesis, mice carrying different genotypes for MHC I have been 
used (Table 1). 
 
Other molecules related to MHC molecules but not encoded in the in the MHC region are the 
CD1 molecules. The CD1 family molecules, as MHC I, associate with β-chain but present 
glycolipids for NKT cells, T cells with a invariant T cell receptor and expression of some NK 
cell markers. 
 
 
Table 1. Mouse strains, MHC I molecules and Ly49r relevant for this thesis 
 
Mouse strain 
 
Haplotype/ molecules expressed 
 
Educating receptor 
 
B6 H-2
b
; K
b 
and D
b
 
 
Ly49C and I 
 
IMSR (B6) H-2
b
; K
b 
and D
b
 
 
Ly49C and I 
β2m
-/- 
and TAP 
-/-
 H-2
b
; low levels expressed 
 
(Ly49C and I) 
K
b 
single H-2
b
; K
b
 
 
Ly49C and I 
D
d 
single H-2
b
; D
d
 
 
Ly49A, and G2, 
 
D8 H-2
b
; K
b
, D
b 
and transgenic D
d
 
 
Ly49A, G2, C and I 
 
129 H-2
b
; K
b 
and D
b
 
 
Ly49I (V and O)* 
 
*Tetramer binding has been demonstrated but if they are also educating is unknown. 
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1.5   NK CELL RECOGNITION: RECEPTORS 
 
1.5.1  Inhibitory NK cell receptors 
 
1.5.1.1   Ly49, KIR and NKG2 families 
 
As mentioned above, activating and inhibitory Ly49 receptors belong to the C type lectin-like 
receptor family. The NK gene complex code for 8-18 different Ly49 genes, depending on 
mouse strain, with extensive allelic polymorphism (8, 78, 79). Most of the genetic studies 
were performed in B6 and 129 mice (80, 81). The 129 and B6 mice (used as wild type, wt, in 
many studies) share some genes and alleles but they also possess strain specific genes. Some 
alleles have occurred through duplication (79). The B6 genome codes for ten Ly49 receptors, 
eight of which are inhibitory, Ly49A,-B, -C, -E, -F, -G2, -I, and –J. Two of these genes 
encode for activating receptors, Ly49D and –H, which are described in the next section (82, 
83). All receptors are not expressed on all NK cells, the Ly49 genes are expressed 
independently of each other on different subpopulations of NK cells in an overlapping 
fashion, creating a diversified NK cell repertoire (84, 85). The inhibitory receptor consists of 
two  disulfide-linked  homodimers,  each  with  a  cytoplasmic  tail  containing  ITIMs  that 
transfers the signal in to the cell (77). The best characterized inhibitory Ly49 receptors are 
Ly49A and Ly49G2) both binding to D
d
, and Ly49C, binding to K
b  
(86, 87). A number of 
studies have addressed how Ly49r bind to MHC I and to which allele(s) each receptor binds. 
Hanke et al. studied Ly49r specificity using cell-cell adhesion assays in combination with 
MHC I/peptide tetramer staining (88). Only Ly49C and -I interacted with H2
b 
products while 
five Ly49r bound to H2
d  
products, including Ly49A and G2  which is of importance in this 
thesis. However, there are conflicting data regarding whether Ly49A can bind also to K
b 
(88- 
90). 
 
In humans, the highly polymorphic killer cell immunoglobulin like receptor (KIR) family 
encodes monomeric receptors recognizing MHC I. The activating KIRs have a short (S) 
cytoplasmic tail while the inhibitory have a long (L) cytoplasmic tails (containing 2 ITIM 
motifs), which is reflected in the terminology, e g KIR2DS1 or KIR2DL1. These receptors 
are completely lacking in mice while only one Ly49 pseudogene has been found in humans 
(33, 91, 92). 
 
Different inhibitory Ly49r and KIRs recognize different MHC I alleles, making it possible for 
certain NK cells to react on down-modulation of one specific MHC I molecule in missing self 
recognition (see discussion below) (82, 88, 93-95). In order to recognize and bind to MHC I 
molecules, Ly49 receptors require that a peptide is bound in the MHC I pocket inducing the 
correct conformational structure (96). Ly49 receptors are not peptide specific in the same way 
as the T cell receptor but there are data suggesting that some Ly49r can display selectivity, i e 
some peptides are non-permissive for K
b  
recognition by Ly49C and I (89, 96, 97).The 
binding affinity of Ly49 to MHC I molecules may be influenced by carbohydrates on the 
MHC molecules, but this probably does not alter the binding specificity (98, 99) 
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CD94/NKG2A, which also belongs to the C-type lectin like family, represents a third type of 
receptor recognizing MHC I molecules. The CD94 and NKG2 genes are genetically linked 
and are expressed both in mice and humans (100-104).  Both the murine and human genome 
contain several genes for NKG2 receptors, A, C and E in mice and A, C, E and F in humans, 
but only NKG2A is coding for an inhibitory receptor (101, 103-107). The CD94 molecule 
can be expressed as a homodimer, without the capability to bind Qa-1 or HLA-E or mediate 
intracellular signaling, or together with a NKG2 molecule (104, 108). CD94/NKG2A is a 
disulfide-linked heterodimer with allelic variation (109-111). The NKG2A receptor monitors 
the MHC I expression by binding non-classical MHC I molecules, Qa-1 and HLA-E (102, 
108, 112, 113) in mice and humans respectively. Qa-1 and HLA-E present peptides from the 
leader sequence from some but not all MHC I alleles in a TAP-dependent manner (114, 115). 
In wild type (wt) B6 mice, Qa-1 presents peptides derived from D
b 
but not from K
b
. 
CD94/NKG2A presents a second layer of MHC I recognition. Why has evolution preserved 
two modes of inhibitory MHC I recognition? It could be that CD94/NKG2A can sense only a 
broader loss of MHC I since it can bind to leader sequences from several MHC I molecules, 
while Ly49r can sense a delicate change in MHC I expression where only one out of several 
MHC I is down-regulated. Both alternatives have been observed in different unhealthy 
settings, e g in certain viral infections or by tumors, indicating a requirement for both. The 
NKG2A system might have evolved first, but it was not enough and therefore an extra layer 
of surveillance was added. However, in the B6 mice the Qa-1-NKG2A system is the only 
system surveilling loss of the D
b 
MHC I molecule since no Ly49r bind strongly to D
b 
in the 
B6 mice (88). 
 
NK cells also express inhibitory receptors recognizing other ligands than MHC I ligands. The 
NKC on chromosome 6 contains genes coding for three receptor families of C-type lectin- 
like transmembrane glycoproteins, Ly49r and NKG2/CD94 described above and the NKR-P1 
gene family (9, 81, 116, 117) The NKR-P1 family is polymorphic and in B6 mice, it consists 
of NKR-P1A , -C, - B/D and –F. Only the NKR-P1A gene has been found in humans (118- 
123). Other mouse strains encode for additional NKRs. The B6 strain code for NKR-P1B
B6
 
(or sometimes referred to as NKR-P1D) (124). (120). Both NKR-P1B and-D are inhibitory 
and recognizes Ocil/Clr-b, which is also a C-type lectin-like transmembrane glycoprotein 
encoded in the NKC. It is expressed on a wide array of hematopoietic cells: myeloid cells, T, 
B and NK cells but not on erythrocytes (121, 122, 125). There have been speculations 
regarding the importance of the NKR-ligand interaction as an additional MHC independent 
missing self system, see section 1.9.3 . 
 
1.5.1.2   KLRG1 
 
KLRG1, Killer cell lectin like receptor 1, is expressed on murine and human NK cells and on 
activated T cells (126, 127). In the mouse, KLRG1 belongs to the family of C-type lectin like 
receptors encoded on the same chromosome but distal to the NK cell gene complex 
containing the Ly49r and NKR-P1 receptors. It is expressed as a monodimer that can use 
disulfide bonds to create di-, tri- and tetramers on approximately 30-50% of the NK cells 
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(128, 129). In NK cell biology, KLRG1 is considered a maturation marker since it is 
expressed on fully mature, CD27
lo
Mac-1
hi 
NK cells, which are less cytotoxic and less prone 
to proliferate, but respond to cytokine stimulation with e g IFNγ production. However, 
KLRG1 is not needed for normal NK cell development and maturation (66, 130) . KLRG1 
can be acquired upon homeostatic or virus induced proliferation (131, 132). KLRG1 binds to 
classical cadherins (E, N and R) which are expressed on epithelial cells and are used for cell- 
cell contacts. Cadherins are sometimes downregulated in tumors, possibly to avoid infiltration 
of immune cells (133). Early studies displayed contradictory results regarding the influence 
of KLRG1 on NK cell function. Gründemann et al. showed that target cells expressing high 
levels of E-Cadherin did not inhibit the killing of the target by IL-2 activated NK cells (133). 
On the other hand, other groups showed that blocking of KLRG1 restores killing of targets 
expressing  E-cadherin,  and  that  antibody  crosslinking  of  KLRG1  can  inhibit  IFNγ 
production, hence indicating an inhibitory function of KLRG1 (134, 135). Furthermore it has 
been reported that it signals via ITIMs recruiting SHIP-1 and SHP-2 upon phosphorylation 
(136). 
 
1.5.1.3   The SLAM family member 2B4 
 
The  murine  and  human  2B4  receptors  were  discovered  by  screening  of  monoclonal 
antibodies that would activate NK cells (137, 138). The 2B4 receptor belongs to the SLAM 
(signaling lymphocytic activation molecule) receptor family and is composed of two Ig-like 
domains and a cytoplasmic tail containing four specific signaling motifs (immunoreceptor 
tyrosine-based switch motif, ITSM) which defines the common signaling pathway used by 
the SLAM-receptor family (see section 1.7.4) (139, 140). 2B4 is expressed on almost all 
immature and mature NK cells, both in mice and humans, and it binds to CD48 which is 
constitutively expressed  on  all  hematopoietic cells  (137,  138,  141).The  SLAM  receptor 
family is mainly important in recognition of hematopoietic target cells which express their 
ligands (142). 
 
In mice, and maybe also in humans, 2B4 can mediate activating as well as and inhibitory 
signals. Some data indicate that it may be mainly inhibitory since blocking of 2B4 can lead to 
increased tumor control, and NK cells from 2B4 deficient mice have displayed increased 
function against CD48 expressing targets (137, 143). 
 
1.5.2  Cell surface molecules involved in NK cell activation 
 
One of the first discovered and most studied activating NK cell receptors is the low affinity 
receptor for IgG, the CD16 (FcγRIII) first described on mouse NK cells by Kumar and 
colleagues (39, 144). It is a glycoprotein belonging to the Ig superfamily. CD16 binds to the 
Fc part of antibodies and can thereby mediate ADCC. This is a function that connects the 
innate and adaptive immune system, since it allows the NK cells to kill target cells labeled for 
destruction by specific antibodies produced by B cells. This function is likely responsible for 
at least part of the effects when monoclonal antibodies against tumor cells are used in cancer 
treatment. 
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1.5.2.1   Activating NK cell receptors 
 
As mentioned above, the Ly49 receptor family also includes activating members, Ly49D and 
–H in B6 mice. The Ly49D receptor associate with DAP12, containing ITAM signaling 
motifs,  and is therefore capable of inducing cytotoxicity after antibody induced ligation or 
binding to its ligand D
d 
(145). Other activating Ly49r (not expressed in the B6 mouse) are, 
Ly49P and –W, which also interact with H-2d (146, 147). The Ly49H receptor expressed in 
B6 mice recognize the protein m157 expressed on cells infected with the murine 
cytomegalovirus (MCMV) (148-150). This protein is encoded in the virus genome and 
resembles MHC I in structure. It is possible that it has evolved as an immune evasion 
strategy, since the m157 also binds to the inhibitory Ly49I in other mouse strains such as 129 
mice. 
 
The NKR-P1 family introduced above also contains activating receptors (119, 120, 123). 
NKR-P1C is an activating receptor with yet no known ligand, but it’s recognized by the 
NK1.1 antibody and frequently used as a marker for NK cells in the B6 mouse strain. 
 
There is also a group of receptors that has mainly been studied in humans, the natural 
cytotoxic receptors (NCR). In humans this “family” consists of four members. NKp30, 
NKp46 and NKp80 are expressed on resting human NK cells while the fourth member, 
NKp44, is expressed only on a subset of NK cells upon IL-2 activation, as reviewed in (151). 
It has been reported that at least NKp30, NKp46 and NKp44 can trigger cytotoxicity against 
both tumor and virus infected cells (152). This effect is mediated through recognition of 
different ligands or epitopes; NKp30, NKp44 and NKp46 recognizes viral hemagglutinins 
from several virus strains but intracellular proteins are also recognized, such as HLA-B 
transcript 3 by NKp30 (153, 154) and reviewed in (155). NKp44 has been shown to bind to 
ligands that are up-regulated during HIV infection leading to lysis and spreading of the virus. 
 
Biassoni et al. discovered a new gene encoding for a murine homologue to the human NKp46 
and termed it MAR-1. It has later been renamed to NKp46 (156). It is the only NKR 
homologue found in mice so far. At least in mice, NKp46 is expressed early in NK cell 
development and it is present on almost all mature NK cells (156). (29). NKp46 is an 
activating receptor. (156). It is important for resistance against some viral infections and 
tumors, through binding to Hemgglutinins and unknown ligands respectively (154, 157). The 
third MHC I binding C-type lectin-like receptor family mainly contains activating receptors, 
the heterodimers CD94/C, -E (and in humans also –F) and the homodimer NKG2D. In mice 
and human, NKG2C (and –E in mice) associates with the intracellular adaptor molecule 
DAP-12 to mediate intracellular signaling (104, 158-160). NKG2D has been extensively 
studied. It recognizes molecules that are up-regulated on cells by stress and it is essential for 
resistance against some experimental cancers, through activation of NK cell mediated 
cytotoxicity (19, 161, 162). This activating receptor is expressed on almost all mouse and 
human NK cells and it is encoded by a non-polymorphic single gene (101, 163). NKG2D is 
distinct from the other NKG2 family members by several criteria, for example it is expressed 
as a homodimer. In mice, the NKG2D receptor exists in 2 isoforms, NKG2D-L (long) and 
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NKG2D-S (short). NKG2L is mainly associating with the adaptor molecule DAP-10 while 
the NKG2D-S isoform is transcribed after activation and can associate with both DAP-10 and 
DAP-12 (164, 165). It is thought that DAP-10 mainly mediates cytotoxicity while NKG2D 
DAP-12 signaling leads to both high cytotoxicity and cytokine production (166).  Human NK 
cells only express the NKG2D-L isotype which mediates both cytotoxicity and cytokine 
production by signaling through DAP-10 (167, 168). 
 
In mice, NKG2D recognize several glycoprotein as ligands; retinoic acid early inducible-1 
(Rae-1) isoforms α, β, γ, δ and ε, murine ULB-binding like transcript-1 (MULT1) and 
histocompatibility 60 (H60) (169-171). These ligands are induced by Toll like receptor 
signaling, virus infection or products generated via the heat shock and DNA damage pathway 
(in response to for example irradiation), leading to expression on many tumor cells, 
strengthening the relevance of NKG2D activation by cellular stress (172), reviewed in (173, 
174). 
 
In humans, NKG2D binds to ligands in a group of proteins called ULBP (up to six variants) 
and 2 ligands encoded by the MHC complex,  MHC I chain-related proteins A and B, MICA 
and MICB (175, 176). These ligands has also been shown to be up-regulated through the 
DNA damage and heat shock pathway upon cellular stress and cell transformation (reviewed 
in (177). 
 
NKG2D ligands, both in mice and human, have been found in a soluble form. The relevance 
of these is not totally clear, however recent studies in mice have shown that Rae-1g and 
Mult1 in soluble forms in certain situations can mediate an enhanced anti-tumor effect (171, 
178). 
 
 
1.5.2.2   Adhesion molecules and NK cell function 
 
In addition to the receptors discussed above, different adhesion molecules such as DNAM-1 
and LFA-1 are important in regulating NK cell functions. In mice, DNAM-1 (adhesion 
molecule and activation receptor DNAX accessory molecule 1) is expressed approximately 
on 50% of the NK cells and recognizes CD155 (Poliovirus Receptor, PVR) (386). DNAM-1 
is involved in regulating NK cell cytotoxicity against tumor and virally infected cells (179, 
180). In addition, the expression of DNAM-1 correlates with the NKs cell educational status, 
i e inhibitory input and responsiveness, implicating a role for DNAM-1 in NK cell education 
(181). LFA-1 (Leukocyte function-associate antigen-1) recognizes ICAM-1, -2 and -3. The 
latter are up-regulated on endothelial cells during the early inflammatory response, making it 
possible for the leukocyte to attach and “roll” as a first step for entering the infected tissue. 
LFA-1 is necessary for signaling through the activating co-stimulatory molecule DNAM-1. 
This was shown by using NK cells from patients with a deficient β1 integrin (leukocyte 
adhesion syndrome). These NK cells had deficient DNAM-1 mediated cytotoxicity that could 
be rescued by restoring the LFA-1 cell surface expression by genetic reconstitution. 
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1.5.2.3   Activating receptors are used simultaneously in combination 
 
Many of the activating NK cell receptors have been suggested to be co-receptors since they 
need to be activated simultaneously with another type of receptor in order to lead to proper 
activation for cytotoxicity and cytokine production in resting cells (182). Human resting NK 
cells have a restricted regulation of their activation compared to IL-2 pre-activated NK cells. 
In experiments with IL-2 activated human NK cells all receptors tested (CD16, NKp46, 
NKG2D, 2B4 and DNAM-1) could induce in vitro cytotoxicity independently of other 
receptors.  Resting  NK  cells  on  the  other  hand  required  co-signaling  through  pairs  of 
activating receptors to induce cytotoxicity or cytokine secretion. It was observed that the 
activating receptors synergize in different constellations, i e most of them did not enhance 
function of all of the other receptors. (182-184). No receptor tested in the study could by itself 
induce NK cell response, with exception of the CD16 receptor. Bryceson et al. suggested the 
term co-activation receptors to describe these receptors that can only function in synergistic 
pairs. 
 
1.6   NK CELLS AND TARGET CELL ELIMINATION 
 
When an NK cell meets a potential target the contact surface that is formed between the two 
cells is called the immune synapse. This formation facilitates receptor interaction and 
signaling. If the NK cell decides to eliminate the target a lytic hit will occur in the synapse, 
mediated by release of cytotoxic granules containing perforin and granzymes. When a 
cytotoxic granule is released from the NK cell to the interaction interface, the vesicle and 
plasma membrane fuse, leading to exposition of molecules on the NK cell surface, including 
lysosomal- associated membrane protein-1 (LAMP-1). LAMP-1 (CD107a) is often used as a 
marker of NK cell mediated degranulation in different functional assays (185). 
 
1.7   NK RECEPTOR SIGNALING PATHWAYS 
 
1.7.1  Activating receptor signaling pathways 
 
In this section I will present an overview of the signaling pathways mentioning some of the 
main players and principles, reviewed in (166, 186-189). 
 
The majority of the activating receptors (such as Ly49r, CD16, NKR-P1C and NKp46) need 
to associate with adaptor molecules to be stably expressed and to be able to signal. All 
receptors do not associate with all adaptor molecules. The adaptor molecules DAP12, CD3 
and FcεRI-γ contain ITAMs in their cytoplasmic tail. Upon activation and receptor 
crosslinking, the two tyrosines (Y) in the ITAM motif (YxxL-x6-8-YxxL) become 
phosphorylated by Src family kinases (Fyn, Lck, Src, Yes, Lyn and Fgr), and act as docking 
sites for Syk family kinases (manily Syk but also Zap70). Activation of Syk family kinases 
lead to triggering of downstream signaling via phosphatidylinositol-3-OH kinase (PI3K) and 
Vav-2/3, phospholipase C-γ PLCγ (PLCγ-1 and 2) and the adaptor protein growth factor 
receptor-bound protein 2 (Grb2). Activating signaling results in proliferation, cytokine and 
chemokine production and cytoskeleton rearrangements needed for cytotoxic granule release. 
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NKG2D preferentially associates with DAP10 carrying a different signaling motif, YINM 
(YxxM). It has been suggested that DAP-10 signaling is initiated by phosphorylation via 
either Src family kinases or by the kinase Jak3. After phosphorylation, the short cytoplasmic 
tail of DAP-10, containing one signaling motif, can recruit two signaling molecules; (Grb2) 
and the phosphatidylinositol-3-OH kinase (PI3K) via the binding site p85. Signaling through 
both molecules are needed for full activation (maximal Ca
+  
influx) but since their binding 
sites overlap only one of them can bind at the time. Only the Grb2 pathway (via Vav-1) can 
by itself trigger cytotoxicity. Studies using mutations in the different binding sites for Grb2 
and p85 has led to the conclusion that Grb2 signals through vav-1, SLP-76 and PLC-γ2. 
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Figure 2, Activating NK cell signaling described in 1.7.1 and 2 
 
 
 
 
1.7.2  DNAM-1 and LFA-1 signaling 
 
An interesting signaling pathway involves the DNAM-1/LFA-1 constellation. When the 
DNAM-1 receptor is activated by crosslinking, it is recruited to lipid rafts and tightly bound 
to the cytoskeleton in the immune synapse (190). Crosslinking also induces phosphorylation 
of the intracellular domain by protein kinase C (PKC) which makes it possible for DNAM-1 
to associate with LFA-1 (191, 192). The DNAM-1-LFA-1 association is necessary for 
DNAM-1 signaling; there is reduced DNAM-1 cytotoxicity in patients with leukocyte 
adhesion deficiency syndrome (191). After association LFA-1 recruits the Src kinase Fyn that 
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helps to phosphorylate another binding site on DNAM-1 leading to signaling via SLP-76, 
Vav-1 and PLCγ2. It has been speculated whether DNAM-1 may be involved in the synapse 
formation since it binds both to the cytoskeleton and the adhesion molecule LFA-1. 
 
1.7.3  Inhibitory receptor signaling pathways 
 
The largest families of inhibitory receptors in mice and humans are the Ly49 and KIR 
families respectively, reviewed in (166, 186, 193). Ly49 receptors mediate their inhibitory 
signal by being within a close distance to the activating receptor signaling molecules. 
Crosslinking of the inhibitory receptors themselves leads to weak phosphorylation (activation 
of the signaling motif) while simultaneous crosslinking of inhibitory receptors and activating 
receptors lead to a higher degree of phosphorylation. Phosphorylation of ITIMs 
(V/IxYxxL/V) is probably dependent on Src family kinases. Phosphorylated ITIMs on Ly49r 
serve as a docking site for two SH2 domain containing protein tyrosine phosphatases 
(deactivators), SHP-1 and SHP-2, (194) but can also recruit the lipid phosphatase SHIP- 
1(166). Ly49r preferentially associate with SHP-1/SHP-2 while KLRG1 mainly recruits 
SHIP-1 (136). After recruitment of phosphatases to ITIM motifs, they may inhibit NK cell 
effector function and proliferation via dephosphorylation of proteins important in NK cell 
activation. Vav-1 has been shown to be one of the main targets for dephosphorylation since it 
is a key component in many activating signaling pathways. Further, ITIM mediated inhibition 
in human NK cell results in two separate inhibitory mechanisms 1) SHP-1 targeting Vav1 for 
dephosphorylation  and  2)  tyrosine  phosphorylation  of  Crk  (195).  Crk  in  complex  with 
another molecule are involved in actin organization in the synapse. There are speculations 
regarding if this phosphorylation and loss of complex formation might lead to reduced actin 
synapse formation. 
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Figure 3, inhibitory NK cell receptor signaling described in 1.7. 3-4 
 
 
1.7.4  The SLAM family member 2B4; activating or inhibitory? 
 
2B4, like other SLAM family members, has four tyrosine-based ITSM in its cytoplasmic tail 
and can mediate both activating and inhibitory function. 2B4 can recruit several signaling 
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molecules that belong to the SLAM-associated protein family (SAP) and contain a SH2 
domain. In mice, three different signaling molecule recognize the ITSM: SAP, EAT-2 
(Ewing´s sarcoma-activated transcript-2) and ERT (EAT-2 related transducer), although ERT 
has been shown to only be expressed in cytokine activated NK cells (196, 197). There are 
conflicting data regarding when 2B4 has an activating or inhibitory function and how this 
process is regulated in mice. Further, human 2B4 is thought to be mainly activating and 
express only SAP and EAT-2 (183). 
 
There are data showing that both SAP and EAT-2 can promote activation in two ways; by 
further activate the signaling cascade and by blocking the access for inhibitory signaling 
molecules (SHIP-1) to bind to the cytoplasmic tail and thereby initiating inhibition (196, 
198). Upon 2B4 ligation, ITSM becomes phosphorylated probably by a Src kinase which 
enables recruitment of SAP and/or EAT-2. SAP recruits Src family protein tyrosine kinase 
Fyn (via SH3 domain binding to SAP via an arginine at position 78 (SAP-78). Activation of 
Fyn leads to phosphorylation of Vav-1. Activation of SAP is important for increased 
conjugate formation,  cytotoxicity and  cytokine production  (142,  198).  However,  EAT-2 
mediate activation via PLCγ2 and Ca+  signaling to accelerate polarization and release of 
cytotoxic granules (196). 
 
There are data showing both inhibitory and activating functions of 2B4. Chlewicki et al. 
showed that loss of 2B4 signaling, either via blocking or in KO mice, leads to increased 
elimination of target (RMA-S CD48
+
) cells and increased IFNγ production (199). However, 
Dong et al. and Pérez-Quintero et al. have shown that the different functions of 2B4 depend 
on if the target is of hematopoietic origin or not, that lack of functional SAP or EAT-2 leads 
to reduced killing (of CD48
+ 
targets) and IFNγ response compared to wt NK cells (142, 196, 
198) 
 
Chlewicki et al. proposed a dual regulatory function of 2B4, in both mouse and men, and that 
the outcome is determined by several factors: receptor expression, level of crosslinking and 
the amount of available adaptor molecules (SAP) (199). Data indicated that SAP may be the 
limiting and controlling factor in the system. The authors speculated that if there is too much 
crosslinking of 2B4, there will not be enough SAP to bind and block 2B4 interaction with 
negatively signaling adaptors ( SHIP-1), mediating an inhibitory signal. This would function 
as a mechanism to protect healthy cells expressing CD48 from elimination. Loss of 2B4- 
CD48 interaction has been observed to result in NK cell dependent in vivo and in vitro killing 
of syngeneic NK cells (200). A recent study provided evidence for 2B4 expression on many 
dendritic cell (DC) subtypes and that the 2B4-CD48 interaction between DC-NK cells 
influences the NK cell activity. DC from 2B4 KO mice induced a higher in vitro 
responsiveness upon co-culture (201). 
 
As will be discussed later in this thesis, NK cells may adapt to “abnormal” signaling input in 
various knockout mice by retuning of their activation threshold. Interpreting results from 
knockout mice may thus be very difficult. How deficiencies in some of these molecules, 
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important in activation or inhibitory pathways, affect the NK cell pool and functions will be 
further discussed in the results and discussion section in relation to the IMSR mice. 
 
1.8   LY49 NK CELL RECEPTOR REPERTOIRE FORMATION 
 
1.8.1  General pattern of Ly49r expression 
 
As mentioned above, mice carry eight or more Ly49 genes (8, 78, 79). Each MHC I specific 
receptor, Ly49 and CD94/NKG2A, is expressed on individual NK cells in an overlapping, 
partly stochastic fashion. Thus, individual NK cells may express from zero to several Ly49 
receptors, the common range being one to five (84, 202-204). Different Ly49r recognize 
different MHC I alleles, but since the genes for receptors and ligands are located on separate 
chromosomes (6 vs 17) they are inherited independently. This means that individual NK cells 
can express receptors specific for non-self MHC I allele, and sometimes only such receptors, 
i e they lack receptors for self MHC I. The same principle is true for the human KIR receptor 
system (389) and as I will discuss below this has implications for the development and 
function of NK cells. Regarding receptors, their expression and importance for NK cell 
education, I will from hereon only discuss the murine system, since that is of highest 
relevance for this thesis. 
 
1.8.2  Ly49 receptor acquisition 
 
NK cells start to express the CD94/NKG2A receptor at development stage II (NK1.1
+
) and 
they proceed to express Ly49 inhibitory receptors at stage III (c-kit
+  αv  
+
). Once Ly49r 
become appear on the NK cell, the expression pattern is stable over time (62, 95, 205, 206). 
 
Little is known about the forces that drive the process of receptor acquisition. It has been 
shown in vitro that CD94/NKG2A expression can be achieved by differentiating NK cell 
progenitors by cytokine stimulation (207, 208), while initiation of Ly49 receptor expression 
needs additional undefined signals from interaction with bone marrow stromal cells (209). 
The critical signal for induction of expression of Ly49r is not known but IL-15 has been 
suggested to play a role. In one study of IL15 deficient mice, both the NK cell number and 
the Ly49 expression could be rescued by administration of exogenous IL-15 (210). On the 
other hand, there are data from two groups showing that NK cells development can still 
proceed in the absence of IL-15. Although these studies revealed that the NK cells from these 
mice are of a less mature phenotype (Mac-1
lo 
and CD43 
lo
), the NK cells had normal Ly49 
expression levels (Ly49A, -G2 and D) and effector functions (cytotoxicity and cytokine 
production) (61). 
 
1.8.3  Allelic expression of Ly49 genes 
 
As mentioned in the beginning of this section, MHC I specific receptors are expressed in a 
partly stochastic pattern. All individuals possess two alleles for each gene - one on each 
homologous chromosome. It has been shown for both Ly49A, -C and –G2, that in almost all 
NK cells, only one of the two alleles is expressed (211, 212). This was first observed by Held 
et al. who initially termed this process “allelic exclusion” (213).   They showed that the 
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process did not involve termination the expression of all Ly49 alleles on the same 
chromosome, it was rather affecting each locus independently (213). Among NK cells 
expressing only one Ly49A allele, the frequency of the allelic expression was divided equally 
between the two chromosomes. In addition, it was also seen that expression from both alleles 
could occur (for Ly49A and G2 but not for C), and that the frequency of the bi-allelic 
expressing cells was close to the frequency obtained by multiplying the mono-allelic 
frequency. Held et al. suggested two models for how this can occur: 1) “independent control” 
meaning that this process could be regulated by several “trans-acting factors”, each regulating 
the expression of a separate Ly49 gene, and every “trans-acting factor” would be active 
during a limited time frame in the sequential order of receptor acquisition or 2) “competitive 
control”, all genes are controlled by the same set of factors but some/one of these “trans- 
acting factors” could be in limited access leading to competition accounting for that only one 
allele is expressed. The ordered expression (to be further discussed below) could be due to 
that different Ly49 genes are only available during a limited time period due to differences in 
their promoters (213). 
 
The second model would result in lower levels of the Ly49 receptors compared to unlimited 
access of regulatory factors. This has been shown for Ly49A, for which the level of 
expression depends on the transcription factor TCF-1. In mice heterozygous for TCF-1, the 
NK cells display approximately a 50% reduction in Ly49A expression compared to TCF-1 
homozygous mice, indicating that the transcription factor is the limiting factor (214). Further, 
TCF-1 deficient mice have alterations in their Ly49r defined NK cell repertoire in a MHC I 
independent manner. TCF-1 seems to activate transcription of  Ly49A and –D (reduced 
expression in TCF-1 β2m
-/-  
mice) while suppressing expression of Ly49G2 and –I, leaving 
Ly49C unaffected (214, 215). 
 
It is still unknown if there is monoallelic expression and if so which mechanism(s) control it. 
The “competitive control” hypothesis fits best with the additional discoveries that have been 
made. There is an emerging field studying different promotors, bi-directional transcription 
and if there is any common transcriptional factor used at low level to ensure monoallelic and 
reduced Ly49r expression but no such TF has been found. However, it has been shown that 
the expression pattern is depending on multiple promoter regions of which some are 
bidirectional. Independent of underlying cause, epigenetic mechanisms such as DNA 
methylation has been shown to preserve the established monoallelic expression (216). An 
interesting finding is that monoallelic expression might be influenced by MHC I expression 
(217). It is not known if this leads to important functional consequences, however it is of 
interest if MHC I has a third effect on the NK cell pool. 
 
1.8.4  Ordered and stable Ly49 gene expression 
 
Regardless of the mechanisms activating the expression of Ly49r, there is evidence that the 
different loci become expressed in an ordered fashion. To study this, two different approaches 
were used with slightly different but not necessarily conflicting outcomes. Early transfer and 
in vitro (stroma cell culture) experiments showed that CD3
-
NK1.1
+ 
NK cells could generate 
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Ly49G2,-C/I and -F expressing NK cells, in that order, while Ly49A expression was only 
observed when CD3
-
NK1.1
- 
precursors were used, indicating that Ly49A commitment 
occurred before NK1.1 expression (205, 209). Ly49 receptors were thus expressed in the 
order of Ly49A-Ly49G2-Ly49C/I. Two models were suggested to explain this; 1) either the 
genes are expressed individually in a sequential fashion starting with expression of only 
Ly49A and then proceeding as stated above or 2) initially all genes are on, but their 
expression is terminated in an ordered way, losing the ability to express Ly49A first and in 
the end genes for only Ly49C/I can be activated. 
 
In the second approach, RT-PCR of RNA was used to identify the kinetics of Ly49 receptor 
expression on NK cells in in vitro culture (84). The result from this study showed that 
receptors could be detected in “sets”. The first set is CD94, -NKG2A, -C and Ly49B, 
expressed in all analyzed NK cell clones. This group was followed by early Ly49r, Ly49G2 
already at day 4 and Ly49C/I begun to be expressed at day 4-7. The group of Ly49A, -D, -E 
and –F was observed later, at day 21. So, here the expression order was Ly49G2, Ly49C/I 
and ending with Ly49A, different from the results reviewed above (84). Analyses of gene 
expression of NK cells in late cultures revealed that some clones expressed for example 
Ly49D but not Ly49C or –I indicating that all genes are not expressed at the same time (84). 
This approach is more a direct study on the actual gene expression, so it is possible that the 
Ly49 genes are transcribed in a different order compared to the order of cell surface 
expression. 
 
In addition to the knowledge regarding the ordered pattern of inhibitory Ly49 receptor 
expression, Smyth et al. showed that Ly49H and -D are expressed after inhibitory Ly49r 
expression in a non-random fashion e g they are often co-expressed and even at a higher 
frequency on NKG2A negative cells (218). 
 
Regardless of order of expression or mechanisms controlling activation of NKG2A and 
specific alleles of Ly49 receptors, several studies have shown that once a gene/allele for 
receptor expression is activated the expression of that receptor is stable over time. This has 
been shown both in vivo in the periphery after transfer (both NKG2D and Ly49r) and in vitro 
in IL-2 cultures (Ly49r) (95, 205, 206, 219). The regulation of Ly49 transcription has still not 
been thoroughly elucidated, but a complex regulation system is emerging, involving multiple 
promoter regions of which some are bidirectional, as well as epigenetic mechanisms to 
maintain expression (220). 
 
1.9 MHC I REGULATED NK CELL EDUCATION; A PROCESS WITH AT LEAST 
TWO CONSEQUENCES 
 
It is now established that MHC I molecules of the host influence the NK cell pool in at least 
two different ways: 1) by shaping the NK cell repertoire such that NK cell subsets expressing 
1-2 self-specific inhibitory receptors become overrepresented and 2) by determining the NK 
cell responsiveness at the single cell level. These processes are called repertoire skewing and 
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“licensing” or “arming/disarming” respectively. These two outcomes together represent 
combined NK cell education and will be discussed below. 
 
1.9.1  Skewing of the NK cell repertoire 
 
The first real evidence for host MHC I influence on the NK cell repertoire was published by 
Held et al. (221). I They compared Ly49A, C and G2 either expressed separately or in 
combination on spleen NK cells from H-2
d
, H-2
b 
and MHC I deficient mice. The major 
alterations in Ly49 receptor expression were found among the subsets expressing two or three 
receptors. NK cells from MHC I deficient mice had approximately a 3 fold higher fraction of 
cells co-expressing Ly49A/C or Ly49A/G2 compared to NK cells from H-2
d 
mice. A reduced 
number of single receptor-expressing NK cells were also observed, but it was not as 
pronounced. These early data suggested that there is an MHC I-dependent process specific 
for sharpening the self-specific inhibitory receptor repertoire which disfavors multiple 
receptor expressing cells (thereby decrease the average no of Ly49 receptors/cell). This 
phenomena is called “skewing of the NK cell repertoire”, where repertoire refers to the 
different NK cell subsets expressing 0-5 inhibitory receptors (204, 221). It should be noted 
that this was at the time studied with limited antibody panels. Today, it is possible to do a 
more complete analysis with slightly different or at least refined conclusions, as discussed 
below. 
 
This general pattern was confirmed by Salcedo et al. studying Ly49A, -C and -G2. They 
observed a reduction of each respective Ly49r in the presence of its cognate MHC I ligand 
(222). An interesting finding in this paper was that very limited amount of MHC I expressed 
on TAP-deficient (both MHC I deficient) was sufficient to introduce skewing of the NK cell 
repertoire. This was shown by a higher frequency of Ly49C expressing cells in NK cells from 
β2m-deficient mice compared with TAP-deficient mice (TAP
-/- 
have a slightly higher MHC I 
expression then β2m
-/-
). 
 
To explain how repertoire skewing could appear, the Raulet group postulated 2 models; “the 
two step selection model” and the “sequential model”. Both these models are built around the 
theory that each NK cell must express at least one self-specific inhibitory receptor to ensure 
self-tolerance. However, it is now known that this assumption is incorrect since NK cells 
expressing no inhibitory receptor for self MHC I have been described.  Skewing may not be 
important for self-tolerance but both models in modified form can still explain the observed 
pattern. However, skewing may nevertheless be important to shape the NK cell repertoire, 
perhaps to ensure existence of sufficiently many NK cells that can selectively recognize lack 
of a specific MHC I allele. 
 
1.9.1.1   The selection model 
 
The selection model postulates that the Ly49 receptor expression starts with a stochastic 
process where each individual NK cell switches on expression of one or a number of 
inhibitory receptors, some being self-specific, others lacking a self MHC I ligand in the host. 
Each NK cell would then go through two steps of selection, similar to T cell selection, with a 
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positive selection step to secure that the NK cell recognize self MHC I by expressing at least 
one self-specific inhibitory receptor to achieve self-tolerance (for how self-tolerance is 
established see education section 1.9.2 ). The second selection step, negative selection, would 
eliminate cells with many self-inhibitory receptors, to ensure that the NK cell have a 
functional repertoire that can sense loss of MHC I alleles in an efficient way. 
 
1.9.1.2   The sequential model: 
 
The selection model suggests that the developing NK cell adds expression of one receptor at 
the time in a sequential, but random fashion. After each round (of new receptor expression) 
the NK cell tests the MHC I mediated inhibitory signal sensed on cells in the environment. If 
the signal is too weak or missing, the NK cell will be allowed to express additional Ly49 
receptor followed by a new signal control step. When the MHC I inhibitory interaction is 
strong enough the process is terminated. This theory would ensure self-tolerance since the 
cell would continue this process until at least one self-specific receptor is expressed and the 
co-expression of self-specific inhibitory receptors would be minimized due to prevention 
from expressing additional receptors. 
 
1.9.1.3   Comparison of the two models 
 
Several  studies  have  been  performed  to  establish  the  mechanism  that  controls  MHC  I 
dependent skewing of the repertoire. Held et al. used Ly49A transgenic mice expressed on H- 
2
d
, H-2
b 
and MHC-deficient background and studied expression of Ly49A, -G2 and -C (223). 
The major effect of the Ly49A transgene on expression was observed in the endogenous 
Ly49G2/A population where the expression was significantly reduced (~3 fold) in H-2
d 
mice, 
moderately reduced in H-2
b 
and unchanged in MHC I-deficient mice. All strains still showed 
Ly49G2/A co-expression and Ly49C expression was almost unaffected in all strains. Further, 
endogenous Ly49A RNA levels were reduced in H-2
d 
but not in MHC I deficient mice upon 
transgenic expression. These data are in favor of the selection model since the sequential 
model states that if strong inhibition is mediated all additional receptor acquisition will be 
stopped. The transgenic mice continued to express endogenous Ly49A and –G2 at reduced 
levels and Ly49C at almost normal levels which could be allowed in the selection model 
since Ly49C is a non-self-specific receptor in H-2
d 
mice. 
 
As described above, Williams et al. cultured NKPs on stromal cells to achieve Ly49 
expression and analyzed the gene expression profile (via PCR) of NK cells after 4, 7 and 21 
days in culture. This in vitro study showed that the Ly49 receptors were acquired in a 
sequential fashion and not all expressed at once.(84). 
 
Two in vivo studies showed evidence for regulation of the Ly49 receptor repertoire according 
to the sequential model using either transgenic mice or several mouse strains expressing 
different MHC I alleles. Fahlén et al. generated Ly49A, -C and Ly49A/C transgenic mouse 
strains on several H-2 backgrounds. The most clear cut data were obtained in the Ly49C 
transgenic mice on H-2
b 
background (224).  Ly49G2, -D and A were all down-regulated on 
NK cells in these mice despite lack of ligands for Ly49G2 and-D and presence of only a 
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weak Ly49A ligand in these mice. These results are consistent with a sequential model since 
the total receptor expression is reduced while, according to the selection model, non-self- 
specific inhibitory receptors would be allowed at a normal frequency. 
 
Hanke et al. studied co-expression of the NK cell Ly49 receptor on NK cells from eight 
congenic mouse strains in correlation to MHC class deficient mice (225). This study is one of 
the first analyzing several Ly49 receptors separately, which was possible due to the 
development of monoclonal antibodies specific for Ly49I and -F. The results indicated that 
all MHC I alleles examined, have an impact and influence the skewing of the NK cell 
repertoire. Co-expression was reduced even in the presence of MHC I ligand for only one of 
the receptors, favoring the sequential model for repertoire skewing. 
 
More recent studies have been performed by members of our group. In the first, two in silico 
models were developed; one to simulate the two-step selection model and one for the 
sequential model. The models were designed to simulate receptor repertoire formation in four 
different single MHC I gene expressing mouse strains; K
b
, D
b
, D
d 
and L
d
. The results were 
fitted to expression of Ly49A, -C, -G2 and -I in MHC I deficient mice and modeled for three 
of these receptors at a time (226). The data were then compared with actual expression of 
receptors on NK cells from these mouse strains, as determined by antibody staining and 
analysis by flow cytometry. The data confirmed that Ly49AG2 co-expression was reduced in 
in D
d 
and L
d 
mice but not in K
b 
and D
b 
mice lacking the ligand for these receptors. 
Interestingly it was found that the fraction of NK cells expressing a single self-specific 
inhibitory receptor was increased. When the experimental data was compared with the 
probabilities generated in silico, the modeling according to the two-step selection model 
predicted the outcome with a higher score. 
 
Brodin et al. generated single MHC I hemizygous and homozygous D
d 
single transgenic mice 
where the former expressed approximately 50% of the D
d 
levels observed in the latter.  The 
increase in D
d  
levels resulted in ~50% reduction of Ly49Asp (single positive, negative for 
Ly49C, -G2, -I and NKG2A) indicating an MHC I dose dependent regulation of the Ly49 
receptor expression (204). All other receptors were expressed at the same level in both 
transgenic mice. Furthermore, the expression of D
d 
skewed the NK cell repertoire by 
enriching for NK cell subsets expressing one to two self-specific receptors (but negative for 
all the other receptors) while reducing the frequency of NK cells expressing three-five self- 
specific inhibitory receptors in comparison to NK cells from MHC I deficient mice. The 
Ly49Asp NK cells showed an MHC I dose dependent reduction in apoptosis and increased 
sensitivity to cytokine stimulation compared to MHC I deficient mice. 
 
The study also provided information on MHC dependent influence on NK cells expressing 
the activating Ly49D receptor, also recognizing the D
d 
molecule. NK cells expressing Ly49D 
without any additional inhibitory MHC receptors are thus potentially autoreactive in D
d 
mice. 
Ly49D single positive cells (negative for inhibitory Ly49r and NKG2D) had an increased 
frequency of staining positive for the apoptotic marker Annexin V compared to MHC I 
deficient mice. This suggested that apoptosis could be the mechanism to eliminate potentially 
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self-reactive  NK  cell  subsets.  In  conclusion,  the  study  confirmed  and  expanded  the 
knowledge regarding MHC I dependent regulation of the NK cell repertoire by selecting 
against cells co-expressing self-specific inhibitory receptors. Further, data indicated that 
proliferation and apoptosis could be mechanisms regulating the observed skewing of the NK 
cell repertoire. 
 
Taken together these data show that MHC I expression regulates the NK cells receptor 
repertoire, perhaps to enrich for the subsets that may be most efficient in detecting lack of a 
single MHC I allele. The exact mechanisms regulating the process are still not known. All 
studies mentioned above have been performed on mature NK cells from the spleen, except 
for the PCR analysis of RNA expression performed on NK cells generated from NKP cells. 
These studies do not reveal if the skewing phenomenon is a peripheral mechanism (due to 
interactions and signals in mature cells) or if it occurs in the bone marrow during NK cell 
development. In addition, the possible processes involved in regulation of the skewing such 
as proliferation and/or apoptosis, is unknown. This topic was further studied in paper IV. 
 
1.9.2  Acquisition and control of NK cell responsiveness and NK cell 
tolerance 
 
Early in vitro and in vivo studies show that lack of MHC I is enough to render otherwise 
normal cells sensitive to NK cell mediated killing. These studies also showed that NK cells 
from an MHC  I deficient host are self-tolerant to MHC
- 
but otherwise normal cells, although 
they still have the capacity to kill other types of targets cells (227-230). These findings raised 
questions regarding how NK cells become self-tolerant towards normal cells. A term 
frequently  used  in  discussions  regarding  NK  cell  education  is  responsiveness. 
Responsiveness is defined by the NK cell’s capability to respond to activating signals through 
degranulation or cytokine production, where low and high responders are called 
hyporesponsive and hyperresponsive/responsive respectively 
 
As reviewed in the previous section, the first hypotheses explaining how NK cells achieve 
tolerance towards self-postulated that all NK cells express “at least one” self-specific 
inhibitory receptor, thus autoreactive NK cells should not exist but should have been deleted 
or adapted to express a self-specific receptor. With the development of techniques and 
antibody reagents, making it possible to co-stain for all known MHC I specific inhibitory 
receptors on the same NK cell, the “at least one” model could later be proven incorrect. NK 
cell subsets lacking expression of any MHC I self-specific inhibitory receptor were 
demonstrated  and  studied.  However,  already  during  the  90’s  the  question  was  raised 
regarding if autoreactive NK cells actually were irreversibly deleted, since they could be 
detected in certain situations. 
 
MH Johansson et al. showed, already in 1997, dynamic features for NK cell tolerance using 
D
d  
transgenic B6 mice “DL6”, in which the transgene was inherited as a single dominant 
gene, but showed a mosaic expression pattern. Between 20-70% of the cells in these mice 
expressed the D
d 
transgene (231). NK cells from these mice were tolerant in vivo towards H- 
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2
b  
bone marrow grafts but rejected MHC I deficient targets. In vitro tolerance for self was 
broken upon short separation time of D
d+  
vs D
d- 
NK cells in vitro, leading to killing of D
d- 
cells by the D
d+ 
NK cell population. This indicated that the autoreactive cells are still present 
and that there may be a need for constant exposure to MHC ligand deficient cells to set and 
retain tolerance. 
 
A new era in the research on NK cell education was initiated in parallel by the Raulet and 
Yokoyama laboratories using the possibility to study potentially autoreactive NK cells at the 
single cell level. Both laboratories published similar results showing that NK cells without a 
self-specific inhibitory receptor exists and that they are self-tolerant. Although the data were 
quite similar, two different hypotheses regarding how this self-tolerance is achieved were 
presented (see below). 
 
Fernandez et al. showed by cell surface staining that there exists a subpopulation 
(approximately 10% of the total NK cell pool) of NK cells in B6 mice which do not express 
any known MHC I self-specific inhibitor receptor and do most probably not express an 
unknown self-specific receptor (203). This population was defined by the lack of expression 
of Ly49C/I/NKG2A- (CI/NKG2A-) while the population expressing self-receptors in B6 
mice (Ly49C/I/NKG2A
+
) was called CI/NKG2A
+
. This NK cell subpopulation was self- 
tolerant and responded poorly (almost as bad as MHC I deficient NK cells) in cytotoxicity 
assays against YAC-1, and β2m-deficent Con A blasts compared to CI/NKG2A
+ 
NK cells. It 
also showed a reduced IFNγ production in response to various in vitro stimuli such as YAC- 
1, RMA-Rae-γ, β2m
-/-
-Con A blasts, as well as a weak response to antibody crosslinking of 
activating   receptors,   such   as   NK1.1   and   Ly49D.   In   other   words,   it   displayed   a 
hyporesponsive phenotype. However, the subset could still mediate function after positive 
stimulation   with   PMA   and   responded   to   Listeria   stimulation   indicating   that   this 
subpopulation has the capability to respond at least in some situations.  The CI/NKG2A
- 
NK 
cell subset had a normal phenotype regarding expression of other receptors and maturation 
markers. A decrease in KLRG1 expression, similar to what has been observed in MHC I 
deficient mice, was observed. The authors put forward a hypothesis stating that NK cells, 
during development and inhibitory receptor acquisition, interact with cells in their 
environment which influence the responsiveness of the NK cells. The model was termed the 
disarming model. It states that an NK cell is responsive by default and to remain responsive it 
needs to receive an inhibitory signal via a self-specific inhibitory receptor. If the NK cell 
lacks such receptors and signals it will become hyporesponsive by an active process to ensure 
self-tolerance. 
 
On the other hand Kim et al. suggested a hypothesis for NK cell self-tolerance called the 
licensing model (202). It postulated that all NK cell are non-functional /unlicensed from the 
beginning and upon interaction between an NK cell expressing self-specific inhibitory 
receptor and cognate MHC I molecules functional competence and a licensed state is 
conferred to the NK cell. Thus, NK cells without a self-receptor are self-tolerant by nature 
and those who are not potentially self-autoreactive receive the license to kill due to inhibitory 
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receptor interaction. This hypothesis was based on data showing that NK cells expressing 
self-specific inhibitory receptors, both in two different wild type mouse strains and in two 
transgenic mouse strains expressing only one MHC class I allele, display an increased IFNγ 
response after antibody crosslinking of activating receptors compared to the same NK cell 
population from an MHC I deficient host. Furthermore, NK cells expressing a modified 
Ly49A receptor with an ITIM mutation in H-2
d  
mice failed to mediate an increased IFNγ 
production upon stimulation, suggesting that the licensing signal might be dependent on the 
inhibitory Ly49 receptor itself, in this case Ly49A. Yokoyama and colleagues suggested that 
licensing may occur through activating signals by Ly49 receptors in an ITIM dependent, but 
a SHP-1 independent, way which results in a functionally responsive NK cell. 
 
These two pioneering papers in the field of immune cell education changed the whole NK 
cell research in several ways, both the view on NK cell development and the way by which 
investigators analyze the NK cell pool. 
 
A third model is “the rheostat model” was postulated by Petter Höglund and colleagues (232- 
234). It states that responsiveness in NK cells is not a fixed and absolute state (on or off), 
instead it is a dynamic quantitative feature that can change over time to adapt or retune to the 
host environment by monitoring the balance between activating and inhibitory input. 
According to the rheostat model, NK cells receiving stronger inhibitory signals will achieve 
higher responsiveness. Strong inhibitory signals could be due to expression of an inhibitory 
receptor for a MHC I allele with high educating impact: some MHC I alleles are better than 
others at educating NK cells and tuning up NK cell responsiveness. Strong inhibitory signals 
could also be due to co-expression of multiple inhibitory receptors actin in synergy. This 
highly responsive NK cell population will be able to respond with multiple functions, 
degranulation (CD107a) and cytokine production (e g IFNγ), and also have a stronger 
response per cell (i e produce more IFNγ). 
 
This model was suggested based on old and new findings. Early studies regarding NK cells 
and self-tolerance have shown that this mechanism is reversible. As mentioned above, MH 
Johansson showed in the 90ths that when the MHC I environment is altered the NK cell can 
change and reset its capability to eliminate a specific target cell type. 
 
Further S Johansson et al. showed that NK cell education is influenced by both the quality 
and the quantity of inhibitory signaling in the NK cell (235). This was shown by using several 
mouse strains expressing a single MHC I allele and measuring the MHC I educating impact 
by in vivo rejection of MHC I deficient targets. Rejection, i e the reactivity of the NK cell 
population, was not only influenced by the impact strength of MHC I molecules but also by 
the frequency of NK cell expressing a receptor for the MHC I allele. Later, it was shown by 
the same authors that each Ly49r have a broader capacity than previously expected to bind to 
different MHC I alleles influencing the responsiveness of the NK cell. By studying in vitro 
responsiveness of specific NK cell subsets from mice expressing only one specific MHC I 
allele they observed that single positive NK cells, for either Ly49A,-C,-G2 or-I, in four 
different  single  MHC  I  expressing  mouse  strains,  displayed  a  higher  frequency  of 
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degranulation after stimulation compared to MHC class I deficient mice. This indicated that 
all of the inhibitory receptors had interacted with all MHC I alleles leading to acquired 
responsiveness though licensing. 
 
This concept was further proven by Brodin et al. by correlating the amount of inhibition to 
the responsiveness at the single cell level. NK cells receiving a higher degree of inhibitory 
input, either by expressing several inhibitory receptors or by coming from an animal 
expressing several MHC I educating alleles, showed increased degranulation or IFNγ 
response (233). Using D
d 
hemizygous and homozygous mice the same authors also showed 
that NK cells expressing a single inhibitory receptor from homozygous mice with a higher 
expression of a strong MHC I educating allele had an increased responsiveness and capability 
to respond to activating stimuli with several functions, such as degranulation and cytokine 
production, compared to the same NK cell subset from a hemizygous animal. This indicated 
that the expression levels of an MHC I allele directly controls the NK cell function and 
responsiveness. The rheostat model states that the NK cell education depends on the quantity 
of inhibitory input. The net balance between the inhibiting and activating signals will 
determine the responsiveness i e NK cells receiving strong signals will be able to respond 
strongly with several functions compared to NK cell receiving a weak signal. Furthermore the 
system is tunable over time, dependent on how much inhibitory signals an NK cell perceives. 
 
As previously described, MHC I influences the Ly49 inhibitory receptor repertoire by 
skewing the repertoire enriching for subsets expressing one or two self-specific inhibitory 
receptors. However, the inhibitory receptor KLRG1, not recognizing MHC I, is also 
influenced by MHC I expression but in a different manner than the Ly49 receptors, i e there 
is a higher frequency of NK cells expressing KLRG1 in the educated (Ly49r
+
) NK cell 
population (128, 204). One of the first studies on murine NK cells and KLRG1 showed that 
the expression was up to 3 fold reduced in MHC-deficient mice (β2m
-/-
, Tap
-/-
, K
b
D
b-/-
). The 
same study also revealed that a strong MHC I ligand increased the expression of KLRG1 
further, thus NK cells from H-2
d 
expressing mice had a higher frequency of KLRG1 
expression compared to NK cells from mice expressing H-2
b
. Although KLRG1 does not 
directly bind to MHC I, the expression may be dependent on signaling generated from MHC 
I-Ly49r interactions since loss of the signaling molecule SHP-1 reduced the KLRG1 
expression (128). KLRG1 expression by NK cells has thus been found to correlate with 
education. However, KLRG1 expression is influenced by other processes as well, such as cell 
proliferation and activation (131, 132). The importance of KLRG1 function in NK cell 
biology in general (and education in particular) is not fully understood. There are indications 
that KLRG1 binds to monomeric E-cadherin and by multiple interactions inhibits NK cell 
function (236, 237). KLRG1 binds to a conserved region, allowing it to monitor expression of 
several  cadherins  and  may  thus  mediate  MHC  I  independent  missing  self  recognition 
important for tumor surveillance (237). 
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1.9.3  MHC I independent missing self recognition and education 
 
Another receptor binding to a self-ligand is the receptor 2B4 binding to CD48 expressed on 
cells of hematopoietic origin. Lee et al. studied NK cells from 2B4 deficient mice using RMA 
(CD48
+
) and RMA-S (CD48
+
) tumor cells in vitro and in vivo. They found that 2B4 deficient 
mice eliminated the two targets with the same pattern as wt mice (increased killing of RMA- 
S due to missing self), however the total responses were increased against both targets i e 2B4 
mediated  inhibition  occurs  independently  of  the  MHC  I  system  (238).  However,  upon 
introduction of Rae-1ᵧ, both the 2B4 and MHC I dependent inhibition were overriden leading 
to an almost identical efficient elimination of both RMA-Rae-1ᵧ and RMA-S- Rae-1ᵧ by 
either 2B4 or wt NK cells. Further, in vivo subcutaneous tumor outgrowth assay showed that 
NKG2D ligand expression could override the influence of both inhibitory systems, although 
RMA-Rae-1ᵧ tumors grow out at later time points. In addition, at an early tumor stage, either 
missing  self  recognition  or  activating  ligands  per  se  were  enough  to  induce  tumor 
elimination. However, both systems were needed to induce complete regression. The authors 
conclusion was that 2B4 is an MHC I independent inhibitory pathway sensing self via CD48 
and that stressed induced ligands can bypass both inhibitory systems. 
 
The accepted concept regarding NK cell education is that NK cells via Ly49 receptors are 
educated on MHC I ligands and therefore receive responsiveness and the capability to 
perform missing self rejection of MHC ligand deficient, but otherwise normal host cells. 
However, other self ligands have been shown to influence this function. Ly49A, but not other 
Ly49r, has been shown to bind to a non-classical MHC I molecule, H2-M3, which is mainly 
expressed on B cells (239). H2-M3 influences the education and responsiveness of the 
Ly49A
+  
population since mice deficient in H2-M3 show a reduced NK cell responsiveness 
and tolerance to H2-M3-deficient bone marrow compared to wild type mice which reject 
such cells. 
 
Further, there are data indicating the importance of MHC I independent missing self rejection 
via the inhibitory receptor NKR-P1B using Clrb-deficient mice (125, 240). Clrb
-/-  
NK cells 
have a higher expression of NKR-P1B compared to wild type NK cells, similar to increased 
Ly49r expression on NK cells from MHC I-deficient animals. Interestingly, Clrb
-/- 
bone 
marrow  was  rejected  in  wild  type  mice  in  a  NKR-P1B
hi   
NK  cell  dependent  manner, 
indicating a missing self function of the NKR-P1B-Clrb system. In vitro stimulation with 
NK1.1 or IL-12 showed differences in IFNγ release between Clrb-/- and wild type NK cells 
but not between NKR-P1B
hi 
and NKR-P1B
lo 
from Clrb
-/- 
mice. However the differences 
observed regarding NK1.1 treatment could be due to reduced NK1.1 expression by the Clrb
-/- 
NK cells. Rahim et al. also studied the NKR-P1B-Clrb system, with focus on NKR-P1B 
receptor deficient mice (241). These mice had a normal phenotypic expression, although a 
reduced KLRG1 expression similar to NK cells from MHC I-deficient mice was observed. 
The NKR-P1B-deficient mice showed a normal IFN response towards in vitro stimulation 
and among the wild type NK cells a higher responsiveness was observed when both NKR- 
P1B and Ly49C/I was expressed, compared to expressing them separately or not at all. In 
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vivo elimination studies revealed that in vivo pre-activated wild type NK cell could reject 
Clrb
-/- 
spleen cells while this capacity was eliminated in the NKR-P1B-deficient mice. 
However, the NK cells from the NKR-P1B-deficient mice had an increased rejection of MHC 
I-deficient spleen cells compared to wild type mice, while both could reject double Clrb
-/- 
MHC I- target cells with a high efficiency. Taken together these two studies using the NKR- 
P1B-Clrb system indicates that the expression of the NKR-P1B receptor can contribute to the 
NK cell education, total responsiveness and that the receptor may have a parallel (to Ly49r- 
MHC I) missing self recognition function regulating for example rejection of bone marrow 
transplants. 
 
In conclusion these data indicate that there are several missing self recognition systems 
influencing the NK cell overall responsiveness and decisions regarding if a potential target 
cell should be eliminated or not. This sheds some light on how complicated and tightly 
regulated the NK cell system is. Although the Ly49r-MHC I interactions may have the 
strongest influence, all pieces will be weighed and summed up shifting the balance towards 
activation or inhibition. 
 
1.9.4  NK cell education and the influence of Ly49-MHC I cis-interactions 
 
Ly49 receptors on NK cells can interact with MHC I ligands in either trans (on another cell in 
the environment) or in cis (on the NK cell itself). There are conflicting data and 
interpretations regarding how much each interaction contribute to the functional and 
educational status of the NK cell. 
 
Early studies by our group and others showed that cell surface levels of Ly49A as detected by 
antibody staining in flow cytometry were lower in MHC I ligand expressing mice compared 
to ligand-negative (242, 243). Furthermore, in studies of NK cell from mosaic D
d 
transgenic 
mice, all NK cells (D
d+ 
and D
d-) 
down modulated Ly49A levels in vivo, while only the D
d+ 
NK cells kept Ly49A levels low upon in vitro culture. This suggested that D
d 
ligands on the 
NK cell itself could interact with Ly49A and modulate expression levels (244). 
 
In addition NK cells were shown to take up MHC I alleles via trogocytosis from surrounding 
cells, influencing the NK cell function (245, 246). Sjöström et al. showed that B6 NK cells 
expressing Ly49A could upon transfer to a Balb/c (H-2
d
) mouse acquire D
d  
molecules on 
their cell surface already 20 min after transfer. This phenomenon was also seen for K
b 
and the 
Ly49C  receptor  in  transfers  of  MHC-class  I-deficient  NK  cells  to  a  K
b   
expressing 
environment. Transfer of D
d 
to Ly49A
+ 
cells in vitro reduced Ly49A mediated NK cell lysis 
of sensitive targets but the Ly49A
+ 
cells that acquired D
d 
molecule could still be inhibited by 
targets expressing the D
d 
molecules. 
 
One of the first papers demonstrating cis interactions shows that Ly49A binds to D
d 
using the 
same binding site in cis and in trans interactions, indicating that cis interaction can prevent 
the NK cell from binding in trans and thereby become inhibited (247). Moreover, Ly49A
+ 
NK cells from a D
d  
expressing animal were less inhibited by target cells, both in IFNγ 
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response and target cell lysis, than NK cells from a D
d- 
mouse indicating that cis interaction 
can influence NK responses by limiting inhibition from trans interactions. 
 
Andersson et al. showed using a GFP-D
d 
molecule that D
d 
is specifically acquired by Ly49A
+ 
but not by Ly49A
- 
NK cells from a B6 mouse while acquisition by NK cells expressing an 
endogenous D
d  
ligand was reduced by approximately 90% due to occupancy (248). 
Acquisition could only partly be restored by acidic treatment (removing the endogenous cis- 
bound D
d
), suggesting a 60% reduction in Ly49A cell surface receptors on NK cells from a 
D
d 
expressing mouse compared to those from a B6 mouse and that 75% of the Ly49A 
receptors  expressed  are  bound  in  cis.  Thus,  only  25%  of  the  expressed  molecules  are 
available for trans interactions and inhibition via MHC I ligands on potential target cells. 
These data explain the reduced inhibition of D
d+ 
Ly49A
+ 
cells described above. 
 
In later studies the role of cis vs trans interaction in NK cell education has been investigated. 
The data are conflicting. Kim et al. showed that the educational process, licensing, of Ly49A
+ 
NK cells depended on a functional Ly49A receptor since the responsiveness was decreased 
when the inhibitory signal was lost (202). Chalifour et al. took this a step further and analyzed 
if Ly49A dependent education was mediated through a cis or trans interaction or both (249). 
NK cells  expressing an  Ly49A receptor with a mutation  in the stalk  region making it 
incapable to bind to MHC I in cis, hence only binding to MHC I in trans, was still fully 
capable to be inhibited via D
d
.  However, NK cells from a D
d+  
host expressing the mutant 
Ly49A receptor displayed a reduced killing of H-2
b 
lymphoblasts in vitro compared to 
wtLy49A
+ 
NK cells from a D
d+ 
host, suggesting that cis interactions were important for 
education. In addition, expression of Ly49A on NK cells in an H-2
b 
animal reduced the 
responsiveness, both missing self killing and IFNγ production, by the NK cells. This was 
presumably due to the presence of a non-educating receptor (Ly49A) since it could be 
restored by introduction of the D
d  
molecule. However, introduction of D
d  
molecules could 
not restore reduced responsiveness in NK cells expressing the mutant Ly49A, indicating a 
role for cis interaction in education. 
 
Further, NK cells from an H-2
b 
animal (B6; educated mostly via Ly49C and I) co-expressing 
Ly49C and -A had a reduced IFNγ production compared to Ly49C+A- NK cells. The 
responsiveness could be restored upon D
d  
expression or by artificially creating Ly49A-cis 
interaction in an H-2
b 
animal by Ly49A antibody binding, indicating a negative effect of the 
unengaged inhibitory receptor, thus dampening the NK cell responsiveness. These data 
indicate that Ly49r-MHC I cis interactions, in the case of Ly49A, may be involved in tuning 
the NK cell responsiveness both positively in response to cis ligand interactions but also by 
reducing the function of NK cells in absence of a cis-bound ligand. 
 
At the end of 2013 two papers were published at approximately the same time, one stating 
that only Ly49-MHC I interactions in trans are of importance for NK cell education while the 
other argued that both cis and trans interactions are needed for education and maintenance of 
responsiveness. 
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Ebihara et al used an inducible MHC I single-chain-trimer: K
b
-β2m-peptide (K
b
-tg) on MHC 
I-deficient background and observed that Ly49C
+  
(vs Ly49C
-
) NK cells became responsive 
already at day one after MHC I up-regulation while responsiveness of Ly49A
+ 
(vs Ly49A
-
) 
cells was not changed (250). This system was used to analyze the influence of cis vs trans 
interactions on NK cell education. K
b 
negative NK cells transferred into a K
b
-tg environment, 
followed by K
b 
induction, gained responsiveness in the Ly49C
+ 
subset while K
b
-tg NK cells 
transferred into a K
b 
insufficient host (followed by induction) remained low responders. This 
indicated that Ly49-MHC I interactions in trans (occurring only in the former situation) play 
a major role in NK cell education. Trogocytosis, i e transfer of K
b  
molecules from host to 
donor K
b  
negative NK cells occurred but it was unspecific since both Ly49C
+  
and Ly49C
- 
NK cells gained K
b  
expression. This could result in cis-interactions on donor Ly49C
+  
NK 
cells. However, since donor K
b
-tg NK cells did not get licensed in K
b
-negative host (despite 
cis interactions), cis interactions may not be sufficient for licensing. In addition, regardless of 
if NK cells expressed K
b 
or not, they only became licensed upon interaction with K
b 
on 
hematopoietic cells while they remained unlicensed if K
b 
was only expressed on the stromal 
cells. In conclusion this study suggests that the NK cell is educated via MHC I interactions in 
a trans and depends on MHC expression on hematopoietic cells. Further, the process can be 
independent from development and there are no clear alterations in the NK cell phenotype 
after licensing has occurred. It should be noted that the results do not exclude a role for cis 
interactions in education. It cannot be excluded that K
b
-negative NK cells were influenced by 
ligands acquired by trogocytosis. 
 
However, Bessoles et al. used two different models to study the loss of MHC I interactions in 
either cis or trans (251). In the first model the D
d  
molecule was depleted from the system 
either in cis (from NK cells) or in trans (from T cells). In the second model Ly49A was 
altered so that it could only interact with MHC I either in cis or trans. Both systems showed 
that cis and trans interactions are both important to gain fully functional NK cells and that 
mainly cis interactions influence the MHC I receptor repertoire. Loss of either cis or trans 
interaction led to impaired in vivo missing self rejection and reduced CD107a responses after 
in vitro stimulation. Similarly, NK cells educated only via cis interactions or only via trans 
interactions did not display D
d 
dependent increase in IFNγ production. These results indicate 
that the NK cell require interactions to MHC I both in cis and in trans to become fully 
functional i e perform missing self rejection and to fully respond to in vitro stimulation. 
 
In conclusion there are different opinions regarding the role of cis vs trans interactions in 
education. However, the cis and trans interactions may be responsible for different parts of 
the education.  The data  suggests  that  cis  interaction  may be more important  to  ensure 
skewing of the repertoire. Bessoles et al. showed that both cis and trans interactions were 
needed to gain full NK cell responsiveness while Ebihara et al. suggested that only the trans 
interaction was needed, however a role for cis interactions could not be completely excluded 
by their data. Thus data from both groups are compatible with a model where both cis and 
trans interactions are involved in education. 
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1.10 NK CELLS AND IMMUNOLOGICAL MEMORY 
 
NK cells are innate cells with a lymphoid origin but the classification as an innate cell and 
the notion that previous antigen encounters are irrelevant for NK cell responses has been 
questioned. NK cells are similar to B and T cells in several aspects. They go through 
several  maturation  steps  and  an  educational  process  to  acquire  fully  functional 
competence (described above) which raises the question if they should be classified as 
belonging to the adaptive immune system. This question has become emphasized by 
several groups who have found indications of immunological memory with long lived NK 
cells and an increased response upon a second pathogenic challenge. 
 
One of the first studies regarding if NK cells could generate an antigen specific response 
involved contact hypersensitivity after administration of a chemical hapten (252). This 
was done in mice lacking T and B cells, where it was observed that the contact 
hypersensitivity to certain haptens was NK cells mediated; NK cell depletion eradicated 
the response and transfer of liver-derived Ly49C/I
+ 
NK cells from hapten-exposed mice to 
naïve mice could induce the higher response. It was antigen specific since an enhanced 
response was observed by a second injection with the same chemical, with persistence up 
to a month after the injection, while injection of a different hapten did not induce an 
increased response. Memory was only transferred via the liver NK cell population 
expressing inhibitory receptors for self MHC I e g Ly49C/I and in a NKG2D dependent 
fashion. These data may imply that licensing via the inhibitory receptor is a prerequisite 
for acquisition of NK cell memory although the receptor responsible for the hapten 
recognition is unknown. 
 
One of the most used virus infection models in NK cell research is murine 
cytomegalovirus (MCMV), where the NK  response has been  characterized in detail. 
Major  breakthroughs  in  this  field  were  made  by  the  groups  of  Welsh,  Vidal  and 
Yokoyama by showing that the recognition of MCMV infected cells is dependent on the 
Ly49H
+ 
receptor (expressed by approximately 40-50% of naïve NK cells from B6 mice) 
and that it binds to the virus encoded protein m157 on infected cells. (150, 253, 254). The 
Ly49H-m157 interaction leads to clearance and virus control. In addition, Sjölin et al. 
strengthened the evidence by showing that the DAP12 signaling molecule coupled to 
Ly49H is crucial to gain resistance to the virus (255). During an MCMV infection, the 
Ly49H
+  
population undergo antigen specific proliferation and expansion; the lack of 
m157 during the MCMV infection does not result in proliferation of the Ly49H
+  
subset 
(256). 
 
In more recent studies Lanier and colleagues used the MCMV model to analyze NK cell 
memory (257). When Ly49H expressing NK cells were transferred to MCMV infected 
mice lacking expression of a functional Ly49H receptor the transferred NK cells expanded 
100-1000 fold and mediated virus clearance. These NK cells were more responsive upon a 
second virus challenge, as measured by degranulation and IFNγ production. The 
transferred NK cells could be detected in several organs such as liver and spleen and 
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persisted up to 2 months after the infection was cleared. The transferred NK cells could 
even be transferred to a second and a third host and continued to proliferate and expand. 
Further, transfer of a Ly49H
+ 
NK cells from a virus experienced host could protect 
neonatal mice from deadly infection. In correlation to education, it is the uneducated 
hyporesponsive NK cells, Ly49C/I negative, within the Ly49H population, that are the 
most proliferative and important in protection against MCMV infections (258). These data 
show that NK cells can be more long lived than the originally determined lifespan with a 
half-life of 17 days (259). It also implies the existence of some sort of memory since the 
competence can be transferred to a second host with the ability to give a more pronounced 
response compared to naïve mice. 
 
Yokoyama’s lab searched for possible memory-like effects with a different approach 
(260). Spleen cells were activated in vitro with IL-12, IL-18 and a low dose of IL-15, 
fluorescently labeled and transferred into naïve hosts. The cytokine activated NK cells 
produced high amounts of IFNγ during the first week after transfer but after that returned 
to background levels. When activated and transferred NK cells were in vitro re-stimulated 
with either cytokines (IL-12 and -18) or crosslinking of activating receptors, they 
responded by IFNγ production. These results were observed up to 4w after transfer and 
indicate that an NK cell intrinsic effect accomplished by cytokine activation can create 
memory-like NK cells with increased life span and responsiveness upon a second 
challenge (261). 
 
In conclusion these studies implies the existence of a memory-like feature since the 
competence can be transferred to a second host with the ability to give a more pronounced 
response compared to naïve mice. However, if this is memory, as defined for T and B 
cells, is still unclear. 
 
As mentioned above, MCMV infection leads to expansion of the NK cell population 
expressing the virus specific activating receptor Ly49H. Similar to this expansion, it has been 
shown in humans that HCMV seropositivity can drive long lasting expansions of NK cell 
populations expressing certain activating receptors, the most dominant is NKG2C but also 
some of the activating KIRs are expressed. They represent a “memory pool” with enhanced 
function such as IFNγ production (262-265). Schlums et al. recently showed that among 
healthy adults there was a correlation between seropositivity and expansion of NK cell 
populations lacking the intracellular signaling molecules FcεRγ, SYK and EAT-2 (266). 
Further, reactivation of HCMV infection after a hematopoietic cell transplant could 
specifically lead to expansion of NK cell populations lacking those signaling molecules while 
seronegative patients or patients with no reactivation of their CMV infection had no 
alterations in their expression pattern, indicating that the expansion is caused by the HCMV 
infection.  The  NK  cells  negative  for  FcεRγ,  SYK  and  EAT-2  displayed  an  adaptive 
phenotype (with a distinct expression pattern of receptors), altered response pattern and 
increased proliferation and survival as a response towards infected cells and ITAM- 
dependent signaling. Together Schlums et al. and Lee et al. has shown that the lack of the 
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EAT-2    and    SYK    signaling    molecules    is    probably    due    epigenetic    alterations 
(hypermethylations) (159, 266). 
 
 
1.11 NK CELLS AND CANCER 
 
Cancer is one of the most growing health problems today. Standard therapeutic procedures 
such as surgery, irradiation and chemotherapy have been proven to be efficient against the 
primary tumor but less successful against aggressive metastatic diseases. New types of 
therapies are on their way including more specific targeting approaches directly aiming at the 
inhibition of tumor-specific pathways and proteins. Another more recent approach is 
immunotherapy focusing on using the destructive properties of the immune system to induce 
anti-cancer activity. This is done by 1) by boosting an existing anti-tumor immune response 
or increasing the tumor recognition by peptide (for example a tumor antigen) or cell-based 
(DC or whole tumor cell) vaccines to produce cellular memory via B and T cells or 2) by 
generally activating an anti-tumor effect via administration of cytokines, such as IL-2, to 
enhance proliferation and function or via effector molecules (antibodies) and immune cells, 
such as NK cells, without generating immunologic memory. 
 
1.11.1 Immune surveillance 
 
In the 1950s Burnet proposed a theory of immune surveillance against cancer and this was 
further developed during the late sixties when the T cells were discovered (267, 268). In its 
original form the theory states that effector cells, T cells, of the immune system are constantly 
searching for and eliminating tumor cells and thereby guarding us from tumors. However, in 
the mid-seventies it was found that athymic nude mice, lacking T cells, did not develop more 
spontaneous cancer than control mice, although they were extremely susceptible to tumor 
formation after polyoma virus infection. In the late seventies, in the beginning of the NK cell 
era, many investigators took an interest in these newly discovered cells as possible actors in 
immune surveillance. To test the involvement of NK cells and to learn if NK cells had 
evolved to protect us from cancer, scientists asked questions such as; do mice completely 
lacking or carrying deficient NK cells develop more spontaneous tumors than wild type 
mice? 
 
Early studies were comparing homozygote C57BL (B6) mutant beige (bg) mice bearing a 
partial NK cell deficiency to heterozygote or normal B6 mice in different settings to evaluate 
the importance of NK cells in tumor development. In summary it was shown that NK cell 
deficient mice had an increased tumor growth and faster death after administration of 
syngeneic leukemia cell lines or by spontaneously developing tumors and had a reduced in 
vitro cytotoxicity. Further, the mutant mice had increased frequency of metastases in the lung 
when using an NK cell sensitive target but had the same amount of tumors as the controls 
when NK cell insensitive target was used (269-271). 
 
Using the B6 beige mice as a model for selective, total NK cell deficiency has been 
questioned since the NK cells are not completely deficient and these mice also have a 
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cytotoxic T cell, granulocyte and platelet deficiency. So other mice and approaches or 
techniques were used to prove the involvement of NK cells in immune surveillance. 
 
Perforin-deficient mice were used to show that NK cells are needed for in vitro and in vivo 
elimination of RMA-S and YAC-1 tumor cells and could protect against lung metastasis in 
two different tumor models. Perforin dependent mechanisms were the major contributors to 
tumor protection (272, 273). 
 
It took many years and technology improvement to be able to generate a mouse that is only 
deficient in NK cells and no other parts of the immune system. Kim et al. used a transgenic 
mouse which lacks almost all NK cells but still have a normal frequency of B and T cells and 
almost equivalent frequency of NKT cells to wild type (274). These mice had a reduced in 
vitro and in vivo elimination of the NK cell sensitive targets YAC-1 and RMA-S tumor cells. 
In addition they had a 60-fold increase of lung metastases caused by injection of B16 
melanoma compared to wild type mice. 
 
Other ways of studying the role of NK cells in immune surveillance and tumor growth has 
been to deplete NK cells by antibody administration or to target e g activating receptor genes. 
As above, many groups have investigated this and it is today an accepted method and used as 
a standard control in almost all in vivo assays involving NK cells. One of the first studies was 
performed by Okumura et al. using anti-asialoGM1 serum to deplete NK cells in BALB/c 
nude mice and then challenging them with syngeneic tumor cells or YAC-1 cells (275). 
Depletion of NK cells resulted in a much higher frequency of tumors and increased tumor 
size. In addition they found that carcinogen induced tumors grew out faster when the mice 
had been NK cell depleted. NKG2D-deficient mice were generated and had normal NK cell 
functions except for the NKG2D signaling. The mice showed an increased and faster 
incidence of both malignant prostate adenocarcinomas and B cell lymphoma but had no 
effect on the development of carcinogen induced sarcomas compared to the controls (161). 
 
The general conclusion from these studies is that NK cells can participate in immune 
surveillance but the effect of NK cells depend largely on the tumor itself. Tu et al. used 
NKC
KD 
mice (mice lacking Ly49r on 80% of their NK cells) to test the influence of MHC I 
specific inhibitory receptors in immune surveillance (276). These mice had an increased 
sensitivity to various MHC I-deficient tumors while MHC I sufficient tumors grew equally 
well in both NKC
KD 
and wild type mice. Introduction of Ly49I on NKC
KD 
background 
restored the tumor elimination capacity in the NKC
KD 
mice illustrating the influence of Ly49r 
and education in immune surveillance against MHC I-deficient tumors. Moreover in a 
spontaneous B cell lymphoma model there was an earlier onset in NKC
KD 
mice and isolated 
tumors from NKC
KD 
mice had a decreased MHC I expression, suggesting that tumor editing 
to escape T cells occurred in absence of missing self reactivity by NK cells. 
 
As mentioned in the beginning of this thesis, NK cells were discovered as cells which had a 
natural capacity to kill and eliminate tumor cells. So why cannot our NK cells protect us from 
cancer? First, NK cells are quite few, so even if they able to kill and eliminate they are simply 
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in many cases not efficient enough to eliminate the cancer cells as fast as the cancer cells are 
growing. Another problem is that NK cells are often located in the periphery of the tumor and 
do not have access to all tumor cells. However, even if they are in the right location the tumor 
itself or the tumor milieu can dampen the NK cell function. 
 
1.11.2 Therapies based on transplantation or adoptive transfer of cells 
 
In early clinical studies, NK cells were used as a tool to treat cancer based on cytokines such 
as  IL-2  administered  systemically.  The  idea  was  to  improve  the  NK  cell  count  by 
proliferation and to boost their function, with or without prior adoptive transfer of ex vivo IL- 
2 activated NK cells (lymphokine activated killer, LAK cells). This early type of treatments 
failed since the high dose of IL-2 caused systemic toxic effects, e g in the form of vascular 
leakage and cardiopulmonary complications; furthermore it could be lethal to the NK cells 
which died by exhaustion (277). Today the field has developed and NK cells can be either 
efficiently expanded ex vivo or generated from hematopoietic stem cells from the bone 
marrow or from umbilical cord blood. In vitro development of NK cells is performed via 
standardized protocols including cytokines only or in combination with feeder stroma cells 
(278, 279). 
 
Another up-coming source of NK cells that can be infused into patients are malignant NK 
cell lines for example NK-92 which is derived from an NK cell lymphoma. (280). Two phase 
1 clinical trials have shown that infusion of pre-irradiated NK-92 cells into patients with 
different solid (such as sarcomas, blastomas, malignant melanomas) tumors is a safe 
procedure and that the cells can persist in the circulation at least 48h after administration. 
Some of the patients had a stable disease after the infusion (281, 282). 
 
1.11.2.1 Therapy based on transplantation of hematopoietic (stem) cells 
 
Allogeneic hematopoietic stem cell transplantation is perhaps the best treatment for blood 
cancers such as leukemia and lymphoma. The donor T cells are known to promote 
engraftment and elimination of cancer cells via graft-versus-leukemia effects. The drawback 
is that mature donor T cells sometimes also recognize the recipient’s healthy cells, resulting 
in graft-versus- host disease, a serious and sometimes lethal complication. Donor T cells can 
be depleted before the transplantation but this increases the risk of opportunistic infections 
and can reduce graft-versus-leukemia effects. NK cells are among the first cells to be 
regenerated and show functional capacity, e g cytotoxicity, after transplantation. 
 
In the setting of transplantation or adoptive transfer, the KIR/ligand mismatch (in the graft- 
versus-host direction) is used to achieve alloreactivity. This means that the recipient lacks at 
least one KIR-ligand present in the donor (KIR incompatibility), so that the educated NK 
cells can perform missing self reactivity against the tumor cells (279). This genetic 
combination is sometimes achieved in haploidentical stem cell transplantations were the 
recipient and the donor are matched for only one HLA haplotype. Ruggeri, Velardi et al. are 
pioneers in this field (21, 22).  In the first report they studied 60 leukemia patients where 20 
were transplanted with a KIR-HLA epitope mismatch. They found that the donor derived NK 
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cells of these patients killed the recipient’s leukemia cells without causing graft-versus- host 
disease (21). In the second extended study 34 out of 92 acute myeloid leukemia patients were 
predicted to have a graft versus host NK alloreactivity. There was a clear correlation between 
such KIR-HLA class I ligand mismatch and reduced risk for leukemia relapse, the probability 
of relapse free survival in 5 years was 60% in the patients receiving alloreactive NK cells 
compared to 5% in the group receiving NK cell without a mismatch (22). They also used 
NOD/ SCID mice, tolerating human cells since they lack lymphocytes, to infuse either AML 
cells alone or in combination with either non-alloreactive or alloreactive NK cells. The mice 
only survived when they had been given alloreactive NK cells. Furthermore, they found that 
alloreactive NK cells can prevent graft-versus-host disease by eliminating recipient APC 
which can prime T cells. In a further extended study adding up to a total of 112 acute myeloid 
leukemia patients the same pattern was observed, only the patients receiving alloreactive 
donor NK cells showed a decrease in relapse and an increased overall survival (283). 
 
Stern et al. observed increased survival after 5 years following a haploidentical stem cell 
transplantations, particularly if the alloreactive NK cells came from the mother rather then 
from the father (284). 
 
More refined and detailed studies focusing on the specificity and phenotype of the allogeneic 
NK cell populations after haploidentical HSCT have shown that not only the inhibitory KIR- 
ligand mismatch can influence the outcome after treatment; also the activating KIRs can play 
a role, both for preventing leukemia relapse and infections (285, 286). This effect was only 
observed in settings with NK cell alloreactivity and might be mediated by the capacity of the 
activating KIR to override NKG2A mediated inhibition (287). These results may help in 
selection of the most “optimal donor” in the future. 
 
The effect of KIR ligand incompatibility has also been studied in hematopoietic stem cell 
transplantations conducted on partially HLA matched unrelated donors rather than 
haploidentical donors. Giebel et al. studied patients with myeloid malignancies(288). Patients 
receiving transplants with KIR ligand incompatibility had an increased probability for both 
disease free and overall survival at 4.5 years after transplantation.  However, several other 
studies have reported different outcomes. Davies et al. tested the impact of HLA allele 
mismatch for at least one allele on 175 patients with acute myeloid or chronic myeloid 
leukemia who received unrelated donor bone marrow transplantations (289). They found a 
trend towards reduced severe graft versus host disease and an increased survival in patients 
without KIR mismatch. Farag et al. studied 1571 patients treated with unrelated donor 
transplantation for myeloid malignancies (290). The KIR ligand matched group had the 
lowest risk of treatment failure and increased survival but there was no difference in leukemia 
relapse between the matched or mismatched groups. The different outcomes in these studies 
may reflect the different conditioning used and/or the preparation of the bone marrow/cell 
graft; for example Giebel et al. used protocols involving T cell depletion while Davies did 
not. 
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Other recent studies have focused on alternative sources of grafts such as umbilical cord 
blood, which carry an NK cell population that is most active after transplantation and 
additional receptors contributing to NK cell activation and anti-tumor effects. There are 
conflicting data regarding the effect of KIR ligand mismatch also in these studies. Willemze 
et al. showed increased survival and reduced relapse occurrence after KIR ligand mismatch in 
umbilical cord blood transplantation (291). However, Brunstein found negative effects 
associated with KIR ligand mismatch, such as increased risk for death and graft-versus-host 
disease after transplantation of umbilical cord blood with reduced conditioning (292). The 
differences observed could be due to different conditioning protocols and/or to whether one 
or two units of cord blood were used. 
 
According to the missing self model, NK cell mediated graft-versus-leukemia effects can be 
achieved when an educated NK cell recognize a leukemia cell in the recipient lacking the 
cognate HLA ligand. However, some studies observe graft-versus-leukemia effects in an 
HLA-matched or KIR ligand matched setting. Yu et al. showed that the hyporesponsive NK 
cells expressing KIR for a non-self HLA class I ligand from a matched donor could become 
activated and produce more IFNγ and become more cytotoxic against tumor targets lacking 
cognate HLA ligand (293). Both effects were transient and gone by 200 days after 
transplantation. However, other studies have shown disparate results. Björklund et al. made a 
retrospective analysis on patients with myeloid malignancies treated with HLA matched stem 
cell transplantation from a sibling (294). In contrast to Yu, Björklund et al. observed that NK 
cells which were NKG2A
-
KIR
+  
for a non-self HLA class I ligand were very similar to 
NKG2A
-
KIR
- 
hyporesponsive immature NK cells both in early and late phase (up to 6 moths) 
after transplantation. Furthermore, Haas et al. used a cohort of 60 patients receiving either 
KIR-ligand matched or mismatched HSCT transplants from either unrelated bone marrow, 
peripheral blood or umbilical cord blood grafts to study long term effects on NK cell 
education (295). Transplanted NK cells displayed a reduced responsiveness during the first 
period (at least 100 days) after transplantation but normalized within a year and remained 
stable for three years thereafter. Using donor HLA ligands they observed a rapid and stable 
educational pattern after HLA-mismatched transplantation which seemed to be determined by 
donor cells i e hematopoietic cells. 
 
It has also been shown that other factors than mismatch of inhibitory HLA specific receptors 
contribute to NK cell mediated graft-versus-leukemia effects, which might contribute to why 
increased NK cell activation and tumor elimination is observed in HLA matched 
transplantations.  Pende et al. tested the expression of activating ligands on both myeloid and 
lymphoblastic leukemia cells and their relevance for tumor lysis (296).  Antibody blocking of 
the activating receptors NKp30, NKp46 and DNAM-1 effectively inhibited lysis of myeloid 
derived leukemia while only partly inhibiting lysis of lymphoblastic leukemia. Blocking of 
NKG2D had a mild effect on leukemia cell lysis independently of origin. The results from the 
antibody  blockade  were  explained  by  a  generally  high  expression  level  of  ligands  for 
DNAM-1 (poliovirus receptor, PVR, and Nectin-2) but low levels of ligands for NKG2D 
(ULBP)  or  2B4  (CD48)  by  several  myeloid  leukemia  subtypes,  while  lymphoblastic 
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leukemia showed variable expression. The latter tended to co-express activating ligands in 
variable combinations In conclusion, the results suggest that the outcome of the treatment 
depend on many factors, such as responsiveness of the NK cell (educational status), 
expression of activating receptors including KIRs and not least, the variability of the cancer 
cells. 
 
1.11.2.2 Therapy based on transfer of NK-cells 
 
Another way of increasing NK cell number or gain NK cell cytotoxicity is to adoptively 
transfer NK cells alone or together with stem cells/bone marrow in a hematopoietic cell 
transplant. In the initial NK cell adoptive transfer studies, autologous (from same individual) 
ex vivo expanded and activated NK cells were used in combinations with low doses of IL-2. 
The upside of the studies was that the treatment could be performed without any severe side 
effects and that low doses of IL-2 could be administrated to achieve an increase in the NK 
cell  number.  However,  the  big  drawback  was  that  the  NK  cells  displayed  reduced 
cytotoxicity in vivo and that the treatment had a limited effect in the cancer patients (297). 
The lack of anti-cancer reactivity by the autologous NK cells was mainly due to KIR-HLA 
class  I  interactions  between  the  NK  cell  and  the  tumor  cell,  i  e  limited  missing  self 
recognition (298, 299). 
 
More recently, adoptive transfer of alloreactive mature haploidentical NK cells has been 
investigated, such cells should perform missing self recognition on recipients tumor cells. 
Benefits with this method are that the patient receives mature functional NK cells and that 
less immune suppression is needed, leading to reduced occurrence of opportunistic virus 
infection. Miller et al. as well as Curti et al. have shown that adoptive transfer of 
haploidentical mature NK cells can increase survival in patients (total 56 patients tested), 
most suffering from acute myeloid leukemia but also other cancer types (300, 301). However, 
this field needs to be further explored. 
 
1.11.3 Improving NK cell infiltration and cytotoxicity against tumors in vivo 
 
The ability to generate, expand and culture NK cells for adoptive transfer in an efficient way 
opens up more possibilities. As stated above, it appears that some cancers may be resistant to 
immune attack due to lack of infiltrating NK cells or due to reduced responsiveness of the 
NK cells caused by the tumor milieu. NK cell activity and infiltration in the tumor can be 
improved by manipulation of the NK cell (homing capacity) or the tumor (by upregulation of 
activating ligands, homing receptors or secretion of chemo-attractants). NK cell activity and 
function can be enhanced by administration of cytokines, such as IL-2, IL-12, IL-15, IL-18 
and IL-21, either separately or combinations (302). Since high doses of IL-2 can lead to 
systemic toxicity, IL-2 dependent NK cell proliferation and activation may instead be 
achieved by autocrine secretion of   IL-2 using genetically modified NK cell line NK-92 
(303). Further, NK cell function (NK cell line or human NK cells) can also be improved via 
transduction with a chimeric receptor with specificity for a certain cell type or a certain tumor 
antigen to increase cytotoxicity (304, 305). 
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It is also possible to make the tumor cells more sensitive to NK cell mediated killing for 
example via inducing up-regulation of death receptors or activating ligands. Doxorubicin is a 
chemotherapeutic drug that can make tumors more sensitive to NK and T cell mediated 
killing via increased expression of the death receptor TRAIL-R (TRAIL- tumor necrosis 
factor-related apoptosis-inducing ligand) (306). 
 
Another way of making tumor cells more NK cell sensitive is to induce expression of 
activating ligands, shifting the balance towards activation and target lysis. For many years 
anti-cancer agents has been used as treatment, mainly because of their direct cytotoxic effect 
on tumor cells. Many of these agents target DNA and induce DNA damage leading to cell 
cycle arrest; and activation of the DNA repair system. If the damage is too severe the cell will 
activate the apoptotic pathway and commit suicide. A problem is that these agents can induce 
DNA damage to all highly proliferating cells, targeting for example cells from the bone 
marrow, hair follicles and epithelial cells in the gastrointestinal track, inducing side effects. 
Other complications are that many tumors are deficient in their activation of the apoptotic 
pathway, by mutations in key genes such as p53. 
 
A more newly discovered function by some of the anticancer agents is that they also activate 
the host immune system, for example the NK cells.  One way of activating NK cells is by 
upregulation of activating ligands on tumor cells. NKG2D is one major receptors used by NK 
cell to eliminate tumor cells. As elaborated in section 1.5.2.1 the expression of NKG2D 
ligands (in human MICA, MICB and ULBP and in mouse Rae-1γ, H60 and Mult1) are in 
general very low at the normal state (reviewed in (307)). But they are often induced by stress 
and the DNA damage pathway in tumors and virus infected cells (172, 173). Several anti- 
cancer compounds are known to induce up-regulation of NKG2D ligands either in a defined 
or an undefined way. For example, melanoma patients are often treated with Dacarbazine 
(DTIC) which has been shown to have a antitumor effect both in human and mice and by an 
undefined way enhance expression of NKG2D ligands on melanoma cells(308). The NK cell 
recognizes the ligand on the tumor cell and becomes activated, kills the melanoma cell and 
produce IFNγ. Production of IFNγ increases the level of MHC I on the tumor cell, making it 
a potential target for cytotoxic T cells (CTL). Khallouf et al. used a mouse model for 
pancreatic cancer and showed that the anticancer effect by the combination of 5-flourouracil 
(5-Fu) and IFNα was due to enhanced NKG2D ligand and MHC I expression resulting in 
activation of NK cells, CTL and DCs (309). 
 
Another way to make NK cells more reactive against tumor cells is to remove components in 
the tumor microenvironment that can cause immunosuppression (reviewed in (310). It has 
been shown that myeloid-derived suppressor cells (MDSCs) have a negative effect on 
lymphocytes by generating reactive oxygen species (ROS). High levels of reactive oxygen 
species in the extracellular space can induce cell and tissue damage. T cells and NK cells are 
sensitive to reactive oxygen species which can induce reduced cytotoxicity by alterations in 
activation pathways. Hellstrand et al. have developed the use of the drug histamine 
dihydrochloride in combination with a low dose of IL-2 as a treatment for AML patients in 
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their first complete remission after chemotherapy (310, 311). This drug/cytokine combination 
has  been  shown  to  increase  T  and  NK  cell  activity in  cancer  patients  and  reduce  the 
frequency of relapses in acute myeloid leukemia patients (311-314). The suggested 
mechanism behind this effect is that histamine reduces the production of reactive oxygen 
species by myeloid cells, resulting in restored cytotoxicity and sensitivity to IL-2 in T and 
NK cells (314, 315). 
 
1.11.4 Activation of NK cell via antibody treatment 
 
Antibodies can be used to activate or guide NK cells to attack tumor cells. There are two 
general types of activation 1) the antibody targets a structure on the tumor cell, thereby 
inducing ADCC upon (CD16/FcγIIIA) receptor recognition of the Fc part of the antibody 2) 
antibody blockade of self-specific inhibitory receptors on the NK cells, inducing missing self 
recognition and killing. The ADCC reactivity may contribute to the anti-tumor effects 
observed in patients treated with monoclonal antibodies. 
 
Trastuzumab (Herceptin®) is a humanized antibody binding to the growth factor receptor 
Her2/neu expressed by breast carcinoma cells. Retuximab (Rituxan®), is a monoclonal 
antibody binding to CD20 expressed on B cells and B cell lymphomas (316, 317). For both of 
both these antibodies, the evidence in the literature suggests that the anti-tumor effect may be 
due both to ADCC and direct effects on the tumor cells (receptor-ligand blockade or a direct 
apoptotic effect). 
 
Unfortunately, in the case of rituximab, many of the patients respond poorly to the treatment. 
Failure of this type of treatment can be due to neutralizing antibodies that block the Fc 
interaction, or polymorphisms in the gene encoding the Fc receptor leading to variation in its 
binding affinity to antibody. It can also be due to that the Fc part of the antibody binds to an 
inhibitory Fc receptor (FcγIIB2) expressed on monocytes and macrophages, thereby reducing 
the total anti-tumor activity (320). 
 
Ravetch et al. have studied the role of activating Fc receptors and ADCC in treatment with 
antibodies against tumor antigens, by generating mutant mice lacking the γ chain necessary 
for assembly of various Fc receptors expressed on murine innate immune cells such as NK 
cells (318). They showed that Fcγ receptor deficient mice were normal with respect to in vitro 
NK mediated killing of YAC-1 cells while they had lost the ability to kill antibody coated 
targets via ADCC. To test if the Fcγ receptors and ADCC are important in tumor immunity in 
vivo, the mutant mice were used to study development of syngeneic melanoma metastasis 
after passive or active immunization (319). In both set-ups, the wild type mice treated with 
passive or active immunization against a melanoma antigen showed significantly reduced 
metastasis compared to untreated wild type mice. However, the Fcγ-deficient animals did not 
acquire any immune protective effect after any of the treatments despite that the active 
immunization induced both B and cytotoxic T cell responses. These data indicate that the Fcγ 
receptor mediating ADCC is important for antibody mediated tumor immunity in vivo. 
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In a follow up study the same group showed that the efficiency of any given treatment 
depends on the net effect on many pathways. The inhibitory FcγRIIB receptor is expressed on 
myeloid effector cells, such as monocytes and macrophages, and on B cells to negatively 
regulate antibody production. 
 
FcγRIIB-deficient mice were generated to test if this receptor influences the outcome of 
antibody mediated anti-tumor activity in vivo. Without treatment, the deficient mice 
developed melanoma metastasis in a manner comparable to wild type mice. However, when 
treated with the antibody against melanoma antigen, the FcγRIIB-deficient mice gained 
significantly more protection by the treatment; they developed less lung metastases than 
antibody treated wild type mice. Furthermore they tested how both the activating Fcγ and the 
inhibitory receptors contribute to function and end-result of two known pharmaceutically 
approved antibody treatments, trastuzumab and rituximab described above. The anti-tumor 
effects of trastuzumab and rituximab were studied using xenograft models based on human 
breast carcinoma and B cell lymphoma respectively. They intercrossed the activating Fcγ and 
the inhibitory FcγRIIB-deficient mice to athymic nude mice (320). In both tumor models, the 
tumors grow and spread equally well in non-treated mice. Treatment with trastuzumab or 
rituximab inhibited tumor growth and development almost completely in control mice while 
in the Fcγ-deficient mice very little protection was observed. However, treating FcγRIIB 
receptor deficient mice lacking the inhibitory Fc receptor with the mouse antibody equivalent 
to trastuzumab resulted in less tumor burden, indicating that other pathways and other cells 
than NK cells are important for tumor eradiation and treatment success. To further prove the 
role for Fc receptor mediated ADCC, the mouse trastuzumab was modified via point 
mutations. These mutations lead to reduced binding to Fc receptors on the effector cell, 
resulting in reduced tumor rejection. 
 
Other groups have studied the how the efficacy of the ab treatment can be optimized although 
the patients have Fc receptor polymorphisms. Busfield et al. developed a humanized 
antibody with improved ADCC capacity targeting the IL-3 receptor expressed in on many 
tumor cells and blasts from acute myeloid leukemia patients (321). This antibody had been 
engineered to achieve increased affinity to CD16, which augmented both in vitro ADCC 
mediated killing and in vivo elimination of leukemic cells. In addition, treatment with the 
antibody increased in vitro elimination of leukemia cell by NK cells from acute myeloid 
leukemia patients. (321). 
 
Taken together these studies show the importance of considering the whole picture, in this 
case the whole immune system, and how it is affected, and not a particular cell type. They 
also address the importance of designing the antibody for optimal effect, either by high 
affinity to the Fcγ receptor and low binding capacity for the inhibitory FcγRIIB receptor, or 
by combining improved efficacy with a specific target increasing the overall function. 
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1.11.4.1 Increased NK cell activity induced by self-specific inhibitory receptor blockade 
 
The second type of antibody treatment used to activate anticancer effects by NK cells is based 
on blockade MHC I binding inhibitory receptors. This is a more specific way of activating 
NK cells, and at least in theory, only the NK cells that have been educated for missing self 
recognition, the most responsive NK cells. In addition, this type of treatment can be used 
when the tumor expresses HLA/MHC I, when other approaches may fail due to the strong 
inhibition overriding the desired NK cell activation. The effect of blocking inhibitory 
receptors on NK cells has been studied by many groups, both in mice and in humans. Koh et 
al. were the first to block self-specific inhibitory receptors for MHC I in the mouse, aiming to 
induce missing self recognition of tumor targets expressing MHC I. They used F(ab’)2 
fragments of the antibody 5E6, blocking the murine inhibitory receptor Ly49C and I. They 
observed increased killing of syngeneic MHC I expressing cells (e g C1498 tumor cells) in 
vitro and in vivo in a NK cell dependent manner (322-324). This concept had not really been 
developed further at the time the studies in this thesis were initiated. It has now applied in 
several settings and explored mechanistically, and the concept of NK cell inhibitory receptor 
blockade is currently in clinical trials. The topic will be further discussed in result/discussion 
section 3.5. 
 
1.11.4.2 Checkpoint blockade 
 
Removal of inhibition, as described above, is used to tilt the balance towards NK cell 
activation and target elimination. This concept is quite similar to what has been termed 
immune checkpoint blockade, a term that is mainly if not exclusively used for T-cell 
regulation. Indeed, immune checkpoint blockade was developed to activate antitumor activity 
by T cells. Checkpoints are inhibitory pathways controlling the immune system to ensure 
self-tolerance, and minimize the risk for tissue damage caused by a too strong or sustained 
immune response. Immune checkpoints are characterized by a receptor-ligand interaction 
which can be targeted by either antibody blockade or by introducing recombinant receptor or 
ligand. Antibodies can be used to target receptors or ligands on lymphocytes to increase 
antitumor activity instead of targeting the tumor cells directly. T cell activation is regulated 
via two signals, binding of a specific Ag to the T cell receptor and a co-stimulatory signal 
(CD28 binding to CD80 or CD86 on the antigen presenting cell). The activation is inhibited 
by CTLA4 (mediating inhibitory signals) on T cells also binding to CD80 and CD86 on the 
antigen presenting cell, dampening the activation. CTLA4 was the first immune checkpoint 
regulating antibody to be approved for clinical use, in patients with metastatic melanoma. 
There is a positive effect on overall survival and a significant number of dramatic, durable 
responses, which for this patient group represents a remarkable progress (325). Blocking the 
inhibitory pathway is associated with a potential risk of toxicity due to a sustained immune 
response, and severe adverse effects of autoimmune or inflammatory nature develop in 
approximately 20% of patients. In the last year, drugs for blockade of another checkpoint; 
PD-1/PD-L1 has been approved for melanoma and lung cancer (326). 
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1.12 IMMUNODEFICIENCIES 
 
1.12.1 Primary immunodeficiencies 
 
This thesis is mainly about murine NK cells with some comparative comments on human NK 
cells in relevant sections, such as the one on clinical application above. The following section 
on immunodeficiencies will deal exclusively with the human system, since the development 
of clinical observations and basic immunology has provided a great opportunity to learn more 
about NK cells and how important they are for our wellness. What we can learn from the 
mouse system will be presented in the discussion together with experimental results obtained 
during the thesis studies. 
 
Primary immunodeficiencies (PIDs) represent a collective name for disorders that is caused 
by the inborn lack or a dysfunctional component of the immune system. This weakens the 
individual’s immune system and host defense against unwelcome intruders. Many of these 
patients are diagnosed as babies or in young life due to recurring and persistent infections 
such as bacterial or opportunistic virus infections (i e herpes simplex virus or Epstein bar 
virus). Milder defects can be diagnosed later in life. To be defined as a primary 
immunodeficiency the cause of the disease must be direct and persistent and not induced by 
circumstances such as medication or infection. Primary immunodeficiencies are caused by a 
genetic defect; most of these affect more than one function or cell type of the immune system 
and  quite  many  of  the  genetic  alterations  have  been  identified  and  explored  at  the 
biochemical level. Some defects cause a developmental arrest, resulting in lack of one or 
more subsets of cells; others do not influence development as much as effector functions in 
mature cells. Different defects generate different symptoms. Other defects can cause 
autoimmunity or even cancer. To treat the patient hematopoietic stem cell transplantation is 
needed. NK cells can be affected by immunodeficiency syndromes. For example, in some 
form  of  severe  combined  immunodeficiency  (SCID)  the  developmental  of  NK  cells  is 
arrested in parallel with impaired T cell and/or B cell development (327). 
 
There are also defects that affect a distinct function in mature lymphocytes. Hemophagocytic 
lymphohistocytosis is a  lymphoproliferative disorder which can be subdivided into primary 
or secondary HLH (reviewed in (328)). Primary HLH or Familiar hemophagocytic 
lymphohistocytosis (FHL) is a group of diseases, FHL1-5, each caused by different mutations 
with an autosomal recessive inheritance. These patients are often infants with life threatening 
symptoms, which is due to a defective T and NK cell cytotoxicity. The common denominator 
between the mutations is that they disturb either the granule content or delivery in cytotoxic 
lymphocytes. This results in an overstimulated immune system causing massive cytokine 
production and infiltration. Familiar hemophagocytic lymphohistocytosis type 2 can be 
caused by different mutations in the perforin gene PRF1 resulting in low or absent levels of 
perforin (constitutively expressed by NK cells, memory CD8 T cells) in cytotoxic T and NK 
cells (329, 330). Common manifestations are reoccurring severe infections and malignancies 
in both children and adults (331-334). The only cure is hematopoietic stem cell 
transplantation. For secondary or acquired HLH which can occur later in life there have been 
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associations to triggering via virus infections. HLH is not a single disease, it is rather several 
syndromes caused by an uncontrolled immune system with massive inflammation. 
 
Other primary immunodeficiencies result in severely impaired development of only one of 
the three lymphocyte lineages. The DiGeorge syndrome involving a thymic defect leads to 
selective T cell deficiency. Brutons X-linked agammaglobulinemia involving a defective 
signaling molecule leads to B cell deficiency. There is also a special branch of primary 
immunodeficiencies that involves a selective NK cell deficiency (NKD). As in the case of 
primary immune deficiencies affecting T and B cells, NK cell deficiency is defined as a 
persistent abnormality in the patient that is stable over time and not induced by as 
environmental alternation as mentioned above. To be defined as a selective NK cell 
deficiency the defect must only affect the NK cell population by size, function or both; it 
must not affect other cell types of the immune system. For example perforin deficiency, 
mention above, is a primary immunodeficiency but not a NK cell deficiency since it also 
affects cytotoxic T cells (335). In fact many primary immunodeficiencies affect the NK cell 
population in several ways such as impaired development, survival or cytotoxic function but 
they also affect other parts of the immune system reviewed in (336-338). 
 
Two types of selective NK cell deficiency have been observed, for which the terms classical 
natural killer cell deficiency (CNKD) and functional natural killer cell deficiency (FNKD) 
have been proposed (336). Classical natural killer cell deficiency is currently defined by the 
complete lack of NK cells in peripheral blood or that NK cells constitute less than 1% of 
peripheral blood lymphocytes. In functional natural killer cell deficiency on the other hand 
there is an almost normal NK cell count in the peripheral blood, but the NK cells are non- 
functional. Both types of NK cell deficiency lead to decreased host defense and increased 
occurrence of virus infections. Both classical and functional natural killer cell deficiency is 
further subdivided by the genetic mechanisms causing the deficiency. The disorders 
discovered so far are termed CNKD1, CNKD2 or FNKD1. 
 
1.12.2 Classical NK cell deficiencies 
 
The first patient with classical NK cell deficiency was documented in 1989.Today at least 19 
patients have been identified, all presenting with the absence or severely reduced number of 
NK cells in the peripheral blood. Furthermore the few NK cells that were found lacked 
cytotoxic capacity.  Many of these patients died prematurely and more than 50% developed 
severe infections with a virus in the Herpes virus family. Three patients have been treated 
with hematopoietic stem cell transplantations, two with a great success (339).  There are two 
known genetic mechanisms causing classical natural killer cell deficiency, CNKD1 and 
CNKD2. The first (CDNKD1) case was caused by haploinsufficiency in the transcription 
factor GATA2. GATA2 is important for correct NK cell development (379). CNKD2 is 
caused by a mutation in the gene minichromosome maintenance 4 (MCM4) which is 
important for correct DNA replication (380). Patients with CNKD2 have a reduced total 
number of NK cells but a higher frequency of immature NK cells) in the small NK cell 
population found. The total NK cells population from these patients shows a low cytotoxicity 
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against known targets, which could be due to lack of mature cells (381). It could be due to 
that the perforin containing mature NK cells are simply too few or that a mutation in MCM4 
impairs NK cell function. 
 
1.12.3 Functional NK cell deficiency 
 
When a patient has no other deficiencies in the immune system except dysfunctional NK 
cells, they are categorized as functionally NK cell deficient (382, 383). These patients have a 
normal total NK cell count but the NK cells lack the cytotoxic capacity. Today only one 
single gene defect is known to cause functional NK cell deficiency, FNKD1, which is a 
mutation in the gene encoding for the receptor CD16, known to be the most important 
receptor for NK cell mediated ADCC. This mutation is in the extra cellular part of the 
molecule but does not affect the CD16-antibody binding, and paradoxically these patients 
show a normal ADCC capacity (384). At least three patients have been diagnosed with 
FNKD1, all of them presenting with recurrent virus infections and with reduced NK mediated 
cytotoxicity against the K562 cells in the clinical immunology testing (382, 385 ). The lack of 
cytotoxicity could be due to that CD16 normally can bind to CD2, a member of the SLAM 
receptor family that can induce spontaneous cytotoxicity, but the mutated CD16 lack this 
capability and can therefore not act as a costimulatory receptor and cytotoxicity will be 
abrogated (as discussed above, most NK cells receptors except CD16 needs to function in 
pairs to be able to give fully activation). 
  
49  
2  AIM 
 
The overall aim of thesis has been to study missing self recognition by NK cells and how 
they are educated by host MHC I molecules to perform this function; in particular, whether 
these processes can be manipulated in an experimental therapeutic setting, as well as their 
relation to a new type of immune defect in the mouse. 
 
Paper I) To characterize the deficient missing self recognition displayed by the Impaired 
Missing Self Recognition (IMSR) mice. 
 
 Is the observed NK cell defect due to the targeted gene in these mice? 
 Is the IMSR NK cell deficiency due to lack of any activating or inhibitory receptor? 
 Are the inhibitory receptors functional i e can they mediate inhibition? 
 Is the observed missing self deficiency intrinsic to the NK cell or/and is it due to lack 
of education? 
 
Paper II) To evaluate if it is possible to manipulate missing self recognition by inhibitory 
receptor blockade in vivo to enhance elimination of syngeneic MHC I
+ 
tumor cells 
 
 Is it possible to mimic missing self recognition and thereby enhance elimination of 
MHC I
+ 
sufficient tumor cells in vivo without breaking tolerance towards self? 
 Can self-tolerance be secured during a longer treatment period and is the anti-tumor 
sustained (important issues for clinical application)? 
 Can the anti-tumor effect be further enhanced by already establised treatments such 
as cytokine stimulation? 
 
Paper III) To study if NK cells can retune their responsiveness upon/due to altered MHC I 
expression 
 
 Is it possible to retune the NK cell responsiveness by altering the inhibitory input, 
either via inhibitory receptor blockade or via transfer of mature NK cells to an 
altered host? 
 If the responsiveness is increased (up-tuned) are NK cells still self-tolerant? 
 Do the retuned NK cells display any phenotypical changes? 
 Is the reduced responsiveness in inhibitory receptor blockade caused by crosslinking 
of receptors leading to direct induction of inhibitory signals in the effector function? 
 
Paper IV) To investigate if the observed skewing of the inhibitory receptor repertoire 
occurs already in the bone marrow during NK cell development 
 
 At which NK cell developmental stage does the skewing of inhibitory receptor 
repertoire occur? 
 Which mechanistic processes are involved in creating the enrichment for certain 
populations, increased proliferation or reduced proliferation? 
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3  RESULTS AND DISCUSSION 
 
In this section of the thesis I will focus on those of my discoveries that I think are most 
interesting, and also on some data that have not been published. I will not follow the order 
of the papers, instead I will discuss them in an integrated way, under six different themes, 
sometimes referring to more than one of them under each theme. For all results and details 
you are welcome to read the papers (I-IV). 
 
3.1   GENETIC DEFECTS AFFECTING NK CELLS 
 
As mentioned in the introduction, selective NK cell defects in humans are classified by 
either lack of NK cells or impaired function of NK cells (with normal numbers). These 
defects are caused by a few known mutations. However, the murine system can be 
manipulated both specifically, by targeting a certain gene. This has been used to show the 
importance of different molecules in NK cell function. NK cells from an MHC I-deficient 
host are hyporesponsive due to lack of licensing/arming via the MHC I self specific 
inhibitory receptors. Although many defects are intentionally induced, others have arisen 
spontaneously and some of them are of unknown basis. 
 
In paper I we characterized a defect observed in a mouse strain, termed IMSR - Impaired 
missing self recognition. As the name implies, this mouse strain shows impaired missing 
self recognition; it lacks the ability to eliminate target cells lacking MHC I. 
 
The IMSR defect was discovered in a gene targeted “KO” mouse strain deficient for a non- 
classical MHC I like gene, CD1, but with otherwise normal MHC I expression. We 
unexpectedly observed that the mice had severely impaired capacity for NK cell mediated 
rejection of MHC I-deficient cells. Control experiments with independently derived KO 
strains for the same gene, as well as F1 and F2 intercrosses with B6 mice indicated that the 
functional NK cell defect was not caused by the targeted gene, that the trait was recessive 
and that the two phenotypes, IMSR and deficiency in CD1 expression, segregated 
independently. 
 
IMSR mice were similar to wt B6 mice in terms of NK cell number as well as NK cell 
surface phenotype regarding activating receptors and maturation markers. All receptors 
expressed in B6 mice are also expressed/present in the IMSR mice. However, there was a 
significantly altered inhibitory receptor repertoire, as evaluated by a large panel of 
antibodies to activating and inhibitory receptors (see section 3.4.2). In vivo, the NK cells 
showed a severely impaired capability for missing self rejection of normal spleen cells 
(β2m
-/-
)  as  well  as  of  tumor  cells  (RMA-S).  Kinetic  studies  and  tumor  outgrowth 
experiments revealed a profound defect rather than just a delay in missing self rejection. 
Experiments  with  mixed  bone  marrow  chimeras  indicated  that  the  defect  is  NK  cell 
intrinsic and not due to the host environment. In vitro assays also showed a prominent 
defect in missing self recognition, which in most settings could not be overcome with 
cytokine stimulation. In contrast, there was a normal or only partly impaired capacity with 
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respect to other NK functions, such as ADCC and NKG2D dependent cytotoxicity. 
Furthermore,  positive  allorecognition  by NK  cells  in  vivo  was  not  affected:  the  mice 
showed a normal capacity for DAP-12 dependent rejection of MHC disparate (D
d
) cells. 
However, NKG2D dependent elimination of tumor targets in vivo was severely impaired. 
For discussion regarding NKG2D and Ly49D see section 3.1.2. 
 
Our results indicate that this mouse strain has a genetically based, NK cell intrinsic and 
almost selective deficiency in the killing pathway used to sense missing self. Our data 
argued against possible causes like a complete lack of inhibitory receptors or lack of one or 
several known activating receptors. As discussed in paper I, lack of inhibitory receptors, 
lack of functional signaling molecules or other cell types has been shown to influence NK 
cell function in different ways, but none of the known characterized defects is really 
consistent with the one observed in the IMSR mice. 
 
The defect may be possible to identify by whole genome sequencing after backcrossing the 
IMSR defect appropriately on the B6 background. At this stage, one can only speculate 
regarding the cause of the observed NK cell phenotype in the IMSR mouse. First, the 
inhibitory receptors or their signaling pathway may be non-functional, which could disturb 
missing self recognition while leaving other NK functions relatively intact. Second, the 
dysfunction may involve an unknown activating receptor or signaling molecule, critical for 
missing self recognition but no other types of activation. Third, at steady state, the NK cell 
may receive too much activating or inhibitory signals inducing hyporesponsiveness either 
via “cross-tolerance” or a too high activation threshold to overcome.  I will discuss these 
possibilities below. 
 
3.1.1  Are abnormal inhibitory receptors causing the NK cell deficiency? 
 
Even if NK cells from IMSR mice expressed inhibitory Ly49 receptors, it was possible that 
these cannot signal, and the lack of missing self recognition would thus due to absence of 
MHC I dependent education similar to what is observed in an MHC I (or Ly49r) deficient 
mouse. (203, 340-342) NK cells from MHC I-deficient mice are tolerant towards “self”, i e 
normal cells lacking MHC I expression. The lack of inhibitory signals from educating 
interactions results in hyporesponsiveness, an inability to respond sufficiently when 
triggered via activating receptors, due to an increased activation threshold. Although MHC 
I-deficient NK cells are hyporesponsive they still have functional inhibitory receptors and 
the ability to use them and interact with MHC I when the opportunity occurs, see below and 
paper III. Further, NK cells in mice lacking SHP-1 and hence the capability to signal via 
inhibitory receptors, are also hyporesponisve, unable to perform missing self reactivity and 
control tumors in vivo (342, 343). 
 
We compared missing self recognition in IMSR and β2m-/- mice by studying the animals´ 
capacity to eliminate MHC I-deficient tumor cells, RMA-S, in vivo. Both IMSR and MHC 
I-deficient NK cells were capable of an increased elimination of RMA-S cells compared to 
the MHC I expressing counterpart RMA, although with a significantly reduced efficiency 
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compared to wild type mice (data not shown). This indicates that NK cells from IMSR and 
MHC I-deficient mice both can be inhibited via their inhibitory receptors. 
 
In addition to what was presented in paper I, we later studied in vitro killing of Con A- 
activated T cell blasts (Con A blasts) by IL-2 activated IMSR and B6 NK cells. In this 
setting  we  actually  observed  a  significant  increase  in  killing  of  β2m
-/-   
Con  A  blasts 
compared to killing of B6 Con-A blasts (data not shown). This was only observed in the 
highest effector target ratio (1:100) and killing was not as efficient as by B6 NK cells. In 
this set-up the cytokine pre-activation could partly override the deficiency normally 
displayed by the IMSR NK cells. In another set of experiments, we used IL-2 activated 
Ly49A
+ 
NK cells, isolated by FACS sorting, in a cytotoxic assay against tumor targets with 
or without expression of the D
d 
ligand. The IMSR NK cells were inhibited via the Ly49A- 
D
d 
interaction to the same extent as NK cells from wild type mice. Another important 
evidence that the inhibitory receptors of IMSR NK cells are functional is that they display 
the pattern of skewing of the NK cell repertoire consistent with education and inhibitory 
input. This will be further discussed in section 3.4.2 and 3.4.3. ). Taken together these data 
indicate that when we push the system either by increasing activating ligands on target cells 
or  by  cytokine  activating  the  NK  cells  we  can  detect  reactivity  regulated  by  MHC 
inhibitory  receptors,  showing  that  IMSR  NK  cells  have  the  capability  to  signal  and 
discriminate via these receptors (344). 
 
The IMSR NK cells showed a partly impaired ADDC against antibody coated targets. This 
is interesting, for at least two reasons 1) the defect in the IMSR mice affects different parts 
of NK cell function with different degrees of severity and 2) in patients with functional NK 
cell deficiency type I, which carry a mutation in the CD16 locus, the NK cells have normal 
or almost normal ADCC but are deficient in killing of a NK cell sensitive tumor K562 
(K562 is the prototype for human NK cell target cells equivalent to YAC-1 in mouse). In 
the case of the FNKD1 patients the mutation in the CD16 locus alters the co-stimulatory 
effect of CD16. Here we observed a reduction in CD16 dependent function per se but it was 
not as severely affected as the missing self recognition. An additional similarity to an NK 
cell deficiency observed in humans is NK cells with a mutation in the Wiskott-Aldrich 
Syndrome protein coding gene which are defective in natural cytotoxicity and in ADCC. 
However, these NK cell regain their function upon IL-2 activation. (345). 
 
3.1.2  Is NK cell deficiency caused by alteration(s) in activating receptor 
pathways? 
 
The observed deficiency in the IMSR NK cells could be due to a mutation influencing one 
or several of the activation pathways. The most obvious would be a loss of function leading 
to lack of activation. Many such mutations affecting signaling pathways downstream of 
activating receptors have been described. As discussed in paper I, none of them fits the 
IMSR profile completely. However, some other specific deficiencies are quite similar in 
their observed phenotype e g Fyn or loss of total activating receptor(s) signaling. Another 
option is that the deficiency is due to a mutation resulting in a gain of function mutation, 
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resulting in hyper-signaling in an activation pathway. How this could fit our results will be 
discussed below. 
 
Ly49D  and  NKG2D  are  two  activating  receptors  which  mediate  their  signal  through 
DAP12  or  DAP10  respectively.  We  tested  these  two  signaling  pathways  in  different 
settings. IMSR NK cells could eliminate Ly49D sensitive target in vivo as well as produce 
IFNγ and degranulate in vitro after Ly49D antibody stimulation. In contrast, IMSR mice 
were  not  capable  of  eliminating  RMA-Rae-1γ  tumor  cells  (expressing  high  levels  of 
NKG2D ligand) in vivo while both B6 and β2m-deficient mice did (figure 7 and data not 
shown). Interestingly, Cerwenka et al. showed that injection of RMA-Rae-1γ tumor cells 
into the same CD1d1 KO mouse strain as ours resulted in prolonged survival of the mice 
compared to mice injected with the parental RMA tumors (346). This is not in total conflict 
with our data. The deficiency in NKG2D-mediated rejection observed by us may not be 
total but rather a severe defect observed in short term experiments which can be overcome 
during a longer time period. In addition, it has been shown that elimination of RMA Rae-1 
is dependent on both NK cells and CD8
+  
T cells (35, 169). It is possible that the CD8
+  
T 
cells mediated tumor elimination was observed in the long term experiments but not in our 
short in vivo assay. Taken together these results indicate that the IMSR mice have a fully 
functional signaling via Ly49D and DAP12 but not via NKG2D, DAP10 or downstream of 
DAP10. These data are further supported by the fact that DAP12-deficient mice show an 
intact missing self recognition (347, 348). Raulet generated an NKG2D-deficient mouse 
which lacks the capability to eliminate NKG2D ligand expressing tumors both in vitro and 
in vivo (161).These mice showed a normal missing self rejection. Even if the NKG2D 
receptor in the IMSR mice is mutated or the signal is severely impaired, the IMSR mice 
must have an additional or a different defect explaining the impaired missing self reactivity. 
 
As mentioned above, no known genetic NK cell defect in mice or humans is really 
consistent with the phenotype observed in the IMSR mice. However, there is at least one 
study of dysfunctional NK cells sharing many similarities with the IMSR NK cells. This 
“NK cell deficiency” is not genetic, but caused by chronic exposure to ligand for the 
activating receptor NKG2D in vitro (349). B6 NK cells were co-cultured with RMA-H60 
(expressing high levels of NKG2D ligand H60) for 3 days. Interestingly, this chronic 
stimulation did not only abrogate the NKG2D-DAP10 mediated killing, it also impaired 
ADCC (via CD16-FcRγ) and missing self killing of MHC I-deficient tumor cells (RMA-S). 
Ly49H-DAP12-mediated killing remained intact. In addition, the NK cells had a reduced in 
vitro IFNγ response to RMA-S cells or plate bound antibody stimulation via NK1.1, while 
Ly49D stimulation gave a significantly increased IFNγ response. The functional phenotype 
observed after chronic ligand exposure is almost identical to the phenotype observed in the 
IMSR NK cells. As may be noted in figure 6 in paper I, NK cell from the IMSR mice 
without antibody stimulation displayed an increased spontaneous release of IFNγ and the 
same was true for the NK cells which had been chronically activated, indicating some sort 
of increased basal activation state (paper I figure 6, my unpublished data and (349). In 
addition, the NK cells chronically exposed to the NKG2D ligand had an impaired Ca
++
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influx (needed for NK cell activation) after stimulation via NKG2D, CD16, NK1.1 and 
NKp46, while Ly49D and Ly49H Ca
++ 
influx remained almost intact. The induced NK cell 
defect affecting multiple activation pathways was only observed when NK cells were 
exposed to targets expressing NKG2D or Ly49D ligands (using DAP10/12 or DAP12 
respectively) but not to targets triggering CD16 or inhibitory Ly49r. So, continuous 
stimulation through either DAP10 or DAP12 can induce, as termed by the authors, “cross- 
tolerance” while the other receptors/adaptor proteins tested cannot. 
 
Chronic exposure to activating ligands for NKG2D has also been studied in vivo. 
Oppenheim et al. generated several transgenic mouse strains with different range of normal 
cells expressing the NKG2D activating ligand Rae-1 (350). Upon constant exposure to its 
ligand, NKG2D was downregulated both in vitro and in vivo. The NK cells from Rae-1 
transgenic mice could not kill targets in vivo expressing the Rae-1 ligand or eliminate MHC 
I-deficient spleen cells. This impairment could be restored by treating the mice with poly 
(I:C) which activates NK cells via Toll like receptor 3 expressed on myeloid cells, resulting 
in type I interferon production. In contrast to NK cells from Rae-1 transgenic mice, those 
from IMSR mice cannot regain ability to kill MHC I-deficient tumors by cytokine pre- 
activation in vitro or gain ability to respond to plate-bound antibody stimulation in vitro 
after in vivo pre-activation with a the type I interferon inducer tilorone. 
 
One can speculate that the defect in the IMSR mice could be due to increased interaction 
with NKG2D ligands in vivo inducing “cross-tolerance”. But if this was the case, IMSR 
NK cells from mixed bone marrow chimeras in wt mice should not display the defect while 
wt NK cells from mixed bone marrow chimeras in IMSR mice should. In contrast, the 
defect was intrinsic to IMSR NK cells (see section 3.1 above). In addition, NK cells in the 
IMSR mouse express NKG2D with a slightly but not significantly reduced MFI (mean 
fluorescense intensity). The reduction in expression levels for NKG2D is most likely not 
responsible for the reduced function since NK cells from MHC I-deficient mice also 
expressed lower levels of NKG2D (paper III and unpublished data) but were still capable of 
rejection of tumor cells expressing NKG2D ligands. Altogether these observations argue 
against that the IMSR NK cells are chronically exposed to NKG2D or Ly49D ligands 
mediating sustained DAP10/12 signaling. 
 
However, the studies by Coudert and Oppenheim et al. support my idea that the cause 
behind the IMSR phenotype could be overstimulation of NK cells, e g that activating 
signaling is constitutively on, even in the absence of cognate receptor-ligand interactions. 
This could potentially be caused by an overexpressed or altered signaling molecule or by 
the lack of a phosphatase so that the signaling is not abrogated. If this would be the case it 
could give the same functional defect as observed in “cross-tolerance” caused by chronic 
exposure to ligand. 
 
Despite the similarities between the IMSR functional phenotype and the effect of chronic 
NKG2D ligand exposure, NK cells with a total lack of NKG2D also share features with the 
IMSR NK cells. Removal of both NKG2DL and -S expression leads to a reduction of the 
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spleen size due to a reduction in the B, T and NK cell compartments (351). This is partly 
true also for the IMSR mice which show a reduction in spleen size and total lymphocyte 
number, have normal proportion of NK cells and T cells but reduced frequency of follicular 
B cells and almost no marginal zone B cells (351) (Mikael Karlsson’s unpublished data). 
Mice lacking NKG2D expression display a normal NK cell maturation pattern in the spleen 
but a reduction of more mature and KLRG1 expressing NK cells in the bone marrow. 
Interestingly, NK cells from NKG2D-deficient mice display the opposite responsiveness 
pattern to IMSR NK cells i e they have an increased cytokine production in response to 
certain types of stimulation and the mice display an increased survival to cytomegalovirus 
infection. In addition, the NK cells from these mice have a faster cell division rate but are 
also more susceptible to apoptosis in both IL-2 and IL-15 in vitro cultures. In summary, we 
cannot exclude that NKG2D is involved in the IMSR deficiency, further investigation is 
needed. 
 
Another strong activating receptor expressed by a considerable proportion of NK cells in at 
least  some  mouse  strains  is  Ly49H,  recognizing  the  MCMV  encoded  protein  m157. 
Bolanos et al. used a transgenic mouse chronically displaying m157 to the NK cells (352). 
This exposure induced reduced function of Ly49H
+ 
NK cells, not only in response to m157 
but also to Ly49H independent stimulation in vitro via NK1.1 and YAC-1. The induction of 
this reduced responsiveness was DAP12 dependent, and was observed in mature NK cells 
but was rapidly reversible if ligand exposure was removed. These results corroborate that 
increased signaling from an activating receptor can lead to impaired general NK cell 
function. 
 
Similar to the NKG2D-deficient mice discussed above (351), mice lacking NKp46 also 
display  a  hyperresponsive  phenotype.  Narni-Mancinelli  et  al.  showed  that  absence  of 
NKp46  function,  either  in  mutant  mice  or  by  antibody  blockade  in  wild  type  mice, 
generated hyperresponsive NK cells with a stronger cytokine response after in vitro 
activation and a prolonged mouse survival after MCMV infection (353). The endogenous 
ligand for NKp46 is unknown, but these observations indicate that it may play a role in 
tuning the NK cell responsiveness. These results may thus be interpreted in the context of 
education but unfortunately the authors did not investigate if there were any differences in 
responsiveness between NK cells expressing inhibitory receptors for self MHC I or not. 
 
However, there are conflicting data regarding if loss of NKp46 induce hyperresponsiveness. 
Sheppard et al. generated NKG2D/NKp46 double knockout (DKO) mice to study the 
influence of activating receptors on NK cell phenotype and function (354). The NK cells 
from the DKO and the NKG2D single KO mouse showed altered phenotypes, increased 
number of mature cells and changed receptor expression. In line with the other NKG2D KO 
mice presented above, these NKG2D KO and DKO mice responded more efficiently by 
IFNγ production to some activating stimuli. However, the NKG2D KO studied did not alter 
resistance to MCMV infection. Further, the NKp46 KO mice showed no alteration in either 
phenotype or functional responses of NK cells which is in contrast to the results presented 
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by Narni-Mancinelli et al.. However, the influence of NKp46 in resistance to MCMV was 
not evaluated. 
 
To summarize, it is hard to draw any conclusion regarding our defect from studies based on 
different KO mice since there are inconsistent data.. In any case, the IMSR mice illustrate 
nicely that something else than the targeted gene can cause functional changes when a KO 
mouse is generated and backcrossed. It cannot be excluded that the critical change affects 
an activating receptor or pathway these mice, this possibility should be further investigated. 
 
3.1.3  Signaling pathways and molecules potentially involved in the IMSR NK 
cell deficiency 
 
Many alterations in signaling pathways downstream of either activating or inhibitory NK 
cell receptors result in similar dysfunction as the defect observed by the IMSR NK cells. In 
this section I will go through some findings in this literature that appear to be of particular 
interest in relation to the IMSR NK cells. 
 
The SLAM receptor 2B4 and its downstream signaling pathway may influence NK cell 
responsiveness. As elaborated on in the introduction (section 1.7.4) the regulation of murine 
2B4 function is dependent on the SAP-family (SAP, EAT-2 and ERT) where all three 
members synergize to mediate activation (142). The ligand of 2B4 (CD48) is expressed on 
all hematopoietic cells, explaining why mice deficient for the SAP family members 
displayed a reduced NK cell killing of hematopoietic cells, such as RMA-S and YAC-1, as 
well as a reduced in vivo rejection of normal MHC class I-deficient spleen cells, while they 
showed an increased killing of non-hematopoietic target cells. Further, in the absence of the 
SAP-family, the 2B4-CD48 interaction inhibits activation through NKG2D and CD16 in a 
SHIP-1 dependent manner (196, 198). These data are in line with the functional phenotype 
of the IMSR NK cells even if reactivity to non-hematopoietic cells has not been tested yet. 
It would be of interest to study the general function of 2B4 in the IMSR mice and to test 
reactivity against a non-hematopoietic target cells. Although western blot analysis indicates 
that the Fyn protein is expressed at normal levels in cells from the IMSR mice, it could still 
be non-functional. It would also be of interest to study the SAP-Fyn pathway and to block 
the EAT-2 pathway in the IMSR mice. 
 
Other important signaling molecules participating in activation of NK cells are 
phospholipase Cγ-1 and -2 (PLC-γ1 and PLC-γ2) and mice mainly express and use PLC-γ2 
(355). Mice lacking PLC-γ2 are perturbed in NK cell maturation, in expression of Ly49 
inhibitory receptors and in NK cell function. Overexpression of PLC-γ1 can restore the 
maturation and Ly49 expression but only partly rescue the function (356). Furthermore, 
PLC-γ2-deficient NK cells lack the ability to respond to almost any activation. They show 
defective killing of targets via NKG2D, Ly49D, missing self recognition, and lack the 
capability to produce cytokines after NK1.1 stimulation, but hyporesponsiveness was not 
due to lack of total function since the NK cells could fully respond to PMA stimulation 
(356, 357). However, an interesting similarity to the IMSR mice is that PLC-γ2 mice lack a 
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large population of follicular B cells and marginal zone B cells in the spleen (358-360) and 
Mikael Karlsson’s unpublished data). In line with the NK cell deficiency, the marginal zone 
B cell deficiency in IMSR mice was also cell intrinsic.; transplantation of bone marrow 
from an unrelated CD1d
-/- 
KO mice with normal marginal zone B cell numbers grow out in 
the IMSR host (Mikael Karlsson unpublished data). Further studies are needed to evaluate 
if both deficiencies in the IMSR mice have the same genetic basis. In addition to the 
mechanism behind the defect(s) per se it would be of interest is to study how the IMSR 
mice and their NK cells can handle a virus or bacterial infection since the PLC-γ2-deficient 
mice cannot control CMV infection although they can handle a Listeria infection (357). 
NKG2D-DAP12 can signal via both Grb2 resulting in the usage of PLC-γ2 but also via 
PI3K (via p85) which is PLC-γ independent. However, as described above, lack of PLC-γ2 
resulted in severely impaired NK cell function in general but also through NKG2D, 
indicating non-complete redundancy in the system. 
 
3.2   HYPORESPONSIVENESS DUE TO RETUNING AND OTHER PROCESSES 
 
3.2.1  Altered responsiveness upon antibody blockade 
 
Interactions between MHC I specific inhibitory receptors and their ligands during education 
regulate  NK  cell  responsiveness  in  encounters  with  target  cells.  As  noted  in  the 
introduction, there were initially two postulated models for how this occurs, via licensing or 
disarming. A third model, the rheostat model, incorporates features from both of the other 
models, and emphasizes that responsiveness is reversible and the NK cell can be retuned 
upon altered MHC I expression or inhibitory receptor input. In addition, a “sequential 
arming/disarming model” stating that NK cells need to interact with MHC I in both cis and 
trans to become fully responsive has recently been proposed (361). This model suggests 
that education is a two-step process; the first step is dependent on Ly49-MHC I cis 
interactions mediating arming and the second step maintains responsiveness via trans 
interactions. It will be further discussed below (section 3.2.2 and 3.4.3). 
 
Studies in adoptive transfer models have yielded results supporting that NK cells can adapt 
their responsiveness after transfer to a host with an altered MHC I expression (362, 363). In 
two separate studies, NK cells were transferred to a host with a different MHC I phenotype 
and the change in NK cell responsiveness was analyzed in vitro. Mature NK cells from a 
MHC I-deficient environment can gain responsiveness, e g aquire the ability to produce 
IFNγ and respond via degranulation, after transfer to a MHC I sufficient host. Conversely, 
mature NK cell from a MHC I sufficient donor can lose their responsiveness upon transfer 
to a MHC I-deficient host. NK cell adaptation was observed to be Ly49 receptor dependent; 
NK cell populations expressing a self-specific inhibitory receptor adjusted their 
responsiveness, while NK cell populations lacking an educating receptor did not adapt the 
responsiveness to altered MHC I expression. 
 
In paper III we investigated the rheostat model and retuning, particularly in relation to NK- 
cell reactivity to tumors. In one part of the study, we used transfer models similar to the 
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ones mentioned above, where we could confirm and extend the observations regarding 
tumor cell reactivity. These results are discussed in section 3.5.2. Here, the discussion will 
focus on the first part of paper III, where we addressed whether it is possible to induce 
retuning by antibody blockade of self-specific inhibitory receptors in vivo. This represents 
another approach to alter the NK cells’ sensing of MHC I expression in vivo which is less 
invasive, avoiding irradiation and high numbers of transferred cells. The studies of possible 
retuning induced by inhibitory receptor blockade were initiated by some unexpected results. 
 
Before this study, we had we demonstrated in paper II that reactivity against syngeneic 
lymphoma cells can be induced in mice by Ab-mediated blockade of self-specific inhibitory 
receptors on NK cells without breaking tolerance to normal cells. In vivo blockade of 
Ly49C/I inhibitory receptors on B6 (H-2
b
) NK cells with F(ab’)2 fragments of the mAb 5E6 
(binding to Ly49C and I) caused increased rejection of syngeneic MHC class I-expressing 
lymphoma cells (RMA) but not of syngeneic spleen cells, BM cells or lymphoblasts (see 
section 3.5). Self-tolerance was thus very robust, and somewhat surprisingly, killing of 
normal  cells  could  not  be  induced  by  releasing  NK  cells  from  inhibitory  blockade. 
However, an unexpected and interesting finding in the course of these studies was that mice 
treated with the 5E6 antibody showed decreased rejection of splenocytes lacking MHC I. 
This seemed puzzling, but this “disturbing” observation was very reproducible. 
 
It occurred to us that the results could make sense when considered from the perspective of 
the rheostat model. A possible explanation for reduced elimination of MHC I-deficient 
spleen cells could thus be that antibody blockade was not only affecting missing self 
reactivity during the effector-target interaction, it was also influencing the NK cell 
responsiveness prior to this event by blocking inhibitory input important for the constant 
tuning of NK cells, thus inducing hyporesponsiveness in the targeted NK cell population. 
We reasoned that this effect had not been visible in the studies of MHC class I expressing 
tumor cells and in paper II, because the effect on retuning would be masked by the opposite 
effect of the inhibitory receptor blockade in the effector-target interaction phase. The 
hyporesponsiveness  would  only  emerge  when  using  MHC  I-deficient  spleen  cells  as 
targets. To test the hypothesis that inhibitory receptor blockade would retune the NK cells, 
we used the in vitro hyporesponsiveness assay, measuring CD107a expression and IFNγ 
production by the NK cell subsets targeted by the blockade.  The Ly49I single as well as 
the Ly49C and I double positive NK cell subset (expressing no other inhibitory receptors) 
demonstrated a significant decrease in total IFNγ production and CD107a expression after 
stimulation with anti NKp46 antibodies. A phenotypic characterization of NK cells after in 
vivo  Ly49C/I  blockade  showed  no  major  alterations  in  the  expression  of  activating 
receptors, maturation markers and inhibitory receptor repertoire. Interestingly, expression 
of KLRG1 was significantly reduced on Ly49I single and Ly49C/I double positive NK cells 
after Ly49C/I blockade. 
 
According to the rheostat model, responsiveness in NK cells is not a fixed state, it changes 
over  time  according  to  the  input  from  inhibitory  receptors  to  adapt  or  retune  to  the 
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environment. Our results are compatible with this model and may indicate that blockade of 
self-specific inhibitory receptors over time retunes mature NK cells to adjust to the lower 
inhibitory  input.  Furthermore,  our  observations  may  even  imply  that  the 
hyporesponsiveness can explain the robust tolerance to normal MHC class I expressing 
cells in spite of inhibitory receptor blockade in paper II: retuning in response to reduced 
inhibitory input would act to preserve tolerance. Regarding the antibody blockade of self- 
specific inhibitory receptors, it has never to my knowledge been shown that antibody 
treatment can induce retuning of NK cell responsiveness. 
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Figure 4. Four examples of NK target interactions studied in this thesis. NK cells are educated via 
MHC I Ly49r interactions to be able to respond against MHC I-deficient targets. NK cells sense the 
balance between activating and inhibitory signals and the sum of the input will determine the decision, 
elimination of the target cell or not. Expression of MHC I will inhibit the NK cell elimination of the 
target (Wt left) while lack of inhibitory input will activate the NK cell to perform missing self 
rejection of the target (Wt right). By altering the NK cells inhibitory input e g via antibody blockade 
NK cell responsiveness can be retuned to a reduced capability to perform missing self rejection (3
rd 
from the left). Finally, the IMSR NK cells express inhibitory receptors and are at least partly educated, 
but are impaired in their missing self recognition and will therefore respond poorly towards MHC I- 
deficient targets. 
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3.2.2  Hyporesponsiveness induced in Ly49I single positive cells but not in 
Ly49C single positive NK cells 
 
Ly49C/I blocking antibody induced hyporesponsiveness inLy49I single positive and in 
Ly49C/I double positive (negative for Ly49A, -G2 and NKG2A) NK cells. This was 
observed by reduced total responsiveness (CD107a expression and IFNγ production) after 
NKp46 antibody stimulation. Stimulation with PMA and ionomycin resulted in full 
degranulation and cytokine production, arguing against exhaustion of the NK cells. This is 
the first data generated in wt mice showing that Ly49I by itself can act as an educating 
receptor and that targeting this specific population affects responses in the mouse. Previous 
studies have only shown evidence for education and retuning of either the total NK cell 
population expressing self-specific inhibitory receptors, (Ly49C/I/NKG2A), have compared 
Ly49C  positive  versus  negative  populations  or  have  studied  Ly49I  introduced  as  a 
transgene. 
 
But why was retuning observed only in the Ly49I single positive population and not in the 
Ly49C single positive NK cell population? It might be that the binding of 5E6 F(ab’)2 
fragment to the two different receptors, Ly49C and -I, have a different influence on their 
function or that the fragment binds stronger to Ly49I and therefore can alter the 
responsiveness of this population. 
 
Another  possibility  is  that  Ly49I  is  more  accessible  and  therefore  influenced  by  the 
blocking to a higher extent. The majority of Ly49C receptors are bound by K
b 
in cis, 
reducing the number of free receptors available for interaction with other cells or blocking 
with 5E6 F(ab’)2 fragments (90, 248) . In contrast, an artificial system based on transgenic 
expression of Ly49I on tumor cells was needed to detect Ly49I bound in cis (90). It is still 
possible that Ly49I may be interacting with MHC I in cis at the normal state but with a 
frequency  below  the  detection  limit.  Ly49I  is  more  selective  in  its  MHC  I/peptide 
interaction than Ly49C, so if the correct peptides are limited, the cis interactions per Ly49I 
expressing cell will be reduced (88-90). This could affect the accessibility of 5E6 F(ab’)2 as 
well as the effect of blockade on inhibitory input and retuning differently for Ly49C and I. 
 
Importantly, Ly49I was also the main receptor mediating the anti-tumor effect of 5E6 
treatment. This was shown by Gustaf Vahlne and Katja Lindholm in unpublished 
experiments done during the study for paper II. B6 mice (expressing Ly49C and –I) and 
Balb/B  mice,  (expressing  Ly49C  but  lacking  Ly49I)  were  treated  with  5E6  F(ab’)2 
fragments and then challenged with MHC I expressing tumors. The 5E6 F(ab’)2 treatment 
failed to induce an increased elimination of tumor cells in the Balb/B mice while a 
significant increase was observed in the B6 mice. Regardless of mechanism resulting in 
induced hyporesponsiveness in the Ly49I sp and Ly49C/I dp NK cell population the results 
are of importance for the understanding of NK cell education in two ways; 1) as mentioned 
above, this is the first time it has been showed in wt mice that Ly49I by itself is educating 
and can influence the outcome of the total NK cell responsiveness and 2) at least in the case 
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of Ly49I the education is mostly, if not completely, dependent on MHC I interactions in 
trans. 
 
Our data can be interpreted in the context of the rheostat model i e reduced inhibitory input 
will alter the balance between activating and inhibitory signals leading to recalibration of 
the  responsiveness.  As  stated  in  paper  III,  other  explanations  are  not  excluded.  For 
example, our data could also be explained by the sequential arming/disarming model (361). 
The model is based on observations regarding that Ly49-MHC I cis interactions are needed 
to gain both functional competence and skewing of the inhibitory receptor repertoire, hence 
giving the licensing/arming signal. However, MHC I interaction is needed in trans for 
educated  NK  cells  to  remain  responsive  and  to  supply  the  disarming  signal.  This  is 
discussed more thoroughly described below. 
 
3.2.3  Hyporesponsiveness in relation to education 
 
One possible explanation for the deficiency in missing self reactivity of the IMSR mouse 
could be an impaired MHC class I dependent education of NK cells expressing inhibitory 
receptor(s)   for   self.   We  tested   this   using   NKp46   stimulation   in   the  single   cell 
responsiveness  assay  and  found  that  the  IMSR  NK  cells  responded  in  a  pattern 
characteristic for education in an H2b expressing mouse, i e higher response by NK cells 
expressing Ly49C/I/NKG2A compared to Ly49C/I/NKG2A negative cells. However, the 
total response of both populations was significantly reduced compared to the response by 
wild type NK cells (paper I). This general hyporesponsivness was also observed when the 
whole NK cell population was analyzed with NK1.1 antibody stimulation. However, when 
IMSR NK cells were triggered via LY49D, a response comparable to wild type was 
observed. 
 
In addition, when responsiveness from wild type and IMSR NK cells were compared in 
mixed bone marrow chimera, the IMSR NK cells preserved their deficiency and remained 
poor responders independently of the host environment, wild type or IMSR. These data 
show that the deficiency in the IMSR NK cells is not simply due to a lack of educating 
signals  from  the  environment  and  that  the  defect  is  NK  cell  intrinsic.  However,  we 
observed that NK cells from MHC I-deficient hosts, which are defined as hyporesponsive 
due to lack of inhibitory signaling (education), responded stronger to unspecific stimulation 
with PMA/ionomycin. This was also observed for the IMSR NK cells. The pattern was very 
consistent (my unpublished data and paper I). One can only speculate why this occurs. It 
may be that the NK cells from MHC I-deficient and IMSR mice do not get triggered to 
respond as frequently to other cells in vivo, and therefore have more stored granules to 
respond with when they stimulated in the in vitro assay. 
 
A similar unexpected finding was that the NK cells from IMSR mice displayed a higher 
background release of CD107 in single cell responsiveness assays i e they responded even 
without added antibodies as the experimental stimulus (paper I fig 6 and unpublished data). 
This is interesting in relation to the hypothesis that the NK cells from the IMSR mice may 
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be   continuously   stimulated   via   NKG2D.   Perhaps   these   hyporesponsive   NK   cells 
accumulate lytic granules and interferons which “leak out”. Another possible explanation 
for the increased spontaneous release could be that the IMSR NK cells have a dysregulated, 
increased  production  of  functional  artillery.  Coudert  et  al  observed  that  continuous 
activation via NKG2D-L in NK cells induces a higher spontaneous production and release 
(364). If the IMSR NK cells suffer from chronic overstimulation, it could potentially lead to 
signals for production and accumulation of lytic granules, especially if they were rarely 
activated enough to trigger the effector machinery. It would therefore be of interest to study 
if wild type, MHC I-deficient and IMSR NK cells produce and store equal amount of lytic 
granules, containing perforin and granzymes, and cytokines in their cytosol. 
 
Further, as mentioned in the introduction, Bessoles et al. used D
d+ 
mice either deficient in 
cis or trans interaction or lacking D
d 
on NK cells or T cells respectively (251). In vitro 
responsiveness showed that Ly49A
+
CIN
- 
NK cells from both mouse strains were 
hyporesponsive upon RMA stimulation (reduced IFNγ and CD107a production). However, 
stimulation via NK1.1 induced increased IFNγ production by Ly49A+CIN-  NK cells only 
educated in cis (trans deficient) while the same NK cell population educated via trans (cis 
deficient) responded poorly. 
 
In conclusion, the NK cell from the IMSR NK cells are hyporesponsive, although the data 
indicates that it is not due to total lack of MHC I dependent education of NK cells with self 
receptors. It might be caused by another mechanism influencing the general responsiveness 
of all NK subsets. The IMSR NK cells do not appear to suffer from generally reduced 
supplies of granules or the machinery used to release them. 
 
3.3 NK CELL MATURATION AND CELL SURFACE MOLECULES INVOLVED 
IN MATURATION AND EDUCATION PROCESSES 
 
3.3.1  NK cell maturation; influence of inhibitory and activating receptors 
 
The NK cell maturation influences the responsiveness to a large extent, since mainly the 
NK cells with high Mac-1 expression are responsive in a normal state (62)(128, 131, 365). 
NK cells from MHC I-deficient mice are hyporesponsive, and they also show an altered 
maturation pattern, detected via altered CD27 and Mac-1 expression (365). We investigated 
the possibility that the hyporesponsiveness observed by the NK cells in IMSR mice and by 
the Ly49I sp and Ly49C/I dp NK cell population after 5E6 F(ab’)2 blockade could be due to 
an  altered  maturation  pattern.  In  both  situations,  the  relevant  NK  cell  subpopulations 
showed no major changes in the maturation pattern. However, the IMSR NK cell pattern 
displayed similar trend, with an increase of the CD27
hi
Mac-1
hi 
subpobulation, as both MHC 
I-deficient and NKG2D ligand transgenic mice (365). This is rather interesting since this 
population, CD27
hi
Mac-1
hi
, has been shown to be the most migratory and the most 
responsive population, both regarding cytotoxicity and cytokine production (66). 
 
So, could this increase of the most “potent” NK cell population be due to a compensation 
trying to achieve stronger responsiveness? If this is correct, it might be that the IMSR NK 
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cells have reached a sufficient level of function so that the full compensatory mechanism 
has not been elicited. In addition, it could be of interest to compare maturation and 
developmental stages in the bone marrow in the IMSR mice. Zafirova et al. showed that 
mice deficient in NKG2D have an altered maturation in the bone marrow with fewer fully 
mature NK cells, although the pattern in the spleen was not changed (351). However, 
Sheppard et al. using a different NKG2D-deficient mouse observed an enlarged mature NK 
cell population in the spleen (354). In conclusion, both gain of activating receptor ligand 
and lack of either inhibitory receptor ligand and activating receptor may potentially 
influence NK cell maturation status while antibody blockade does not, at least not the in the 
time frame used in paper III. Future studies may reveal if such a compensatory mechanism 
exists and what role it may play. 
 
3.3.2  KLRG1 expression in relation to education and retuning of NK cells 
 
Approximately 50% of the mature NK cells express the inhibitory receptor KLRG1(131). 
KLRG1 is the only marker that has shown some association with education; it is up- 
regulated on mature educated NK cells expressing inhibitory receptors for self (128, 204, 
365). The IMSR NK cells have the same KLRG1 expression levels and frequency as NK 
cells from wild type mice. This is a further sign supporting that the IMSR NK cells have 
gone through the education process, since NK cells from MHC I-deficient mice have a 
significantly reduced KLRG1 expression (128). The normal KLRG1 expression observed 
on IMSR NK cells also suggest that the inhibitory signaling pathway is functional in these 
NK cells since NK cells from SHP-1-deficient mice displays a reduced KLRG1 expression, 
although not as reduced as in MHC I-deficient NK cells(128, 343). 
 
Early studies showed that KLRG1 expression could be induced on homeostatically 
proliferating cells and also in response to strong stimulations such as a virus infection or in 
vitro cytokine stimulation (130, 131). In addition, Fogel et al. showed that KLRG1 is up- 
regulated during an early MCMV infection, although during the infection the high KLRG1 
expression is maintained on Ly49H
+ 
virus specific NK cells for a longer time period (in a 
Ly49H interaction dependent manner) than on the Ly49H- NK cell population. (132). 
 
However, KLRG1 is rarely discussed as a direct functional determinant for “education” i e 
acquired responsiveness, it has rather been perceived as a downstream consequence of the 
educated state. It was therefore of interest to investigate how this marker would behave 
upon altered responsiveness, i e when “the license” is suspended, could the KLRG1 
expression be reversed? Interestingly, we found in paper III that retuning via antibody 
blockade as well as transfer of wild type NK cells to a MHC I-deficient host, could reverse 
a high established KLRG1 expression on previously educated NK cells. Similar results 
have been reported by Joncker et al. using the transfer model, however it has never been 
studied after inhibitory antibody blockade (363). This strong correlation with “educational” 
and status suggests that KLRG1 may be more closely associated with education then 
preciously described, and may be a potential marker for induced responsiveness. 
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The actual function of KLRG1 in NK cell function is not so well understood. This molecule 
may be upregulated  on  mature  and  activated  NK cells  to  increase their  possibility to 
migrate out in the peripheral tissue and/or to improve biding to target cells. However, the 
increased expression of KLRG1 on educated, highly responsive NK cells expression may 
reflect a regulatory function in protection against elimination of healthy cells in the 
surrounding (66). One can speculate that when an NK cell has a high Ly49r expression, 
optimal maturation (CD27hiMac-1hi) and gain maximal responsiveness a counter balance 
is needed, hence there is an up-regulation of an additional inhibitory receptor (KLRG1). 
 
Ebihara et al. studying the role trans vs cis interactions for MHC I dependent education 
using mice and NK cells with inducible MHC I expression, saw no alterations of KLRG1 
after induced education. However, this could be due to that they studied the total NK cell 
population and not only the NK cells who acquired responsiveness e g NK cell expressing 
inhibitory receptors for self (250). 
 
3.4 SKEWING OF THE NK CELL REPERTOIRE AND THE INFLUENCE OF 
MHC I 
 
3.4.1  Skewing of the NK cell repertoire and the influence of MHC I in the 
bone marrow 
 
When I started my Ph.D. studies it was known from earlier studies (221, 224) and ongoing 
studies from our lab (204, 226) that splenic NK cells display a clear MHC dependent 
skewing of the inhibitory Ly49 receptor repertoire. This was observed as an increase of NK 
cell subsets expressing one or two different receptors (and in particular, only one self- 
specific inhibitory receptor) and a reduction of NK cell subsets expressing three to five 
receptors in a MHC I sufficient compared to a MHC I-deficient host. Little was known 
about where or when during NK cell development the skewing was induced. We decided to 
investigate this further (paper IV). By monitoring five inhibitory Ly49r individually, 32 NK 
cell subsets from the bone marrow were analyzed in D
d 
single, K
b 
single, D8 and MHC I- 
deficient mice (see table 1 for additional information). We found that NK cells expressing 
one or two inhibitory receptors for MHC I were overrepresented while NK cells expressing 
three to five inhibitory receptors for MHC I were underrepresented in all three MHC I 
expressing mouse strains compared to MHC I-deficient mice already in bone marrow NK 
cells.  In  addition, we found that the NK cells expressing only one self-specific Ly49 
receptor showed the most prominent increase in frequency. By studying NK cell 
development from the developmental stage when Ly49r are first expressed we observed 
that in D
d 
single mice the skewing of the NK cell population expressing single Ly49A or - 
G2 occurred already in stage III. This is the first stage where NK cells express Ly49r, but 
the skewing became more pronounced in stage IV, in which considerable NK cell 
proliferation/expansion occurs (62). In the case of Ly49A single positive NK cells the 
skewing was correlated to increased proliferation, as measured in vivo by BrdU 
incorporation. The same trend was observed for Ly49G2 single positive NK cells but the 
difference  was  not  statistically  significant.  Regarding  the  reduction  in  the  population 
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expressing several receptors it seemed to be a combination of both proliferation and 
increased apoptosis where the latter was already observed in stage III. 
 
This is interesting in relation to observations on skewing of the Ly49r repertoire in the 
spleen by Brodin et al. (204). They used D
d 
hemizygous or homozygous mice and observed 
not only an increase of Ly49A single positive NK cells in D
d+/+ 
vs D
d+/- 
mice but also that 
the Ly49A single NK cells ex vivo had an increased IL-15 induced proliferation and a 
tendency to reduced apoptosis,  measured by Annexin V and the pro-apoptotic marker Bim. 
It may be that in both the bone marrow and in the spleen, the MHCI dependent skewing of 
the NK cell repertoire is due to two processes taking place at the same time; increased 
proliferation  of  certain  subsets  and  apoptosis  of  others,  which  may  contribute  to  this 
pattern. These processes may act to create the most responsive, yet self-tolerant population. 
 
In paper III we studied if the NK cell receptor repertoire can be adjusted in the short term in 
response to an altered MHC I environment. Transfer of splenic NK cells from a MHC I 
deficient to a MHC sufficient host or vice versa did not alter the expression pattern of 
activating or inhibitory receptors. This has also been observed by Hayakawa et al.; who 
transferred splenic NK cells from either a MHC I sufficient or deficient donor into RAG- 
2cg
-/- 
mice (MHC I sufficient (365). Independently of which mechanism that is responsible 
for the skewing, proliferation or apoptosis, it may be so that the “settings” for the repertoire 
are determined at an early stage of development after which it cannot be altered. However 
the studies so far do not address if NK cells can alter their receptor repertoire expression if 
the MHC I expression is altered during development from an earlier NK cell precursor in 
the bone marrow. These questions are of high interest and needs further investigation. 
 
Regarding NK cell function during development, it has previously been shown that only the 
mature Mac-1
hi 
bone marrow NK cells are the potent IFNγ producers and that in the spleen 
the cytotoxicity is mediated by the CD27
hi
Mac-1
hi 
NK cell population(62, 65, 66). In 
addition, Rosmaraki et al. showed that the NK1.1
+
Dx5
+  
NK cells in the bone marrow are 
the most efficient killers of YAC-1 cells, although the NK1.1
+
Dx5
- 
also showed a low 
cytotoxicity (54). It would be of interest to study if the bone marrow NK cell needs to be 
educated via an Ly49 inhibitory receptor for self in order to aquire responsiveness, or if 
early expressed receptors such as NKG2A and NKG2D can play a major role in the early 
ontogeny NK of cell function. This could be investigated by analyzing the responsiveness 
of the 10% of the NKP cells that express NKG2D (61). 
 
 
3.4.2  Skewing of the NK cell repertoire in missing self deficient mice and 
after altered MHC I recognition 
 
The skewing of the NK cell repertoire can be used as a marker for that MHC I dependent 
education has occurred. This was used in both paper I and III where we studied either a 
mouse strain with impaired missing self recognition, IMSR, discussed in sections above, or 
retuning of NK cell responsiveness to altered MHC I expression. When analyzing the 
expression pattern of Ly49r after inhibitory receptor blockade, there was no difference in 
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repertoire formation. However, the inhibitory receptor repertoire of   IMSR NK cells, for 
Ly49C, -I, -A, -G2 and NKG2A, we found that total frequency of NK cells expressing any 
given inhibitory receptor (independently of expression of other receptors), self-specific or 
not, was significantly reduced in the IMSR mice compared to B6 wild type mice. On the 
other hand, when analyzing single Ly49r positive NK cell populations (expressing no other 
inhibitory receptor) from the IMSR mice, we observed a significant increase in the 
populations expressing self-specific, Ly49C, -I and NKG2A, compared to B6 NK cells. The 
skewing of the repertoire was thus even more pronounced in the IMSR mice than in the B6 
mice. This is an additional indication that the IMSR NK cells can sense MHC I via the 
inhibitory receptors. Further, SHP-1-deficient NK cells lack the skewed receptor repertoire 
pattern, NK cell population, and are more similar to MHC I-deficient NK cells(342, 343). 
This indicates that also the initial steps in the inhibitory receptor chain is functional in the 
IMSR NK cells and that at least SHP-1 is, a shared factor necessary for both NK cell 
inhibition and for the skewing of the NK cell repertoire (342, 343). 
 
Even  though  the  mechanism(s)  behind  skewing  and  NK  cell  education  still  remain 
unknown, these data, in combination with the results showing a relative increase in 
responsiveness of CIN
+  
NK cells in IMSR mice, are indicating that the NK cells from the 
IMSR mice go through at least on part of MHC I dependent the education process. In 
addition, reduced MHC I inhibitory input on mature splenic NK cell was not enough to 
alter the inhibitory receptor repertoire in the short term (within 4-7 days). 
 
3.4.3  Why does skewing of the NK cell repertoire occur in the presence of 
MHC I? 
 
We do not know the answer to this question. There are many speculations. It could be a 
mechanism to enrich for the NK cell populations with the most favorable offsetting of 
activation  thresholds  in  interactions  involving  self  MHC  I.  If  the  largest  NK  cell 
populations in an MHC I sufficient environment would express several inhibitory receptors 
for self, all of these NK cells might receive too much inhibition in the effector target 
interaction (221). Another more qualitative aspect is that NK cells expressing only one 
inhibitory receptor for self may be more sensitive to alterations in the environment. If a 
virus causes down regulation of one MHC I molecule the NK cells expressing only the 
inhibitory receptor for that specific molecule will react but if all NK cells express several 
inhibitory receptors there is still the possibility to be inhibited via another receptor (366). In 
this way skewing of the NK cell receptor repertoire may tune the system and make it more 
sensitive to changes in the MHC I expression. So, why is there an even more skewed NK 
cell inhibitor receptor repertoire observed in the IMSR mice compared to B6 mice? 
 
Our functional data indicate that the IMSR NK cells are incapable of performing missing 
self responses, regulated via inhibitory receptor signaling which could be explained by lack 
or dysfunction of any signaling molecule in the inhibitory signaling pathway. However, the 
phenotypic data indicate that the inhibitory pathway of the IMSR NK cells is at least partly 
functional and capable of mediating the signals needed for the skewing of the repertoire. 
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So, one speculative idea of why an increased skewing is observed is that the inhibitory 
pathway signals constantly. This would result in an increased activation threshold, and to be 
able to respond at all, subsets expressing one self-specific inhibitory receptor are enriched 
for to a higher extent than in the wild type B6 strain. This can thus be seen as a “selection” 
for the NK cell with lowest possible amount of inhibition to still achieve responsiveness. 
This  could  also  explain  why  there  is  a  reduced  or  impaired  function  through  other 
activating receptors. If there is always a strong inhibitory signal the activation signal, e g by 
NKG2D, may not be sufficient to achieve a response. 
 
In line with this hypothesis and any other explanatory model for the IMSR defect, it has 
previously been shown that human IL-2 activated NK cells are easier to trigger/stimulate 
activate compared to resting NK cells which have a more restricted regulation. To be able 
to respond with cytotoxicity or cytokine secretion, resting NK cells require co-signaling 
through pairs of activating receptors, each receptor contributing. Only CD16 was able to 
induce a NK cell response by itself, this was not observed by any other natural cytotoxicity 
receptor (182, 184). The term co-activation receptors were suggested to describe these 
receptors that can only function in synergistic pairs. This reasoning could be used to explain 
why some receptors are less affected and some not (e g CD16) in the IMSR mice. 
 
If the “hyperinhibition” hypothesis is correct, the data could be interpreted in the following 
way: the activating Ly49D receptor and NKG2D could represent opposite poles. Ly49D as 
a strong activating receptor induces enough stimuli to overcome the inhibition while 
NKG2D could be mediating a too week signal to overcome the higher inhibition. It may be 
argued that NKG2D signaling in mice is strong enough to overcome inhibitory receptor 
signaling since RMA-Rae1γ (NKG2D ligand transfected) cells are rejected while the RMA 
mock transfected cells are not (paper I and (346). However, on RMA there are probably 
additional unknown activating ligands mediating co-stimulation, tilting the balance towards 
activation by NK cells in wild type mice. The theory regarding different stimuli needed to 
activate resting or pre-activated NK cells might also explain the increased in vitro killing of 
β2m
-/- 
Con A blasts observed by the IL-2 activated IMSR NK cells. In this case the cytokine 
pre-activation alters the triggering signals needed to shift the balance by reducing the 
required co-stimulation. 
 
Another way by which MHC I influences the NK cell and its receptors is by regulating the 
expression level of the cognate inhibitory receptors. When a MHC I ligand is present there 
is a reduction in the expression levels of the corresponding self-specific inhibitory receptor 
on the NK cells. This can be due to at least two different mechanisms 1) internalization of 
the receptor-ligand complex when they are interacting in trans or 2) via cis interaction on 
the same cell blocking the antibody staining. There is no difference in expression level of 
educating receptors on NK cells from the IMSR mouse compared to B6 NK cells. This 
indicates that it is not a defect causing problem to perform a cis interaction by the Ly49C 
NK cell subpopulation. 
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Bessoles et al. disrupted the Ly49r-MHCI interactions, either the ones in cis or the ones in 
trans, in two different ways, and showed in both systems that cis interactions are needed to 
induce skewing of the repertoire while trans interactions seemed less important (251). 
Based on this and functional data showing that lack of cis induced NK cell 
hyporesponsiveness, the same group proposed a new model for NK cell education; the 
sequential arming and disarming model for NK cell education (361). The authors state that 
Ly49r-MHC I interactions are needed to occur in both cis and trans to achieve a long term 
functional NK cell population. The principle is that NK cells become armed via Ly49r cis 
interactions, achieve responsiveness, and as a consequence skewing of the receptor 
repertoire is induced. However, to avoid chronic or overstimulation (inducing 
hyperresponsivness) NK cells interact with surrounding cells in trans to gain 
inhibition/disarming. However, if only trans interactions occurs, there will be no skewing of 
the repertoire and no gain of responsiveness. This model can be used to interpret the IMSR 
defect in the following way: IMSR mice have a functional interaction to MHC I in cis, 
inducing responsiveness and skewing of the repertoire, however the interaction in trans is 
defective i e the NK IMSR NK cells are render hyporesponsive due chronic overstimulation 
as implied in section 3.1.2. 
 
In  conclusion,  there  are  at  least  two  theories  which  can  explain  the  reduced  Ly49r 
expression and increased skewing of the NK repertoire in IMSR mice; too much or too low 
signaling via an inhibitory or an activating receptor respectively. In the case of too much 
signaling,  it  could  be either constant  signaling  or excess  of a signaling molecule, for 
example SHIP-1. One could speculate that over expression of SHIP-1 would generate too 
much inhibitory signaling via inhibitory Ly49r and therefore alter both activating threshold, 
skewing and increased termination of Vav-1 signaling (observed as reduced NKG2D 
function).  In  addition,  it  could  possibly  out-compete  SAP  and  EAT-2,  making  2B4 
signaling only inhibitory and tilting the balance through other activating receptors, which 
could explain the function of IMSR NK cells. However, if the phenotype is altered due to 
reduced activating signaling, as for Fyn, this would also affect the function via several 
receptors, although not NKG2D or Ly49D which are Fyn independent, which is partly seen 
in IMSR. It would however be of interest to eliminate the function of either SHIP-1 or Fyn 
in the IMSR and see if this alters the receptor repertoire or the NK cell function. 
 
3.5 MANIPULATION OF MISSING SELF RECOGNITION IN CANCER 
TREATMENT 
 
3.5.1  Increased tumor elimination by mimicking missing self recognition via 
Ly49C and I receptor blockade 
 
Can our knowledge regarding NK cells and missing self recognition be applied in 
immunotherapy against cancer, i e to induce missing self recognition by NK cells against 
tumor cells expressing MHC I molecules? Koh et al. were the first to study this in an in 
vivo  model  for  inhibitory  receptor  blockade.  After  blocking  self-specific  inhibitory 
receptors by treatment of mice with Ly49C and I with antibody F(ab’)2  fragments against 
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Ly49C and I, they demonstrated increased in vitro cytotoxicity towards MHC I
+ 
malignant 
cells, and reduced vivo outgrowth of transplanted tumor cells (322-324). However these 
studies did not address whether the inhibitory receptor blockade affected reactivity towards 
healthy normal cells, how it affected the NK cell population over time and whether it 
actually directly increased NK cell mediated elimination of tumor cells. 
 
The study resulting in paper II was collaboration with the companies Novo Nordisk 
(Copenhagen) and Innate Pharma (Marseille) where we investigated the biological function 
and safety of blocking self-specific inhibitory receptors as a preclinical evaluation for 
development towards a clinical trial and future treatment of patients. We could demonstrate 
that blocking of the inhibitory receptors Ly49C and I in both short and long term treatment 
(3 days to 9w) induced increased in vivo rejection of fluorescence labeled syngeneic 
lymphoma cells, while there was no effect on in vivo killing of healthy syngeneic spleen, 
bone marrow cells or lymphoblasts. Nor was there was any tissue damage, changes in 
hematological parameters or other detrimental effects after long term treatment. This 
indicated that the administration of antibody fragments inducing increased NK cell 
reactivity, which potentially might induce autoreactivity, was actually safe. Part of these 
results,  and  other  additional  data  were  used  in  the  preclinical  data  file  submitted  for 
approval of the first phase I clinical trial based on NK cell inhibitory receptor blockade 
(with KIR antibody). 
 
As already discussed, we now realize that the robust NK cell tolerance against normal cells 
despite inhibitory receptor blockade may be due to the induced hyporesponsiveness 
observed in paper II. NK cells were however, still capable of efficient rejection of MHC I- 
deficient tumor cells. In addition, the effect on lymphoma cell killing effect was even more 
efficient when the treatment was administrated in combination with IL-2. This combined 
therapy also significantly reduced outgrowth of syngeneic melanoma transplants. 
 
In parallel with and following the studies in paper II, our contact at Novo Nordisk, Nicolai 
Wagtmann was responsible for the first studies conducted on human cells using the same 
principle, blocking MHC class I specific inhibitory KIR.(367, 368).The anti KIR antibody 1 
7F9 (later called IPH2101 or lirilumab as a  pharmaceutical generic name) recognizes and 
binds  to  the  common  inhibitory  KIR2DL-1,  -2  and  -3  receptors,  thereby  blocking 
interaction to all HLA-C haplotypes and preventing inhibition (hereafter, the term anti-KIR 
antibody blockade I refers to such blockade of inhibitory KIRs) (368). 
 
The anti-KIR antibody increased cytotoxicity of IL-2 activated human NK cells from a 
HLA-C matched donor against patient derived acute myeloid leukemia blasts. In vivo, pre- 
treatment with 1-7F9 in KIR2DL3 transgenic mice increased rejection of injected CFSE 
labeled human PBMC (peripheral blood mononuclear cell) or spleen cells from a HLA-C 
transgenic mouse expressing the inhibitory ligand. NOD-SCID mice inoculated with human 
NK cells and acute myeloid leukemia blasts showed a high mortality rate within 4 weeks 
due to leukemia, but if they were also treated with 1-7F9 they survived 3 months (367). In 
conclusion, the first study blocking with an anti-KIR antibody increased cytotoxicity in 
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vitro as well as rejection of HLA expressing tumor cells in vivo. The next step was a phase 
I trial performed on 23 elderly patients with acute myeloid leukemia in remission. This trial 
showed that the dose of antibody required to give full saturation of KIR on NK cells was 
safe, and could be administered to induce inhibitory KIR blockade for a longer period with 
minimal side effects (369). NK cells from patients treated with higher doses of anti-KIR 
antibody expressed markers for activation such as increased expression of CD69 and 
elevated levels of TNF-α and MIP-1β, but there were no signs of changes in the NK cell 
population defined by number in peripheral blood, expression of activating and inhibitory 
receptors and no change in the capability to degranulate. 
 
Treatment with anti-KIR antibody has also been tested against other types of cancer 
expressing HLA molecules (thereby possibly escaping NK cell mediated lysis) and in 
combination with other substances to enhance the efficacy. Benson et al. conducted studies 
on multiple myeloma using both the human setting with anti-KIR antibody and the 
equivalent murine system blocking the inhibitory receptors Ly49C and I with 5E6 F(ab’)2 
fragments. In the murine setup, treatment with 5E6 fab2 fragment in combination with a 
NK cell stimulatory substance lenalidomide increased in vivo rejection of syngenic tumor 
cells (RMA) in the liver, but there was no significant effect when each treatment was given 
by itself. (370). These data are somewhat conflicting to our data since we observed a 
significantly increased rejection of RMA cells in vivo after 5E6 F(ab’)2  treatment alone. 
These are most likely to the big differences in t doses of  5E6 F(ab’)2 (we used at least a 20 
fold increased dose) or/and different assays for NK cell mediated rejection used. When the 
equivalent anti-KIR was used, blocking in combination with lenalidomide in vitro enhanced 
NK cell function, immune complex formation, cytotoxicity and IFNγ production against 
autologous myeloma cells but there was no effect on NK cell activity against healthy cells. 
The positive effect of lenalidomide was due to up-regulation of activating molecules on the 
myeloma cell line. In a phase I trial conducted on 32 patients with refractory multiple 
myeloma, administration of the IPH2101 anti-KIR antibody in doses resulting in total 
occupancy, was tolerated without any toxicity (371). Comparing PBMC (peripheral blood 
mononuclear cell) samples before and after administration of anti-KIR showed that the 
patients NK cells cytotoxicity against myeloma cells had increased in vitro. The treatment 
led to NK cell activation e g a higher expression of CD69, but no significant changes on 
IFNγ response or other cytokine vivo as opposed to their first in vitro study. 
 
In the most recent paper on the subject of increasing NK cell anti-cancer activity by 
combined treatment, anti-CD20 antibody (rituximab) was used in combination with 
inhibitory receptor blockade (372) in a murine model. Rituximab is used as a standard 
treatment for B cell lymphoma; it is considered to act directly on lymphoma cells by 
inducing apoptosis, and via ADCC by NK cells. However, some patients respond poorly. 
The authors used a murine lymphoma cell line transfected with the human CD20 to co- 
analyze the response of mice both to anti-CD20 antibody and anti-Ly49C and I fab2 
fragments. They found that the combinatorial treatment, compared to anti-CD20 alone, 
increased  CD107a  expression,  IFNγ  production  and  ADCC  upon  co  culture  with  the 
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lymphoma cells. In addition, the combined treatment increased anti-lymphoma activity and 
prolonged survival in mice with already established tumors compared to the treatments with 
each of the agents separately. Anti-KIR antibody therapy using a recombinant variant of 1- 
7F9 with a stabilized hinge, lirilumab, was tested in combination with anti-CD20 using the 
KIR transgenic mice. Mice injected with HLA-C expressing tumor cells and treated with 
the combination had a 2-2.5 fold increased NK cell dependent survival compared to mice 
given the substances separately. In conclusion, both removing the inhibitory signal from the 
most potent killers in combination with inducing a strong activation pathway via CD16 
increases NK cell activity and leads to prolonged survival of treated mice. 
 
Neuroblastoma (NB) is the most common extracranial solid tumor among children with a 
poor long term survival prognosis despite treatment such as surgery, radiation or 
chemotherapy. A reduced recurrence risk and a longer overall survival has been seen for 
high  risk  neuroblastoma  patients  treated  with  a  monoclonal  antibody  recognizing  the 
surface antigen disialoganglioside GD2. The antibody acts by activating complement to 
directly kill neuroblastoma cells but also by inducing NK cell mediated ADCC (3-5). An 
interesting finding made by Tarek et al. is that the unlicensed NK cell population (NK cells 
expressing inhibitory KIRs for which cognate HLA class I ligand is absent) is the most 
effective population mediating the antitumor ADCC effect (373). Patients missing at least 
one HLA ligand for their inhibitory KIRs were considered unlicensed while patients 
expressing HLA ligands for all their inhibitory KIRs were termed licensed. Functional in 
vitro tests showed that anti-GD2 treatment induced increased ADCC by both licensed and 
unlicensed NK cells, but the unlicensed cells responded more efficiently while the licensed 
ones were inhibited by the KIR-HLA interaction. As described more thoroughly above, NK 
cells that has been educated (KIR-HLA interaction) gain increased responsiveness. Both the 
human study by Tarek et al. and the murine study by Orr et al. showing that unlicensed NK 
cells drive the response against cytomegalovirus (258), demonstrates that the gained 
responsiveness through education cannot override the inhibition mediated by the HLA-KIR 
interaction. So, NK cell education is enough to ensure tolerance at steady state during 
normal  conditions  but  can  be  overcome  during  certain  conditions,  such  as  a  strong 
activation via either mAb treatment or viral infections. 
 
The most efficient way harness NK cells for immunotherapy against cancer will most 
probably be based on combining several treatment strategies to increase the elimination 
efficacy by the NK cell, as mentioned in the beginning of this section. Benson et al. showed 
one way to do that using an anti-programmed death receptor-1 (PD-1) antibody in 
combination with lenalidomide against multiple myeloma (374). They showed that resting 
NK cells from healthy individuals express very low levels of the inhibitory PD-1 molecule 
but the expression was significantly elevated on both NK cells from healthy donors who 
had been incubated in IL-2 for 48h and on NK cells from a multiple melanoma patient. 
Treating NK cells with anti-PD-1 antibody enhanced both elimination capacity, by blocking 
the inhibitory signal and increasing granzyme B and IFNγ production via an unknown 
mechanism,  and  the   migration  towards  multiple  melanoma  cells.   In   addition  the 
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lenalidomide contributed by decreasing the expression of PD-1 ligand on the target cells 
and boost the NK cell response by inducing IL-2 production by the T cells (375). 
 
3.5.2  A complicating factor: retuning of NK cell responsiveness via altered 
MHC I perception 
 
As discussed above, inhibitory receptor blockade shows promising therapeutic potential. 
How can those results be reconciled with our results in paper III, where we found that 
blocking of inhibitory Ly49C/I receptors in a B6 mouse or transfer of B6 spleen cells or 
mature NK cells to a MHC I-deficient host resulted in retuning i e reduced rejection of 
MHC I-deficient spleen cells in vivo? Importantly, we found that in both systems the NK 
cells were still capable of efficient rejection of MHC I-deficient tumor cells 
 
In summary, we speculate that the induced tolerance towards MHC I-deficient normal cells 
after removal of the inhibitory signals (in paper III), via antibody blockade or transfer to an 
MHC I-deficient host, is induced by an increased activation threshold towards normal cells 
in the environment. It is a consequence of retuning, resulting in tolerance towards normal 
cells but preserving function towards diseased targets expressing more activating ligands; 
the latter can still overcome the increased activation threshold and will be eliminated. This 
hypothesis could further be investigated if the activating ligands on normal spleen cells and 
the activating ligands triggering elimination of RMA-S were known. A relevant 
phenomenon can actually be observed if a strong activating ligand is ectopically expressed 
in RMA, the NKG2D ligand Rae1γ. Both B6 and β2m-deficient mice eliminate RMA- 
Rae1γ tumor cells in vivo with a similar efficiency (data not shown). This proves that the 
increased activating threshold inducing hyporesponsiveness in the β2m-deficient NK cells 
can be overcome when the activation is strong enough, as in the case of elimination of 
tumor cells but not of healthy cells after retuning. In addition, when such a strong activating 
ligand is present in the system, one would not expect any additional effect of inhibitory 
receptor blockade since the “window” to observe an altered effect is too narrow. 
 
Using the transfer approach we also observed that NK cells can retune to gain function e g 
when an NK cell from a MHC I-deficient mouse is transplanted into a MHC I sufficient 
host: The NK cell responsiveness was altered to gain the capacity to eliminate MHC I- 
deficient tumor cells but still remained tolerant towards MHC I-deficient spleen cell in 
vivo. Why and how the NK cell remains tolerant towards MHC I-deficient spleen cells is 
uncertain. It could be due to education on neighboring transferred NK cells, although they 
are quite few in respect to the total cell count, or it might be some sort of imprinted baseline 
setting that cannot be altered to always ensure tolerance towards self. Independent of the 
mechanism, these data indicate that the interaction needed to become educated and gain 
responsiveness is presented, perhaps not only but at least also, in trans. However, there is 
also the possibility that the NK cell acquire MHC I from surrounding cells via trogocytosis 
and become educated via a cis interaction (245). The reduce responsiveness achieved after 
transfer of cells from B6 to β2m
-/-  
mice cannot be explained entirely by cis interactions 
since if that would be the only way needed for ligand presentation, the B6 NK cells would 
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remain efficient killers of MHC I-deficient spleen cells. However, these data could be 
explained by the sequential arming/disarming model. After transplantation, the B6 NK cell 
still engage in cis while they lack the trans interaction on surrounding cells (except the 
graft) leading to chronic “anergy”, hence they become tolerant towards the new 
environment. However this model does not explain how MHC I-deficient NK cells remain 
tolerant towards MHCI- deficient spleen cells while gain function against tumors both 
lacking MHC I expression. 
 
These data show that the NK cell responsiveness can be tuned in both directions in vivo, 
either to preserve tolerance towards the normal tissue (B6 to β2m
-/- 
transfer) or to achieve 
wild type responsiveness towards tumor targets (β2m
-/- 
to β2m
-/- 
transfer), which has never 
been shown before. Evidence that NK cells can retune their responsiveness as adaptation to 
changed MHC I expression has been shown previously. However, those studies were on 
rejection of MHC I-deficient spleen cells and did not include tumor cells; furthermore, in 
the case of for gain of responsiveness they addressed this only with in vitro assays for in 
NK cell responsiveness. The retuning impact on tumor elimination or that retuning can be 
induced by mimicking missing self via antibody blockade has never been shown before 
(362, 363) In addition, we observed that independently of transplantation direction, B6 to 
β2m
-/- 
or β2m
-/- 
to B6, two functions are always present 1) the strict self-tolerance is ensured 
and 2) the ability to eliminate MHC I-deficient tumors is either induced or preserved 
dependent on the direction. 
 
Our results may be of importance for understanding and optimizing usage of NK cells as 
immunotherapy in a haploidentical setting and for activation via inhibitory receptor 
blockade. Transfer of NK cells from a non-HLA matched donor could theoretically contain 
both responsive and hyporesponsive NK cells. The responsive donor NK cells can 
potentially mediate graft vs host reactivity. Our data indicate that the NK cells educated on 
one type of MHC I allele in the donor would retune and become self-tolerant toward 
healthy recipient cells expressing another MHC class I allele, while preserving effective 
elimination of leukemia cells due to missing self recognition of the recipients MHC I- 
deficient  tumor cells.  However, the hyporesponsive  NK cells  (lacking  a ligand  in  the 
donor), would display the opposite pattern. These NK cells would remain self-tolerant but 
at the same time gain a strong anti-leukemia effect mainly against MHC I negative tumors 
due to  induced  education  by the  “right  MHC  I allele”  expressed by the recipient.  In 
addition, the newly educated NK cell subset could also possibly have an effect, at least in 
the early phase, against MHC I expressing tumor cells with additional activating ligands 
even if the recipients educated NK cells are inactive, since the recipient NK could be non- 
functional due to influences from factors in the tumor microenvironment. It would be of 
great interest to study elimination of haploidentical tumors that are not completely lacking 
MHC I, which could be observed by analyzing elimination of RMA tumor cells after 
transfer of D8 NK cells to a B6 host. This was partly done by Kijima et al. 
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Kijima et al. transduced bone marrow cells with an oncogene and transplanted them to 
irradiated mice with different haplotypes to study the influence of NK cell functions against 
primary chronic myeloid leukemia (CML) (376). NK cell response against CML was 
dependent on missing self recognition and not due to upregulation of activating ligands 
(NKG2D) or alloreactive activating receptors (Ly49D). MHC I matched recipients 
developed disease after transplantation of chimeric grafts (cancer bone marrow cells and 
MHC  I  matched  bone  marrow)  while  transplantation  to  full  mismatched  recipients 
remained disease free. In a haploidentical situation (loss of one MHC I allele), missing self 
recognition delayed the onset of the disease but was not enough to mediate full anti-cancer 
protection in all recipients. Further, the NK cell influenced the disease by elimination of 
leukemia initiating stem cells. These results demonstrate that a functional missing self 
recognition is enough to render cancer cells sensitive to NK cell mediated killing, in line 
with the early results on hybrid resistance and MHC I transgene induced NK cell rejection 
of tumors discussed in the beginning of this thesis. 
 
In addition, in the setup using F(ab’)2 fragments, the elimination of MHC I expressing 
tumors, RMA, was not as robust and strong as we had expected. This could be explained by 
that two individual mechanisms opposing each other were affecting the outcome. The 
“early” effect of the Ly49C/I blockade was observed by an increased elimination of the 
tumor cell induced by blocking the effector-target interaction mimicking missing self 
recognition. However, this effect might be much stronger if it would not have been 
counteracted by induced hyporesponsiveness caused by retuning, the second effect of the 
inhibitory receptor blockade. Evidence that the tumor killing is actually also negatively 
influenced to a certain extent is provided by the tumor outgrowth experiments with RMA 
and RMA-S (paper III, Table I). When the system was challenged to the limit with a very 
large tumor transplant, inhibitory receptor blockade reduced the rejection of MHC-deficient 
tumor cells (RMA-S). To improve this system to gain the maximum effect and a stronger 
elimination of MHC I sufficient tumor cells one could consider to 1) reduce antibody 
saturation and perhaps avoid retuning and induced hyporesponsiveness or 2) reduce the 
stability of the F(ab’)2  fragments and therefore block the inhibitory receptors for a shorter 
time period and therefore avoid retuning but treat repeatedly to gain the anti-leukemia 
effect. 
 
NK cell education and responsiveness are influenced by other parameters then MHC I. In 
the model that we use to interpret our results, retuning alters the activation threshold 
ensuring tolerance towards healthy cells while they still maintain or gain function towards 
tumor cells. However, not only retuning by altered inhibitory input can change the NK cell 
responsiveness, virus infections and “cytokine storms” also influence the responsiveness. 
The NK cell pool consists of both fully responsive and hyporesponsive NK cells. The MHC 
I-deficient NK cells are at steady state tolerant  towards self. However, Salcedo  et  al. 
showed  that  NK  cells  from  both  β2m
-/-   
and  TAP1
-/-   
mice  could  be  induced  to  break 
tolerance and kill autologous lymphoblasts but remained tolerant towards MHC I sufficient 
targets in vitro after 4 days of IL-2 activation (344). In addition, mixed B6/β2m
-/-  
bone 
76  
marrow chimeras are also tolerant towards MHC I-deficient cells although this tolerance is 
broken upon infection with cytomegalovirus. These results indicate that the missing self 
system and tolerance can be calibrated and induced when the NK cell develop in an 
environment containing MHC I-deficient cells although strong stimuli, for example 
cytokines, can break the achieved tolerance (377). 
 
Regarding NK cell education, retuning and responsiveness, it has been shown in mice that 
paradoxically the uneducated hyporesponsive NK cells are the most important in protection 
against Cytomegalovirus infections (258). This is probably due to lack of inhibitory signals 
in the interaction with infected cells and illustrates that the hyporesponsive state does not 
represent complete anergy, but rather a changed activation threshold so that NK cells 
cannot respond to the activation signals presented by normal cells, even if they lack 
inhibitory receptors for their MHC I molecules. This does not exclude that they can respond 
in other contexts where a qualitatively or quantitatively altered set of activation signals are 
presented. Further, Fernandez et al. showed that both the educated and uneducated NK cell 
pool responded equally well with IFNγ to a Listeria infection, indicating that the 
unresponsive NK cell pool has the capability to respond when it is stimulated enough (203). 
 
In  addition,  Ardolino  et  al.  showed  recently  that  MHC  I-deficient  tumors  induce  an 
“anergic state” in the tumor infiltrating NK cell population leading to a reduced 
responsiveness and survival while MHC I sufficient tumors did not (378). However, 
cytokine treatment could reverse the induced anergy. This strengthen our and other´s 
conclusion that a combinatory treatment of inhibitory receptor blockade and cytokine 
treatment may be the best strategy to to activate NK cells against MHC I sufficient tumors. 
Only blockade induces retuning or “anergy” but according to our study (paper II) and 
Ardolino’s data this effect may be reversed or kept in balance by cytokine administration. 
 
NK cell responsiveness and tolerance is tightly controlled by Ly49r-MHC I interactions and 
the balancing effect of activating receptors. During special circumstances the well- 
controlled system can be bypassed. This may reflect different levels of function by the NK 
cell population. Maybe the educated NK cell pool is there to patrol the tissues for stressed, 
infected or transformed cells. They are tightly controlled to not become autoreactive but 
they have the ability to respond strongly when it is justified. To complement this regulated 
responsive NK cell pool, there are NK cell subsets expressing no inhibitory receptor for self 
which are a less controlled NK cell population (if activated), but they are in a 
hyporresponisve state during healthy conditions to ensure tolerance. This less controlled 
population is able to rapidly expand and give an even stronger response (seen by for 
example IFNγ production and CD107a expression, after PMA/Ionomycin, as discussed in 
section 3.2.3) by MHC I-deficient NK cells) when the activation is strong enough, since 
they are less inhibited. These NK cells might only be used when the danger is acute and 
rapid as in the case of infection. 
 
In conclusion, the rheostat model takes all the interactions (both inhibitory and activating) 
and the strength of the interaction into account and the net sum will regulate the decision 
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and responsiveness. Brodin et al. showed that NK cells with more inhibitory signals has 
increased    responsiveness  and  also  respond  in  a  more  diversified  way  (e  g  several 
cytokines) (233). This should theoretically mean that if the NK cell receives a lot of 
inhibitory signals, it becomes educated and responsive, but it also needs an increased 
amount of activation to get triggered if inhibitory ligands are present. However, too much 
activation as in the case of chronic stimulation via an activating receptor leads to an overall 
hyporesponsiveness. To my knowledge, it has not been specifically studied how the 
educated NK cells respond under conditions of chronic stimulation, which would be of 
great interest. In addition, removal of activating receptors such as NKp46 and NKG2D 
results in hyperactivated NK cells clearly shows an influence of activating receptors in 
control of NK cell response. Further, as described above (see section 1.9.2-3), there are 
both MHC I dependent and MHC I independent molecules participating in the education, 
regulating total responsiveness observed by the NK cells. When more of the ligands (for 
example the endogenous ligands) are identified we will have a better understanding for how 
the system works and how it can be used for immunotherapy. 
 
4  CONCLUDING REMARKS 
 
I see a common thread throughout my thesis: investigation of NK education and missing self 
recognition, even though these themes have been approached with different questions and 
methods. 
 
During my doctoral studies my colleagues and I have used IMSR NK cells as a tool to 
investigate how missing self recognition is related to other NK cell functions (paper I). The 
dogma of the field is that MHC I-deficient NK cells are hyporesponsive due to lack of 
inhibitory signals needed to achieve licensing/disarming. The IMSR NK cells are exposed to 
inhibitory ligands and can be inhibited by them upon interaction. Further, they are 
phenotypically mature and show signs that they have gone through education, implying 
inhibitory receptor mediated licensing/disarming. However, they are still missing self 
deficient and overall hyporesponsive in most settings. We know that the defect is not due to 
the targeted CD1d1 gene in these KO mice. The next step should be to identify the gene(s) 
responsible for the defect. 
 
Further, we used missing self recognition to demonstrate that Ab-mediated blockade of self- 
specific inhibitory receptors on NK cells can induce reactivity against syngeneic lymphoma 
cells without breaking tolerance to normal cells. In vivo blockade with 5E6 F(ab’)2 fragments 
binding to Ly49C/I inhibitory receptors on NK cells caused increased rejection of syngeneic 
MHC class I-expressing tumor cells (RMA) but not of syngeneic spleen cells, bone marrow 
cells or lymphoblasts, thus the self-tolerance was thus very robust. The anti-tumor effect was 
sustained over long time and could be enhanced by co-treatment with IL-2. These results are 
interesting for development of therapy in the in clinical setting. However, an unexpected but 
very reproducible an interesting finding during this study was that mice treated with the 5E6 
5E6 F(ab’)2 fragments showed decreased rejection of splenocytes lacking MHC I. This was 
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the starting point for the studies of inhibitory receptor blockade in paper III, were we 
addressed if it is possible to use this procedure to quench the inhibitory input for NK cells and 
as a consequence induce retuning, as predicted by the rheostat model for NK cell education. 
This approach to alter the NK cell sensing of MHC I expression in vivo is minimally 
invasive, and was therefore an important complement to the second model used in paper III 
based on irradiated recipients receiving high numbers of transferred cells. We could 
demonstrate retuning of NK cell responsiveness in both models. In this study we aimed for an 
almost complete (100%) receptor blockade. However, our results show that for use in 
treatment of cancer, the blockade needs to be optimized, by titration of dose and dosage 
intervals, with the goal to increase effector function in the interaction with target cells without 
inducing hyporesponsivness via the interactions with educating cells. 
 
In the last manuscript of my thesis we studied one effect of MHC I education, skewing of the 
inhibitory receptor repertoire. We established that skewing of the NK cell repertoire occurs in 
the bone marrow at the developmental stage where Ly49 receptors start to be expressed. In 
addition, we observed a possible influence of proliferation and apoptosis as possible 
mechanisms    regulating    the    frequency    of    different    NK    cell    subpopulations. 
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